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ABSTRACT 
One of the most striking features of developmental biology is the dramatic 
morphological changes that an embryo must undergo to achieve its final form. Arguably, 
the most stunning example of this is found in the embryonic vasculature: not only does the 
vasculature undergo morphological changes, it must continue to do so adaptively as the 
size and nutritional needs of the embryo change during gestation. As embryonic blood 
flow starts long before the end of vessel morphogenesis, the vessels must maintain the 
integrity of their cell-cell contacts while at the same time remodeling into their final state. 
Receptor tyrosine kinases and their ligands have been implicated in the rcgulation of blood 
vessel growth and remodeling during development. Recently, the Eph receptors and their 
ephrin ligands were found to be expressed in the developing vasculature. While one Eph 
receptor, EphB4, is restricted to veins, its specific ligand, ephrinB2, is restricted to 
arteries. Furthermore, the ephrinB2 knockout mice exhibit defects in blood vessel 
remodeling, angiogenesis. Although the reciprocal expression of ephrinB2 and EphB4 
suggested that Eph signaling from arteries to veins was important for blood vessel 
development, the presence of additional Eph receptors suggested EphB4 might not be 
required for this process. Additionally, the widespread expression of ephrinB2 outside the 
vasculature suggested that vascular-specific expression of this ligand might not be the 
tissue source necessary for angiogenic remodeling. 
To determine which Eph receptor was mediating the ephrinB2 signal, I generated a 
knockout of the EphB4 gene in mouse. A reporter gene replacement in the EphB4 locus 
confirmed the vein-biased expression of this receptor. Homozygous EphB4 mutant mice 
exhibit angiogenesis and cardiac defects, and embryonic lethality indistinguishable from 
those of ephrinB2 knockout mice. This suggests that EphB4 is the main Eph receptor 
responsible for transducing the angiogenic ephrinB2 signal. To examine the importance 
of endothelial specific expression of ephrinB2 in angiogenesis, in contrast to its non-
vascular expression, I generated a conditional ephrinB2 mouse. These mice carry a 
functional ephrinB2 gene, which can be inactivated in a tissue specific manner. Mice 
with endothelial-specific inactivation of ephrinB2 (and intact non-vascular ephrinB2 
expression) exhibit severe angiogenesis and cardiac defects identical to those of the 
v 
conventional ephrinB2 mutant mice. This suggests that vascular ephrinB2 is essential, 
and cannot be compensated for by non-vascular ephrinB2 from surrounding vessels. 
These studies have clarified two important issues. The first is that the ephrinB2 
signal is received by EphB4 expressing endothelial cells (of the veins), rather than by 
perivascular cells that also express Eph receptors. Second, cphrinB2 expression in 
endothelial cells of the vessels is an essential tissue source of angiogenic ephrin signals. 
Together, these studies reinforce the original interpretation of the ephrinB2 mutant, that 
Eph signaling between arteries to veins is essential for angiogenesis in the early embryo. 
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Chapter 1 
Introduction 
2 
Angiogenesis, the development of the vasculature, IS an essential ongolllg event 
during embryonic development. Simple diffusion of nutrients and waste becomes 
insufficient as the size of the embryo grows and it therefore becomes dependent on the 
vasculature to provide rapid, distributed supply of nutrients, oxygen, and waste removal. 
As the embryo grows, so must the vasculature, adaptively as thc needs of the embryo 
change, and all while maintaining luminal integrity to ensure proper confinement and 
transport of blood. The endothelial cells (ECs) that form the inner layer of all vessels 
require careful coordination of their morphological, proliferative, migratory, and adhesive 
activities to guarantee proper growth of the embryo and establishment of a functional 
mature vascular network (Risau, 1997). This is mediated by a variety of signaling 
pathways involving secreted and cell-surface ligands and receptors. Figuring 
prominently is the presence of endothelial specific receptor tyrosine kinases (RTKs) 
(Gale and Yancopoulos, 1999). Recent progress in the field of angiogenesis has revealed 
the importance of the Eph family of RTKs and their cell-surface tethered ligands, the 
ephrins (Adams and Klein, 2000; Yancopoulos et aI., 2000; Gale and Yancopoulos, 
1999). Known primarily for their roles in tissue domain segregation and repulsive 
activities on migratory cells and pathfinding axons (reviewed in Wilkinson, 2000), they 
are also expressed in and around the endothelium of the vasculature (Adams et aI., 1999; 
Wang et aI., 1998). Initial mouse knockout studies have indicated that Eph signaling is 
essential for angiogenesis (Adams and Klein, 2000; Adams et aI., 1999; Wang et aI., 
1998). This family of RTKs, EphB4 (Andres et aI., 1994; Bennett et aI., 1994) and its 
specific ligand ephrinB2 (Bennett et aI., 1995; Bergemann et aI., 1995) in particular, are 
the main focus of my thesis work. 
Vascuiogenesis 
The initial formation of blood vessels occurs through a process termed 
vasculogenesis: endothelial precursors, angioblasts, segregate from the mesoderm, 
proliferate and then aggregate to form blood islands in the yolk sac and endothelial 
strands in the embryo proper (see figure lA, and Risau and Flamme, 1995). Blood 
islands are multi-cellular structures with an internal lumen, containing hematopoetic 
cells, which fuse with neighboring blood islands to form endothelial tubules. The result 
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of this process is the formation of a primitive, homogeneous capillary network called the 
primary plexus (Patan, 2000; Risau and Flamme, 1995). 
Angiogenesis 
The transformation of this simple primary plexus to the highly branched, hierarchical 
structures we are used to seeing in anatomy texts is termed angiogenesis (see figure 1 B). 
This process is understood to occur though a variety of morphological changes of the 
capillary network (Patan, 2000). It includes the sprouting of new branches, the pruning 
of existing branches, the fusion of neighboring capillaries, the splitting of single 
capillaries into two (intussuception), as well as proliferative, apoptotic, and migratory 
events (reviewed in Patan, 2000; Yancopoulos et aI., 2000; Risau, 1997). Embryonic 
tissues devoid of angioblasts, such as the brain, are vascularized primarily through the 
sprouting of vessels from preexisting networks. It is becoming clear that the recruitment 
of supporting pericytes (Hirschi and D'Amore, 1996; Schor et aI., 1995) and smooth 
muscle cells (Oh et al.. 2000; Yancopoulos et aI., 2000; Folkman and D'Amore, 1996) is 
an essential event in angiogenesis. These cells provide trophic factors, stabilize vessels, 
and regulate their angiogenic state. Although most prominent during development, 
angiogenesis continues into adulthood, dependent on the organism's changing demands of 
blood supply. For example, angiogenesis during estrus (Tsukada et aI., 1996), wound 
healing, cardiac damage (Rasukan et a!., 1995; Schaper et a!., 1991), arthritis (Folkman, 
1995) and in tumor progression and growth (Fukumura et aI., 1998; Zetter, 1998; 
Folkman, 1995). 
Molecular Biology of Angiogenesis 
Inter-cellular signaling is an essential mediator of vasculogenic and angiogenic 
processes (Yancopoulos et aI., 2000; Gale and Yancopoulos, 1999). This fact has been 
revealed by the recent cloning and analysis of a number of vascular specific growth 
factors, receptor tyrosine kinases (RTKs), cell-adhesion molecules, and proteases 
(reviewed in Carmeliet, 2000; Yancopoulos et a!., 1998; Merenmies et aI., 1997; 
Friedlander et aI., 1995), including Vascular Endothelial Growth Factor (VEGF, 
Carmeliet et aI., 1996; Ferrara et aI., 1996), Angiopoietin-l (Ang-l, Davis et aI., 1996; 
Suri et aI., 1996; Sato et aI., 1995; Dumont et al., 1994), Platelet-Derived Growth Factor 
A 
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(PDGF, Hellstrom et ai., 1999: Hirschi et aL 1999). Transforming Growth Factor-~ 
(TGF-b Goumans et ai., 1999; Pepper, 1997; Oshima et a!., 1996; Dickson et aI., 1995), 
neuregulin (Kramer et aL 1996; Meyer and Birchmeier. 1995; Marchionni et aI., 1993), 
Delta-4 (Krebs et aI., 2000: Shutter et al., 2000), integrin avb3 (Friedlander et ai., 1995; 
Brooks et al., 1994a) and VE-Cadherin (Gory-Faure et ai., 1999; Breier et ai.. 1996). 
Mouse loss of function mutants of these genes have demonstrated their importance in 
embryonic angiogenesis (Adams et aI., 1999; Wang et ai., 1998; Merenmies et aI., 1997; 
Carmeliet et a1.. 1996: Ferrara et ai., 1996; Suri et aI., 1996: Guo-Hau et aI., 1995; Sato et 
aL 1995; Shalaby et al.. 1995). Continued expression of these genes in late embryonic 
and postnatal life suggested that they play additional important roles in vascular biology. 
Unfortunately the early lethality of most of the mutants has complicated an assessment of 
additional, later roles they might play. 
Most identified receptor tyrosine kinase systems mediate signaling between 
endothelial cells and their surrounding support cells (Gale and Yancopoulos, 1999). 
Recently, the Eph family of RTKs and their ligands, the ephrins, were identified as the 
latest RTK system involved in vascular development (reviewed in Adams and Klein, 
2000; Wang et al.. 1998). Extensive expression of multiple Eph receptors and their 
ligands in endothelial cells suggest that they mediate signaling between endothelial cells 
within vessels (Yancopoulos et aI., 2000; Adams et aI., 1999). Their additional 
expression outside the vasculature, though, has complicated our understanding of what 
tissue interactions are mediating their angiogenic acti vities in vivo (Y ancopoulos et aI., 
2000; Gale and Yancopoulos, 1999). Additionally. it is not clear which molecules are 
even essential for blood vessel development, given the expression of multiple ligands and 
receptors in overlapping in the vasculature (Adams et aI., 1999; Wang et aI., 1998). 
Initial knockout studies in mouse. however, clearly point to an important role for this 
RTK family in angiogenesis (Adams et aI., 1999; Wang et aI., 1998). 
I focus first on two important endothelial-specific receptor tyrosine kinases and their 
roles in angiogenesis. Although there are a growing number of molecules involved in 
angiogenic remodeling. I chose to describe Tie2 and VEGFRs in some depth given their 
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historical and developmental importance. They are arguably the most important 
regulators of vascular development identified to date (Carmeliet, 2000; Patan, 2000; 
Yancopoulos et aI., 2000: Gale et aI., 1996). This is followed by a detailed background 
on Eph receptors and their ligands in angiogenesis, which forms the basis for my thesis 
research, presented in Chapters 2 and 3. 
Vascular Endothelial Growth Factor 
The earliest identified RTK system whose expression is restricted to the vasculature 
is the Vascular Endothelial Growth Factor Receptor (VEGF) family of tyrosine kinase 
receptors (reviewed in Carmeliet and Collen, 1999; Dvorak et aI., 1999; Ferrara, 1999b; 
Ferrara, 1999a: Risau, 1997). These include VEGFRI (previously known as t1tl, 
Shibuya et aI., 1990), VEGFR2 (t1kl, Matthews et aI., ]991), and VEGFR3 (t1t4, 
Finnerty et aI., 1993). Neuropi1in-l, previoLlsly identified as the receptor for the 
semaphorin family of secreted axon guidance molecules (reviewed in Raper, 2000), has 
been recently shown to possess VEGF binding activity, and is also expressed by 
endothelial cells (Soker et aI., 1998). Neuropilin-l binds to a specific splice variant of 
VEGF-A, VEGF 165. and appears to act as a co-receptor with VEGFR2 (Whitaker et aI., 
2001; Miao et al., 2000; Soker et aI., 1998). This specificity ret1ects an emerging degree 
of complexity characteristic of most VEGF binding proteins (Robinson and Stringer, 
2001; Whitaker et al.. 2001; Poltorak et aI., 2000; Neufeld et aI., 1996). 
The VEGF ligands are a growing family of related proteins (reviewed in Carmeliet, 
2000; Poltorak et aI., 2000; Neufeld et aI., 1999). They are expressed on many stromal 
and mesenchymal cells, particularly in the area surrounding developing blood vessels 
(Miquerol et aI., 1999). VEGF-A, the founding member, exists as five different splice 
variants. VEGF 121 lacks the heparin-binding domain of the longer variants, and is 
therefore more diffusible. The other splice variants tend to bind to extracellular matrix 
adjacent to the cells in which they are expressed. VEGF-B through E, ligands related to 
VEGF-A, have been recently identified and appear to have more selective affinities for 
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the different VEGF receptors (reviewed 10 Carmeliet, 2000; Poltorak et aI., 2000; 
Neufeld et aI., 1999). 
Endothelial-specific expression of VEGF receptors 
Expression of VEGFR2 is initiated on mesodermal presumptive angioblasts around 
E7.0 in mOllse, marking endothelial precursors before they coalesce into blood islands 
(Drake and Fleming, 2000). VEGFRI expression follows soon after, at around E7.S, and 
is detected in the angioblasts of the blood islands (Fong et aI., 1996). The expression of 
these two receptors follows a similar time-course in the vasculature of the embryo proper 
(Drake and Fleming, 2000; Fong et aI., 1996). Their expression is maintained throughout 
embryonic development, and while VEGFR2 subsequently disappears, VEGFRI 
expression persists into adulthood (Beck and D'Amore, 1997; Merenmies et aI., 1997). 
Neuropilin-l expression appears to be restricted to arterial endothelial cells within the 
vasculature (Herzog et aI., 200 L Moyon et aI., 200 I), while Neuropilin-2 is restricted to 
veins (Herzog et aI., 2001) suggesting independent regulation of arterial and venous 
vessel development by differential receptor expression. VEGFR3 is expressed widely in 
the early vasculature, but becomes restricted to lymphatic vessels during embryonic 
development. VEGFR3 does not bind to VEGF-A, but instead is specific for VEGF-C 
and D, providing a mechanism by which vascular and lymphatic development can be 
regulated independently (Hamada et a!., 2000; Kaipainen et aI., 1995). 
Functional requirement for VEGF receptors during vascular development 
The targeted mutations in each of the VEGF receptors has suggested unique roles for 
each, from the earliest stages of vascular development (reviewed in Carmeliet, 2000). 
Mice lacking VEGFR2 fail to form any detectable endothelial cells, dramatically 
demonstrating this receptors' essential role in the specification and/or progression of 
endothelial precursors into mature endothelial cells (Shalaby et aI., 1995). The absence 
of hematopoetic precursors as well suggests a very early role for VEGFR2, in 
hemagioblast development. In contrast, VEGFRI knockout embryos do develop 
endothelial cells in the yolk sac which form blood islands, but these fail to coalesce 
normally, resulting in a disorganized and fused primary yolk sac plexus (Fong et aI., 
8 
1995). In the embryo proper. analogous defects are found in the assembly of major 
primary vessels, characterized by a striking overgrowth of their endothelial lining (Fong 
et al., 1995). This phenotype, unique to VEGFRI mutants, results in the presence of 
endothelial cells within the vascular lumen of most vessels. Both VEGFR1 and 2 
mutants die between E8.5 and 9.5 (Fong et al., 1995: Shalaby et al., 1995). It is believed 
that VEGFR2 signaling plays a major role in angiogenic sprouting, but this phenotype is 
masked by its earlier role in vasculogenesis (Carmeliet, 2000; Patan, 2000). VEGFR3 
knockout mice show normal vasculogenesis, but defective angiogenesis of the yolk sac 
and embryonic vasculature (Hamada et al., 2000; Dumont et al., 1998). Although 
restricted to lymphatic vessels after Ell, VEGFR3 is expressed in most endothelial cells 
in the early embryo, and appears to have an early role in the remodeling of these vessels. 
Neuropilin-l mutant mice, in contrast, show a much less severe phenotype, suggesting a 
later, more restricted role in vascular development (Miao and Klagsbrun, 2000; Kawasaki 
et al., 1999). 
VEGF function and cardiovascular development 
VEGF is a powerful endothelial mitogen and chemoattractant in vitro (Keyt et al., 
1996; Wilting et al., 1996), as well as a trophic factor for these cells (Benjamin et al., 
1998; Alon et al., 1995). VEGF can induce endothelial sprouts and tubule formation in 
cultured ECs (reviewed in Breier and Risau, 1996). Adult retroviral gain of function 
experiments in chick have demonstrated the ability of VEGF to enhance vascular growth 
in vivo (Flamme et al., 1995). VEGF-A homozygous mutant embryos display drastically 
reduced endothelial cell differentiation, aberrant angiogenic remodeling and vessel 
patterning, poor lumen formation, absence of large vessels, as well as defective 
endothelial interconnections (Carmeliet et al., 1996; Ferrara et al., 1996), resulting in 
embryonic lethality. Cardiac development was also arrested. This phenotype is seen, to 
a lesser extent, in heterozygous VEGF-A mutant mice, suggesting that a careful 
regulation of VEGF gene dosage is essential in orchestrating vascular development. The 
growing number of VEGF ligands may explain why a less severe phenotype is seen in the 
VEGF-A knockout compared to the VEGFR2 knockout (Carmeliet et al., 1996). 
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If VEGF can stimulate the proliferation of endothelial cells, why would loss-of-
function mutations in one of its receptors, VEGFR 1, lead to increased endothelial cell 
number and growth? Biochemical properties of this receptor, compared to those of 
VEGFR2 may be critical. VEGFR1 has a tenfold higher affinity for VEGF, yet also has a 
tenfold lower response to VEGF binding, as measured by kinase activation (Ferrara and 
Davis-Smyth, 1997; Sawano et aI., 1997; Sawano et a!., 1996; Mustonen and Alitalo, 
1995; Seetharam et a!., 1995; Shibuya, 1995). These data together suggest that VEGFRI 
may be acting as a competitive antagonist to VEGF signaling via VEGFR2, regulating 
the levels of free VEGF by binding and sequestering ligand. This model is supported by 
a study in which the intracellular, kinase-containing domain of VEGFR 1 was knocked 
out (Hiratsuka et a!., 1998). This resulted in no observable cardiovascular phenotype in 
either embryos nor postnatal animals. Thus the presence of the extracellular, ligand 
binding domain of VEGFR1 was sufficient to recapitulate its vascular function. In 
further support of this antagonist model, careful analysis of chimaeric mice derived from 
VEGFR 1-/- and +/+ ES cells have pointed to a cell non-autonomous function for 
VEGFR 1 in the negative regulation of hemangioblast determination: the absence of 
VEGFR1 appears to result in increased generation of endothelial precursors by 
specification, and not proliferation or reduced apoptosis (Fong et aI., 1999). Thus, the 
earliest role of VEGFRI may be to negatively regulate the generation of angiogblasts, 
without which ECs are produced in excess numbers, leading to vascular disorganization 
(reviewed in Yancopoulos et aI., 2000). 
VEGF signaling plays an important role in postnatal vascular development as well. 
Soluble VEGF receptor (VEGFR2), used as a VEGF antagonist, decreases postnatal 
angiogenesis in the mouse kidney (during nephrogenesis, Kitamoto et a!., 1997) and rat 
corpus luteum (during ovulation, Ferrara et aI., 1998). More recently, conditional 
knockout and in vivo knockdown studies in postnatal mice have revealed a more 
widespread requirement for VEGF in postnatal vascular development (Gerber et aI., 
1999). This study found that decreased levels of postnatal VEGF activity resulted in 
dramatic growth arrest and lethality. Analysis of endothelial cell survival in these mice 
revealed an increase in apoptosis, consistent with a trophic role for VEGF signals 
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(Benjamin et aI., 1998; Alon et aI., 1995). Treatment initiated progressively later after 
birth, however, revealed that the requirement for VEGF was gradually lost after 4 weeks 
of age (Gerber et aI., 1999). This result suggests that either the quiescent state of ECs, or 
additional survival factors, restrict the trophic requirement for VEGF to embryonic and 
early postnatal stages. 
Arterial and venous specific expression of neuropilin-l and 2, respectively (Herzog 
et a!., 2001; Moyon et aI., 2001), and the differential affinities of these and other VEGF 
receptors to spice variants of VEGF-A, and VEGF-B through E. reveal a high degree of 
complexity within the VEGF signaling system (Robinson and Stringer, 2001; Carmeliet, 
2000; Neufeld et aI., 1999; Poltorak et aI., 2000). While the importance of VEGF 
signaling in blood vessel development is undeniable, it is now clear that the nature of 
VEGF-induced blood vessel remodeling and growth is highly context dependent 
(Carmeliet. 2000). Although transgenic overexpression of VEGF does induce increased 
blood vessel growth, these vessels are leaky and highly permeable (Detmar et aI., 1998; 
Larcher et aI., 1998), suggesting that VEGF alone is insufficient to generate healthy 
mature vessels. This has had significant impact on initial hopes for the use of VEGF as a 
single-factor angiogenic therapy (Yancopoulos et aI., 2000). The identification and 
analysis of additional vascular specific receptor tyrosine kinases have shed light on the 
broader network of signals that are integrated in the tight regulation of blood vessel 
development (Carmeliet, 2000; Yancopoulos et aI., 2000; Gale and Yancopoulos, 1999). 
Endothelial-specific Tie receptors and their Angiopoietin ligands 
The Tie family of RTKs and their cognate ligands, the Angiopoietins, are expressed 
in a complementary fashion on endothelial cells and perivascular non-endothelial cells. 
respectively (Davis et aI., 1996; Dumont et aI., 1995; Dumont et aI.. 1992). Both Tie 1 
and Tie2 expression are initiated at E7.5 in the yolk sac, are shortly thereafter found in 
the rest of the embryonic vasculature, and persist into adulthood (Maisonpierre et aI., 
1997; Schlaeger et a1., 1997). Angiopoietin signaling is important for the remodeling of 
primary vascular plexi and stabilization of resulting vessel networks (Maisonpierre et aI., 
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1997; Suri et aI., 1996; Sato et aI., 1995). In contrast to the VEGF signaling pathway, the 
Ang/Tie system appears to have little function in earlier, vasculogenic processes. 
Tie2 function in embryonic cardiovascular development 
Tie2 knockout miee reveal a significant role for Angiopoietin signaling in 
angiogenesis. Tie2 homozygous mutants die around E9.5 of severe cardiovascular 
defects (Sato et aI., 1995). The primary plexi of the yolk sac and embryo form normally, 
but subsequent remodeling and growth of the vasculature is absent or severely retarded. 
Myocardial trabeculation of the heart is also absent, and is likely to be the ultimate cause 
of embryonic lethality (Sato et aI., 1995). Angiopoietin-1 (Ang-l), a secreted ligand for 
the Tie2 receptor, is expressed around E9 in the mesenchymal cells surrounding most 
developing blood vessels (Davis et aI., 1996; Suri et aI., 1996). Ang-l expression is 
maintained into adulthood (Maisonpierre et aI., 1997). The Ang-l knockout mouse 
shows a phenotype similar to that of the Tie2 mutant (Suri et aI., 1996). This suggests 
that Ang-1 may be the primary ligand for Tie2 in vivo (Gale and Yancopoulos, 1999; 
Suri et aI., 1996). The phenotypes of both the Tie2 and Ang-l knockout mice include the 
poor recruitment of, and association of ECs with, Ang-l expressing support cells, 
pericytes and smooth muscle cells around capillaries and larger blood vessels (Suri et aI., 
1996; Sato et aI., 1995). The same failure of association is seen in the heart. This 
suggests an intimate relationship between, and interdependence of, endothelial cells and 
their support cells during angiogenesis. Ang-l exhibits chemoattractive properties on 
cultured endothelial cells and can induce in vitro sprout formation under certain 
conditions (Koblizek et a1.. 1998; Witzenbichler et aI., 1998; Davis et aI., 1996), 
providing possible mechanisms by which Ang-1 signals from support cells could 
modulate endothelial cell behavior. 
Current models of Ang-l/Tie2 signaling involve a reciprocal relationship between 
endothelial cells and support cells (see Figure 2, and Folkman and D'Amore, 1996). It is 
believed that Ang-l stimulation of endothelial cells induces expression of signals 
chemoattractive to smooth muscle cells and pericytes, perhaps via the ligand PDGF 
(Crosby et aI., 1998; Lindahl et aI., 1998; Lindahl et aI., 1997; Leveen et aI., 1994). 
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Contact with endothelial cells induces the expression of TGF-~ in support cells, which 
inhibits endothelial cell proliferation and motility (Hirschi et aI., 1999; Pepper, 1997; 
Dickson et aI., 1995; Antonelli-Orlidge et aI., 1989). In this way, reciprocal signaling 
between endothelial cells and their surroundings results in recruitment of support cells, 
and a decrease in angiogenic activity (Hirschi et aL 1999; Pepper, 1997). The net result 
is a recruitment of support cells, ensuring the stabilization of newly formed vessels 
(reviewed in Folkman and D'Amore, 1996). Genetic analysis of human familial venous 
malformations has pointed to mutations in the human Tie2 gene as the responsihle defect, 
arguing that the function of Ang/Tie2 signaling may be conserved between species 
(V ikkula et al., 1996). 
Ang-l / Ang-2 antagonism 
Angiopoietin 2, (Ang-2), a ligand related to Ang-l, can bind to Tie2 receptor 
(Maisonpierre et aI., 1997). Unlike Ang-l, however, Ang-2 hinding does not induce 
receptor activation in Tie2 expressing endothelial cells. Likely due to this property, Ang-
2 can antagonize Ang-l signaling through the Tie2 receptor, and is thus believed to he a 
negative modulator of this signaling system (Maisonpierre et aI., 1997). Transgenic 
vascular overexpression of Ang-2 results in a phenotype nearly identical to that of both 
Tie2 and Ang-J loss of function mutants (Maisonpierre et aI., 1997), supporting the idea 
that Ang-2 antagonizes Ang-IITie2 signaling (reviewed in Yancopoulos et aI., 2000; Gale 
and Yancopoulos, 1999; Korpelainen and Alitalo, 1998). It has been proposed that a 
careful control of Ang-lITie2 signaling, in part modulated by Ang-2 antagonism, 
regulates the angiogenic competence of blood vessels (Maisonpierre et aI., 1997). By 
promoting the association of ECs and support cells, Ang-l signaling is thought to 
stahilize vessels. This stabilized state is thought to be non-permissive, reducing 
angiogenic competence. EC-pericyte association decreases the anglOgel1lC and 
proliferative response of endothelial cells to VEGF (Hirschi et aI., 1999; Antonclli-
Orlidge et al., 1989), thereby reducing angiogenic events (see Figure 2). By antagonizing 
Ang-l signaling, Ang-2 would oppose such vessel stabilization, thus promoting a more 
plastic EC state (see Figure 3). 
Ang-l 
# 
PDGF 
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Figure 2 - Endothelial-pericyte interactions mediated 
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Angiogenesis is regulated by the integration of VEGF and Angiopoietin RTK 
systems 
According to current models (see Figure 3). Ang-2 antagonism in the presence of 
VEGF results in sprouting and invasive angiogenic growth: this relieves Ang-1 
stimulation, and decreases pericyte association, thus restoring angiogenic responsiveness. 
Conversely, Ang-2 signaling in the absence of VEGF results in vessel regression and 
pruning: the stabilizing activity of Ang-I is lost, and no angiogenic or EC trophic factor 
is present (Yancopoulos et a!., 2000; Gale and Yancopoulos. 1999; Maisonpierre et aI., 
1997). The observed Ang-2 expression pattern supports this model. While Ang-l 
expression is widespread (Davis et a!., 1996; Suri et al.. 1996). Ang-2 is found primarily 
at sites of vascular remodeling (Maisonpierre et a!., 1997). In the embryo, Ang-2 is 
expressed by mesenchyme and other cells surrounding vascular sprouts (Maisonpierre et 
a!., 1997). Its expression does not persist into adulthood except in tissues still undergoing 
angiogenesis, for example in the post-natal kidney and the female reproductive system 
(Maisonpierre et al.. 1997). During ovulation, Ang-1 and Ang-2 are simultaneously 
expressed in the adult rat corpus luteum with VEGF, promoting invasive angiogenic 
vascularization. During the vascular regression phase, VEGF expression is decreased, 
while Ang-2 is still present, leading to a controlled regression of blood vessels. Finally, 
Ang-l is expressed alone. stabilizing the remaining vessels (Maisonpierre et al.. 1997). 
IS 
Both VEGF and Angiopoietin signaling systems are essential for angiogenesis, but 
appear to act through different morphogenic mechanisms (Carmeliet, 2000). VEGF acts 
directly on endothelial cell behavior, survival, and proliferation to affect vessel growth. 
Tie2/ Angiopoeitin signaling promotes association between endothelial cells and the 
adjacent support cell population in both the vasculature and heart. This signaling from 
support cells to receptor expressing ECs appears to be critical for their association, as 
well as the remodeling of the vessels they comprise. Endothelial cells experience a 
combination of positive and negative Angiopoietin signals on the same receptor system, 
which results in a net output of the Tie2 signaling pathway. This Tie2 signaling is 
interpreted in combination with all other angiogenic signals, such as VEGF, integrated to 
give the required endothelial and vessel behavior (see Figure 3, and Maisonpierre et aI., 
1997). 
Cadherins and integrins 
Two types of adhesion molecules with roles in angiogenesis are the cadherins and 
the integrins (Bazzoni et aI., 1999). VE-cadherin is specific to endothelial cells (Breier et 
aI., 1996), and is essential for some aspects of vasculogenesis and angiogenesis (Corada 
et aI., 2001: Cam1eliet et aI., 1999; Gory-Faure et aI., 1999; Vittet et aI., ] 997). Although 
cadherins typically mediate homophilic adhesion, inter-endothelial junctions appeared to 
form normally, as did the primary vascular plexi in VE-Cadherin mutant mice. Rather, 
vessel remodeling and maturation was affected, including increased endothelial apoptosis 
(Carmeliet et a1., 1999; Gory-Faure et aI., 1999). VE-Cadherin mutant endothelial cells 
appear unable to respond to VEGF, demonstrating a potential mechanism for the 
observed defects. 
Integrins have dual roles of adhesion to extracellular matrix and detecting 
extracellular cues (i.e., prothrombin, Van Wildebrand Factor, and vitronectin, Alberts et 
a1.. 1994). Particular integrins have been implicated in embryonic and tumor-induced 
angiogenesis (Friedlander et a1., 1995; Brooks et aI., 1994a; Brooks et al., 1994b). a5~3 
integrin has been detected on angiogenic ECs (Brooks et al., 1994a), and antibodies to 
a5~3 block normal angiogenesis as well as FGF- and tumor-induced angiogenesis in 
16 
chick (Friedlander et aI., 1995: Brooks et aI., 1994a; Brooks et aI., 1994b), and human-
mouse xenografts (Mitjans et aI., 1995). Integrins have been shown to interact with both 
secreted and cell-surface molecules. Integrin ~3 can be co-immunoprecipitated with 
activated, but not unstimulated, VEGFR2 (Soldi et aI., 1999). a5~3 has also been shown 
to modulate the activation of VEGFR2 by VEGF-A (Soldi et aI., 1999). Recently, it was 
shown that VEGF-A can activate a5~3 through VEGFR2, and blocking antibodies to this 
integrin inhibit VEGF-induced proliferation, migration, and polarization of ECs in vitro 
(Byzova et aL 2000: Soldi et a1.. 1999). These data implicate integrins in a number of 
aspects or angiogenesis, and reveal important interactions with other endothelial 
signaling pathways. 
Ephrins 
There is accumulating evidence that the EPH receptor tyrosine kinases and their 
ligands play an important role in cardiovascular development (Adams and Klein, 2000; 
Yancopoulos et aI., 2000; Gale and Yancopoulos, 1999). Initial evidence came from 
expression data and cell culture experiments (Daniel et aI., 1996; Pandey et aI., 1995; 
Sarma et aI., 1992; Holzman et at., 1990), but has recently been strengthened by mouse 
knockouts of selected ephrins and Eph receptors (reviewed in Adams and Klein, 2000; 
Yancopoulos et aI., 2000; Gale and Yancopoulos, 1999). We are just beginning to 
uncover the role played by Eph signaling in angiogenesis. The objectives of my thesis 
research arose from previous work in our lab and others (Adams et aI., 1999: Wang et aI., 
1998). I will present this background of the involvement of Eph signaling in 
angiogenesis here. My contributions to this field, the actual contents of my thesis 
research, will be presented separately, as Chapters 2 and 3, which represent published 
work, and work submitted for publication, respectively. 
The Eph receptor tyrosine kinases comprise the largest family of RTKs (Wilkinson, 
2(00). Members of this receptor family have been classified into A and B subfamilies 
based on sequence homology (see Figure 4). This categorization is also ret1ected in their 
differential affinity for two structurally distinct classes of ligands, the A and B ephrins 
(Gale et ai., 1996). EphA receptors bind to ephrin A ligands, a group of GPI linked, cell 
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surface anchored proteins. The EphB receptors bind to ephrin B ligands, which are 
transmembrane proteins with a highly conserved intracellular domain. Surface 
localization of ephrins limits them to mediating signaling via direct cell-cell contact. 
This is in contrast to the longer range signaling available to the secreted VEGF and 
Angiopoietin ligands. Within a receptor subfamily. ligand binding is typically highly 
promiscuous, providing a variety of potential receptor-ligand interactions (Gale et aI., 
1996; Sakano et aI., 1996; Brambilla et aI.. 1995). Notable exceptions to this promiscuity 
are the restricted specificities of EphA 1 to ephrinA 1. EphB4 to ephrinB2, and between 
families, of EphA4 to ephrinB2 (O'Leary and Wilkinson. 1999; Gale et aI., 1996). The 
ability of recombinant soluble ligand-bearing molecules to stimulate receptor activation 
depends on the degree of multimerism of the ligands (Stein et aI., 1998; Davis et aI., 
1994). A similar degree of clustering may be required at the cell-surface for ephrin 
signaling in vivo (Adams et a1., 1999; Davis et aI., 1994). Transmembrane ephrinB 
ligands, upon receptor engagement, can undergo phosphorylation on a series of 
conserved tyrosine residues in their intracellular domain (reviewed in Adams et aI., 2001; 
Wilkinson, 2000; Mellitzer et aI., 1999; Xu et aI., 1999; Bruckner et aI., 1997; Holland et 
aI., 1996). This suggests that ephrinB ligands, in addition to acting as traditional RTK 
ligands. can transduce signals cell-autonomously. This provides a mechanism for 
Eph/ephrin signaling to mediate reciprocal, or bi-directional signals between receptor and 
ligand bearing cells. 
Eph receptors and their ligands are often found expressed in complimentary patterns 
in the developing embryo, with ligand and receptor present in adjacent tissue domains 
(Flanagan and Vanderhaeghen, 1998; Flenniken et aI., 1996; Gale et aI., 1996)]. In the 
developing hindbrain, for example, ephrin ligands and receptors are found in alternating 
rhombomere domains (Krull et aI., 1997; Wang and Anderson. 1997; Gale et aI., 1996). 
Ectopic expression of ligands and receptors can disrupt normal tissue patterning in the 
hindbrain, leading to cell mixing across normally restrictive tissue boundaries (Mellitzer 
et aI., 1999; Xu et aI., 1999; Xu et aI., 1995). Ephlephrin signaling has been found to be 
important in vertebrate axon guidance, fasciculation, neural crest cell migration, and 
somite patterning (Adams et aI., 2001; Durbin et aI., 1998; Frisen et al., 1998; Krull et aI., 
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1997; Wang and Anderson, 1997; Henkemeyer et aI., 1996; Xu et aI., 1996; Drescher et 
aI., 1995). In most of these studies, Eph signaling has been ascribed repulsive roles, and 
may contribute to the formation and/or maintenance of tissue boundaries during 
development (reviewed in Wilkinson, 2000; Gale and Yancopoulos, 1997). 
A Subfamily 
The earliest evidence of ephrins in the vasculature comes from the original cloning 
of the ephrin-A 1 ligand, which was identified based on its differential expression in TNF-
a stimulated versus unstimulated endothelial cells (Sarma et aI., 1992; Holzman et aI., 
1990). It has since been shown that ephrin-Al can induce neoangiogenesis in a rat 
corneal pocket assay. Antibodies to this ligand block the angiogenic activity of TNF-a in 
this same assay, revealing a role in this angiogenesis model system (pandey et aI., 1995). 
Subsequent ill vitro work has demonstrated that clustered ephrin-A 1 can induce tube and 
sprout formation in cultured endothelial cells. suggesting a potential angiogenic role for 
ephrin signaling to ECs (Daniel et aI., 1996). EphrinAI is expressed in the early 
embryonic mouse vasculature (McBride and Ruiz, 1998; Flenniken et aI., 1996) and is 
present in most, but not all vessels between E7.5 and E 10.5 (McBride and Ruiz, 1998). 
This includes sites of both vasculogenesis and angiogenesis. EphrinA 1, however, is not 
expressed in the yolk sac, a site of extensive vasculogenesis and angiogenesis at the 
stages examined (McBride and Ruiz, 1998). This reveals a level of heterogeneity 
between endothelial cells of different vascular beds at early stages of vascular 
development. This suggests a role for ephrins in endothelial cell diversity, a feature also 
present in ephrinlEPH B family member expression (see below: Adams et aI., 1999; 
Wang et aI., 1998). These data argue that an ephrinA 1 knockout might disrupt blood 
vessel development. No ephrinAl knockout has yet been described. 
B Subfamily 
Expression 
EphB 1 and ephrinB 1 are expressed in both cultured human renal microvascular 
endothelial cells, and human umbilical vein endothelial cell, as well as postnatal and 
adult rat kidney microvessels (Daniel et aI., 1996). EphB2 has also been detected in 
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cultured human renal microvascular endothelial cells (Stein et a!., 1998). More recently, 
embryonic vascular expression of B family receptors and ligands was shown in the yolk 
sac and embryo proper and of mouse starting at E7.S (Wang et a!., 1998). EphrinB2 
ligand and EphB4 receptor expression was found in endothelial cells of large and small 
vessels. The pattern of expression is striking, with ephrinB2 restricted to arteries and 
EphB4 restricted to veins (see Figure 5, and Wang et a!., 1998). This complimentary 
expression of ligand and receptor is the earliest molecular indication of Arterio-Venous 
(A-V) endothelial diversity. These data suggest that ephrin signaling occurs between 
arteries and veins throughout the embryo (Wang et a!., 1998). 
Although Wang et a!. determined EphB4 to be the only B family receptor expressed 
in the early vasculature, a later study described more extensive representation of EphB 
receptors and their ligands in and around the embryonic vasculature (Adams et a!., 1999). 
EphrinB 1 was shown to be expressed in both arteries and veins. EphrinB2, although 
restricted to arterial endothelial cells within the vasculature, is also expressed widely in 
non-vascular tissues of the embryo (see Figure 6 and Adams et a!., 1999; Wang et a!., 
1998). EphB3, like EphB4, is primarily restricted to venous vessels, but is expressed in 
the aortic arches of the heart as well (Adams et a!., 1999). EphB2 was shown to be 
expressed in perivascular mesenchymal cells of the embryo proper (by lacZ allele 
replacement) and in the yolk sac (by RT-PCR, Adams et a!., 1999). It is not clear which 
cells in the yolk sac express EphB2. Therefore, while the study by Wang et a!. suggests 
that that ephrin/Eph signaling is mediating EC-EC communication (artery to vein), 
Adams et a!. present evidence of a more complex situation in which epbrin/Epb signaling 
occurs both between EC cells, and between EC cells and their surrounding environment 
(see below for more discussion, and Adams et a!., 1999; Gale and Yancopoulos, 1999; 
Wang et a!., 1998). 
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Figure 5 - EphrinB2 expression in the vasculature 
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Figure 6 - EphrinB2 is widely expressed in the embryo 
Previously, it was generally believed that vessel and endothelial cell identity was 
established by the local hemodynamic forces, and arterial versus venous identity was 
defined simply by direction of blood flow. Additionally, capillary beds were thought to 
bear neither arterial nor venous identity (Hanahan, 1997; Risau, 1997; Folkman and 
D'Amore, 1996). The expression of ephrinB2 in arteries but not veins at E7.S (Wang et 
al., 1998) indicates that vessel and EC identity are in fact established before the onset of 
blood flow. As will be described below. these differences appear to be essential for the 
development and remodeling of the vasculature. Additionally, careful analysis of the 
lacZ knock-in to the ephrinB2 locus showed that arterial and venous identity extends far 
into the capillary beds, to what may be a direct arterio-venous interface, delimited by 
ephrin ligand and receptor expression (Wang et al., 1998). These data have therefore 
changed the way we think about arterial and venous identity, and vascular topography 
(Adams and Klein, 2000; Yancopoulos et aI., 2000; Gale and Yancopoulos, 1999; 
Yancopoulos et aI., 1998). 
Knockout phenotypes 
The knockout of ephrinB2 shows a dramatic arrest of vascular development at the 
primary plexus stage, and defective cardiac development (Adams et aI., 1999; Wang et 
aI., 1998). By E8.S primary vascular pie xi have formed in both yolk sac and embryo 
proper. By E9.S, however, it is evident that angiogenic remodeling and growth are 
stunted in the ephrinB2 mutant. The yolk sac vasculature of mutant embryos retains its 
immature, homogeneous pattern of small capillaries. Sites of angiogenic invasion, such 
as the brain and neural tube show defective vascularization (Adams et aI., 1999; Wang et 
aI., 1998). In the wild type, the yolk sac at this stage has remodeled into a hierarchy of 
large and small vessels, and the brain and neural tube have extensive vascular in-growth. 
As mentioned above, the expression of ephrinB2 in all arterial ECs, and the observed 
expression of only one EphB receptor in the vasculature, EphB4 (Wang et aI., 1998), 
restricted to venous vessels, suggested signaling from arteries to veins. The angiogenic 
defects in the ephrinB2 knockout further indicated that this A-V signaling may be 
important for blood vessel development. In the ephrinB2 knockout, not only venous, 
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EphB4 receptor-bearing capillaries were affected, but the arterial ephrinB2 ligand-
bearing capillaries also failed to undergo angiogenesis (Wang et a!., 1998). Consistent 
with the concept of reverse signaling through ephrin ligands (Holland et a!., 1996), these 
data argue that reciprocal signaling between ephrinB2 and EphB4 on arteries and veins is 
an obligate event in angiogenesis (Wang et aI., 1998). This model has been further 
validated by a recent study in which the intracellular domain of ephrinB2 was shown to 
be essential in vivo (Adams et aI., 2001), without which angiogenesis defects were 
observed. similar to the conventional ephrinB2 mutants. 
The more extensive expression of multiple ephrinB ligands and receptors described 
in a later study (Adams et a!., 1999) suggested a more complex scenario. It raised the 
possibility that the phenotype of the ephrinB2 knockout reflects not only interactions at 
the A-V boundary, but also signaling between ECs and their surrounding environment, 
between ECs within arteries, and within veins (see Figure 7). Consistent with this, the 
ephrinB2 knockout phenotype showed defective intersomitic vessel guidance (Adams et 
ai., 1999), where vessels normally migrate adjacent to ephrinB2-expressing somitic 
mesenchyme. These data suggest that different ephrins and Ephs might mediate different 
signaling modalities (Artery to Vein, mesenchyme to endothelial cell), and multiple 
independent activities of endothelial cells during angiogenesis (i.e., sprouting versus 
guidance) (Adams et aI., 1999). EPH-B2IEPH-B3 double homozygous mutant mice 
exhibit a low penetrance, variable expressivity phenotype in which some aspects of 
angiogenesis are shown to be defective, similar to the ephrinB2 knockout phenotype 
(Adams et a1.. 1999). The lack of a phenotype in the EphB3 knockout mice suggests that 
this receptor may be redundant to EphB4 function in veins during angiogenesis (Adams 
et aI., 1999). Furthermore, the function of EphB2 in perivascular cells may be in a 
related genetic pathway, given that a phenotype is seen only in the compound 
homozygote for the EphB2 and B3 mutations, but not in either single knockout. It is, 
therefore, not clear whether expression of multiple Ephs and ephrins represents 
independent pathways (Adams and Klein, 2000; Adams et a!., 1999), redundancy, or 
simply non-essential expression of some receptors and ligands. 
~ ephrinB1 ~ EphB2 
'ephrinB2 Y EphB3 
Y EphB4 
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Figure 1- Range of potential Eph signaling in the vasculature 
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It is counterintuitive that multiple ephrin/EphB subfamily members would be used in 
a given organ, let alone in a single cell type, for mediating multiple independent 
developmental functions: the observed binding promiscuity that is the supposed hallmark 
of the Eph signaling system suggests this would not be possible (Labrador et ai., 1997; 
Gale et aI., 1996), The regulation of this specificity. however, may lie in the observed 
differences in cellular responses to clustered versus mono- and dimeric ligand (Stein et 
aI., 1998; Davis et al., 1994), in receptor- or ligand-specific downstream effectors, or 
simply through differences in receptor/ligand affinities not manifested in soluble ligand 
binding assays. Cultured endothelial cells expressing EphB receptors can discriminate 
between dimeric and multimeric forms of ephrin-B 1, while the EphB receptors 
themselves cannot, as they are phosphorylated upon stimulation by either form in vitro 
(Stein et aL 1998). Despite structural similarities, therefore, different receptors may 
activate different downstream signaling pathways. An important exception to the 
promiscuity of Eph receptors is EphB4, whose binding is restricted to ephrinB2 (Sakano 
et aI., 1996; Brambilla et aI., 1995). This suggests a potentially unique role for this 
receptor (Gale and Yancopoulos, 1999). 
EphrinB 1: Redundant, or irrelevant? 
Despite being co-expressed with ephrinB2 ligand in arteries, ephrinB 1 is unable to 
compensate for the loss of this ligand in the ephrinB2 knockout (Adams et aI., 1999; 
Wang et aI., 1998). Why does ephrinBI not compensate for the loss of ephrinB2? Of all 
ephrinB ligands, only ephrinB2 can bind to EphB4 with high affinity (Sakano et a!., 
1996; Brambilla et al., 1995). If EphB4 and EphB3 have some non-overlapping 
functions during angiogenesis, then the inability of ephrinB 1 to signal through EphB4 
would result in a phenotype. As I will show in Chapter 1, EphB4 is in fact not 
compensated for by EphB3, leading to defects in vessel remodeling 111 the EphB4 
knockout apparently identical to those of the ephrinB2 knockout (Gerety et a!., 1999). 
Second, differences in expression levels between the two ligands could result in different 
signaling outcomes. Third, the reverse signals transduced by these two ligands may in 
fact activate different downstream pathways. Finally differences in expression pattern 
could account for the observed inability of ephrinB 1 to compensate for ephrinB2. While 
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ephrinB 1 is expressed in all endothelial cells, ephrinB2 expression in the vasculature is 
restricted to arteries (Adams et aI., 1999; Wang et aI., 1998). Thus, the arterial restriction 
of ephrinB2 may be an important aspect of its angiogenic function. In non-vascular 
tissues as well, these two ligands are not expressed in completely overlapping patterns 
(Wang and Anderson, 1997), and ephrinB 1 may be absent from tissues in which 
ephrinB2 expression is essential for angiogenesis. 
Outstanding issues 
Which molecules are required for angiogenesis? 
In developing and refining models of Eph/ephrin function in angiogenesis, there are 
important questions to be answered. Identifying which molecules are required enables us 
to reduce the complexity of potential interactions (see Figure 7). This approach has 
identified ephrinB2 as an essential angiogenic factor (Adams et aI., 1999; Wang et aI., 
1998). The importance of both EphB2 and EphB3 is unclear, since neither knockout 
alone shows any vascular phenotype (Adams et aI., 1999). It is difficult, though not 
impossible, to imagine that they are redundant to one another given that they are 
expressed in different cell populations. This means they either have no role, or are 
redundant to other Eph receptors such as EphB4. Although ephrinB 1 cannot compensate 
for the loss of ephrinB2, it may still have some function in angiogenesis (Adams et aI., 
1999). We await with interest the description of a mice lacking ephrinB 1. Given the 
importance originally ascribed to EphB4, even more so after the EphB3 knockout was 
shown to have no phenotype, I chose to carry out the knockout of EphB4 in mouse. 
Chapter I that follows is an analysis of the phenotype seen in this mutant, identifying it as 
the only Eph receptor required for angiogenesis (Gerety et aI., 1999). 
Which tissue source is required for angiogenesis? 
Determining which tissue source for ephrins/Ephs is required for angiogenesis is 
another important question in understanding the actual cellular and morphological 
function(s) of Eph signaling in vascular development (Yancopoulos et aI., 2000; Gale and 
Yancopoulos, 1999). Since some receptors and ligands display more restricted 
expression patterns, conventional knockouts will help address this issue (see Figure 7, 
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and Adams et aI., 1999; Wang et aI., 1998). For example, I show in Chapter 2 the EphB4 
expression is restricted to endothelial cells, mainly in veins, and is absolutely required of 
angiogenesis (Gerety et aI., 1999). Thus signaling through vein-specific EphB4 is one 
essential tissue interaction. Signaling by VEGF and Angiopoietin enables a given tissue 
to signal to neighboring vessels (Yancopoulos et aI., 2000). The question arises, 
therefore, as to whether ephrins might play a similar role (Adams and Klein, 2000; 
Yancopoulos et aI., 2000; Adams et aI., 1999). 
Expression of ephrinB2 in the yolk sac is specifically in ECs, and not in perivascular 
cells (Wang et aI., 1998). In this tissue, therefore, the ephrinB2 knockout phenotype 
leads to a clear interpretation: ephrinB2 expression is required in ECs, arterial in this 
case, for angiogenesis (Wang et aI., 1998). This does not, however, preclude a role for 
perivascular ephrinlEph signals in the rest of the embryo. In fact, even in the yolk sac, 
such an apparently clear result is complicated by the fact that ephrin ligands may act as 
receptors. Therefore, Eph receptors expressed in non-vascular yolk sac cells may provide 
reverse signals to vessels (Adams et aI., 1999). The lack of yolk sac phenotype in the 
EphB2 knockout (Adams et aI., 1999), however, suggests that this its presence may not 
be required in angiogenesis. 
In the embryo proper, where more widespread expression is seen of both ephrinB2 
and Eph receptors, the role of perivascular cells is less clear (Adams et aI., 1999; Gale 
and Yancopoulos, 1999). There are many sites of Eph receptor and ligand expression 
surrounding regions undergoing angiogenesis (Adams et aI., 1999; Wang et aI., 1998). 
The development of intersomitic vessc!s (ISVs) of the trunk is a striking example: 
ephrinB2 ligand is expressed both in arterial ISVs, and in adjacent somites (Adams et aI., 
1999; Wang et aI., 1998; Wang and Anderson, 1997), while EphB3 and EphB4 are 
expressed on venous ISVs (Adams et aI., 1999; Gerety et aI., 1999). In some ephrinB2 
homozygous mutant embryos, the ISVs grow aberrantly into the somites, rather than 
following their normal pathway along the intersomitic space (Adams et aI., 1999). A 
similar situation is seen in Xenopus embryos after forced expression of ephrins or 
dominant negative Eph receptors (Helbling et aI., 2000). Unfortunately, both studies 
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involved systemic disruption of Eph signaling, thus yielding unclear results as to which 
tissue expressing ephrinB2 was actually required for the observed guidance role. I chose 
to address the crucial issue of required tissue source by performing a tissue-specific 
conditional knockout of ephrinB2, in the vasculature, described in Chapter 2. This study 
reveals the importance of ephrinB2 expression in arterial endothelial cells for proper 
angiogenesis, thus underscoring the original interpretation of the ephrinB2 knockout 
(Wang et aI., 1998). 
What is the cellular role of ephrin signaling in angiogenesis? 
In other systems, Eph receptors and ligands are expressed 111 adjacent tissue 
compartments, and appear to repulsively inhibit cell-mixing between tissues (reviewed in 
Wilkinson, 2000). Restricting arterial and venous cells from intermixing would have 
obvious benefits in maintaining vessel-specific identity and function (Gale and 
Yancopoulos, 1999; Wang et aI., 1998). The data from the ephrinB2 knockout, however, 
reveal that ephrinB2 does not fulfill this role. In the absence of this ligand in arteries, the 
yolk sac arterial and venous domains appear to be normally segregated: no increase in 
cell mixing is observed at the A-V boundary (as revealed by ephrinB2 expression, Wang 
et a!., 1998). Since no other known ephrin ligands show artery or vein specific restriction 
(Adams et aI., 1999), it is unlikely that the lack of mixing in the ephrinB2 mutants is due 
to redundancy. There must be, therefore, other molecules responsible in the segregation 
of arterial and venous endothelial cells at the A-V interface. The persistent arterial 
restriction of ephrinB2-lacZ expression in the ephrinB2 null mice also suggests that this 
ligand is not required for the actual specification of arterial or venous identity (Wang et 
a!., 1998). Since the publication of the original ephrinB2 knockout mice, there has been 
an increased interest in arterio-venous identity, including studies identifying genes with 
differential A-V expression patterns (Moyon et a!., 2001; Shutter et a!., 2000), and others 
that appear upstream of ephrinB2expression in arteries (Larsson et a!., 2001; Lawson et 
aI., 2001; Oh et a1., 2000) that might fulfill these roles. 
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Model I: sprouting 
The most harmonious, if simplistic, model of Eph/ephrin function in angiogenesis is 
a sprouting, or arborizing effect on vessels. EphrinB ligands can promote endothelial cell 
sprouting in vitro, with activities similar to that of VEGF (Adams et aI., 1999). Eph 
signaling can also induce endothelial tubule formation (Daniel et aI., 1996). The 
ephrinB2 knockout results in defective and arrested elaboration of a capillary plexus (in 
the head, and intersomitic vessels, respectively) (Adams et aI., 1999; Gerety et aI., 1999; 
Wang et aI., 1998). Since extensive elaboration of a capillary network occurs typically at 
the A-V interface, the reciprocal expression of ephrinB2 and EphB receptors at this locus 
provides them with the opportunity to fulfill a pro-angiogenic, sprouting role (see Figure 
8A). Together, these data strongly argue that Eph/ephrin signaling plays this role. 
A10del II: inhibition of vessel fusion 
Ephrin signaling could have a very different function, however, that would result in 
the same appearance of elaborative remodeling in wildtype mice. Eph/ephrin signaling at 
the A-V interface could inhibit the fusion of microvessels into larger diameter vessels 
(Gale and Yancopoulos, 1999). Thus in the capillary beds, vessels would remain small, 
while vessel regions farther from the A-V interface, not experiencing Eph signaling, 
would be capable of fusing, creating larger vessels (see Fig. 8B). Since we know that the 
arborization in some vessel beds (i.e., intersomitic vessel network) does not result simply 
from remodeling of preexisting vessels, but rather the appearance of new ones (by 
sprouting), this model would require a separate mechanism to generate these new vessels 
upon which Eph signaling could act. The sprouting and proliferative effects of VEGF 
make this angiogenic factor a good candidate for this function. The apparently graded 
expression of EphB4 receptor in veins and some arteries (see Chapter 1, Gerety et aI., 
1999) is consistent with both this and the previously described model. 
Data from ephrinB2 knockout mice suggest that neither of these mechanisms alone is 
correct. While vessels in some tissues do show increased fusion in the ephrinB2 
knockout (head and trunk), others appear to show an opposite phenotype, remaining in a 
primitive plexus state (yolk sac, anterior cardinal veins). While the lack of elaboration of 
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Figure 8 - Models for Ephlephrin activity at the A-V interface 
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intersomitic vessels in the ephrinB2 mutant supports a sprouting model, the head 
vasculature does show some degree of sprouting angiogenesis, albeit disorganized 
(Adams et aI., 1999: Gerety et al.. 1999: Wang et aI., 1998). The diversity of 
angiogenesis defects in the ephrinB2 knockout could be due to region-specific 
differences in angiogenic mechanisms. Endothelial cells of di fferent vascular beds (yolk 
sac, head) could have tissue-specific responses to Eph signaling. This is supported by 
known tissue-specific endothelial-cell diversity. Alternatively, non-endothelial 
differences in tissue environment could change the final vessel remodeling. EphrinB2 
knockout mice show decreased Angiopoietin-l expression in the embryo (Adams et aI., 
200 I). Since Ang-l promotes larger vessels, decreased Ang-l signaling in the yolk sac 
could lead to the phenotype seen there (absence of large vessels). Tissue-specific 
differences 111 Ang-112 signaling would then generate the different phenotypes seen 
throughout the ephrinB2 knockout. The presence of other, as yet uncharacterized ephrins 
(A 1, B I) in the vasculature could represent some level of redundancy. Finally, some of 
the observed phenotypes could be secondary to other vascular and cardiac defects. For 
example, the absence of yolk sac remodeling could be due to poor or absent blood flow 
through this tissue, rather than a requirement for ephrinB2 in the yolk sac itself (see 
Chapters 2,3 and concluding remarks). These issues cannot be resolved without more 
controlled genetic manipulation of Eph/ephrin expression in vivo (i.e., conditional 
knockouts ). 
Whether Eph/ephrin activities arc restricted to inter-endothelial signals is not clear, 
since both ephrinB2 and EphB2 are expressed in perivascular cells (see Figures 6 and 7, 
and Adams et aI., 1999: Wang et aI., 1998). The absence of a phenotype in EphB2 
mutant mice (Adams et al., 1999), and as I shall present in Chapter 2 the requirement for 
EphB4 specifically in veins for angiogenesis (Gerety et aI., 1999), strongly argue that 
inter-endothelial signals are the crucial angiogenic stimuli. Nonetheless, as described 
above, expression of ephrinB2 in perivascular mesenchymal cells, and the observed 
EphB expression in these tissues, is consistent with a model of endothelial to 
mesenchymal cell reciprocal signaling. As I present in Chapter 3, perivascular ephrinB2 
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is insufficient to support angiogenesis in the absence of vascular expression, suggesting 
endothelial ephrinB2 plays a critical role. 
The steadily expanding repertoire of known endothelial-specific tyrosine kinase 
receptors is revealing a high level of complexity in the regulation of vascular remodeling. 
Most evidence indicates extensive interaction and coordination of these signaling 
pathways: Ang-I can modulate VEGF activities (Asahara et ai., 1998), Ang-2 modulates 
Ang-l signaling on Tie2 (Maisonpierre et ai., 1997), Tie2 can phosphorylate ephrin-BI 
(Adams et ai., 1999), as can PDGF-R (Bruckner et al., 1997), ephrinB lIEphB 1 signaling 
can induce cell-attachment via integrins (Huynh-Do et aI., 1999), integrins can modulate 
VEGF signaling (Soldi et aI., 1999), and VEGF can induce integrins (Byzova et ai., 
2(00). Recently, it was show that expression of both Tie2 receptor and Ang-l ligand 
expression were greatly reduced in the ephrinB2 knockout (Adams et al., 2001). This is 
interesting in light of the fact that the phenotype of the ephrinB2 knockout mice 
resembles that of the Tie2 and Ang-l knockout mice (Gale and Yancopoulos, 1999; 
Wang et ai., 1998): this suggests that some aspects of the ephrinB2 knockout phenotype 
is due to decrease in Tie2/Ang-l expression and signaling. 
Although ephrins participate In the angiogenesis signaling network (reviewed in 
Adams et ai., 2001), they appear to occupy a specialized niche, revealing the importance 
of A-V differences in blood vessel development (Gale and Yancopoulos, 1999; Gerety et 
aI., 1999; Wang et aI., 1998). The elucidation of these complex interactions, both 
between Ephs and ephrins, and between different RTK systems, represents an important 
challenge in vascular biology. By dissecting the role of one component, Eph/ephrin 
signaling, I hope to contribute to the overall understanding of the regulation of vascular 
development. Chapter 2 reveals the importance of vein-specific expression of EphB4, 
suggesting it IS the main receptor for ephrinB2 in early embryonic angiogenesis. 
Chapter 3 addresses the issue of signaling modalities, revealing the importance of arterial 
endothelial ephrinB2 expression for angiogenesis. 
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Summary 
Ephrin-B2 is a transmembrane ligand that Is specifi-
cally expressed on arteries but not veins and that is 
essential for cardiovascular development. However, 
ephrin-B2 is also expressed in nonvascular tissues 
and Interacts with multiple EphB class receptors ex-
pressed in both endothelial and nonendothelial cell 
types. Thus, the identity of the relevant receptor for 
ephrln-B2 and the site(s) where these molecules inter-
act to control angiogenesis were not clear. Here we 
show that EphB4, a specific receptor for ephrin-B2, is 
exclusively expressed by vascular endothelial cells in 
embryos and is preferentially expressed on veins. A 
targeted mutation in EphB4 essentially phenocop-
Ies the mutation in ephrin-B2. These data indicate 
that ephrin-B2-EphB4 interactions are intrinsically re-
quired in vascular endothelial cells and are consistent 
with the idea that they mediate bidirectional signaling 
essential for angiogenesis. 
Introduction 
The assembly of the embryonic circulatory system pre-
sents a fascinating problem in genetiCS and cell biology 
that is relevant to both development and disease. The 
cardiovascular system is the first organ system to form 
during embryogenesis. Beginning on about day 8 of 
gestation (E8.0) as the heart starts to beat, individual 
angioblasts assemble into a primitive capillary plexus, 
In a process known as vasculogenesls (reviewed In Ri-
sau and Flamme, 1995). Over the next 24-36 hr, this 
plexus undergoes a remarkable morphogenetic trans-
formation, termed angiogenesis, In which it is remodeled 
into an intricately branched network (reviewed in Risau, 
1997). This rapid and dynamic process involves both 
capillary remodeling and recruitment of smooth muscle 
cells to form the external walls of the vasculature (Folk-
man and D'Amore, 1996). It is also coordinated with the 
establishment of blood flow. 
The cellular and molecular mechanisms underlying 
vasculogenesis and angiogenesis are still poorly under-
stood. However, an increasing number of Intercellular 
signaling molecules have been Identified that play an 
essential role in this process. Prominent among these 
are transmembrane receptor tyrosine kinases (RTKs) 
and their ligands (reviewed in Hanahan, 1997; Gale and 
'To whom correspondence should be addressed (a·mall: mancu 
sog@Cco.caHech.edu). 
Yancopoulos, 1999). These include the vascular endo-
thelial growth factors (VEGFs) and their receptors, which 
are essential for vasculogenesis (Fong et al., 1995; Sha-
laby et al., 1995; Carmeliet et aI., 1996; Ferrara et al., 
1996), PDGF-B and its receptors (Benjamin et al., 1998; 
Hirschi et aI., 1998), and the recently discovered angio-
pOietins (Davis et al., 1996) and their receptors, which 
are critical for angiogenesis (Sato et al., 1995; Suri et 
aI., 1996). How these different signaling systems func-
tionally interact, and the cellular processes they control, 
is not yet clear. Nevertheless, manipulation of these 
signaling systems has already been employed as a new 
approach to therapeutic intervention In several impor-
tant clinical settings, such as cancer (Folkman, 1998a) 
and heart disease (Folkman, 1998b). 
Eph receptors, which comprise the largest family of 
RTKs, and their membrane-associated ligands, the 
ephrins (reviewed In Gale et aI., 1996), have also been 
implicated in angiogenesis (Pandey et al., 1995; Stein et 
al., 1998). Recently, ephrin-B2, a transmembrane ligand 
(Bennett et al., 1995; Bergemann et al., 1995), was shown 
to be essential for angiogenesis and cardiac develop-
ment in vivo (Wang et aI., 1998). The phenotype of 
ephrin-B2 homozygous mutant embryos was superfi-
cially similar to that of other RTK ligands required for 
angiogenesis (Sato et al., 1995; Suri et al., 1996). Re-
markably, however, In contrast to these other ligands 
that are uniformly expressed within the Circulatory sys-
tem, ephrin-B2 is specifically expressed by arteries but 
not veins (Wang et aI., 1998; Adams et al., 1999) while 
EphB4, one of Its receptors (Brambilla et al., 1995; Sa· 
kano et al., 1996), is expressed conversely on veins but 
not arteries (Wang et al., 1998; Adams et al., 1999). These 
data provided one of the first examples of a genetic 
distinction between these two vessel subtypes and sug-
gested that ephrin-mediated interactions between them 
may be essential for angiogenesis. 
These observations left several important issues unre-
solved, however. First, although artery specific within 
the circulatory system, ephrin-B2 is expressed by sev-
eral other nonvascular tissues, many of which contact 
developing blood vessels (Bergemann et al., 1995; Wang 
and Anderson, 1997; Wang et al., 1998). This raised the 
question of whether the essential angiogenic function 
of ephrin-B2 is intrinsic to the Circulatory system or, 
rather, Is exerted indirectly in other tissues. Further com-
plicating the picture Is the fact that this ligand can inter-
act with multiple EphB class receptors (Gale et al., 1996), 
which are expressed In both vascular and nonvascular 
tissues (Adams et al., 1999). This suggested that a ge-
netic identification of the relevant receptor(s) for ephrln-
B2 In angiogenesis would be complicated by genetic 
redundancy. Consistent with this expectation, muta-
tions In EphB2, which Is expressed by nonvascular cells, 
and EphB3, which like EphB4 is expressed on veins, 
individually had no phenotype, while EphB2; EphB3dou-
ble mutants exhibited variable cardiovascular abnormali-
ties with only 30% penetrance (Adams et al., 1999). 
Here we have generated a targeted mutation In 
EphB4, Introducing a tau-lacZ marker Into the locus to 
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Figure 1. Targeting of the EphB4 Locus 
WTIOcus~' ________ -L __ ~ ______ ~,r-~'~~IIr-__ ~' ~'~ •• 
'r:~~fr Targeting vector 
(A) Restriction maps of the wild-type (WT) 
EphB4 locus, the targeting vector, and the 
targeted locus. The targeting vector contains 
a tau -JacZ reporter gene fused in-frame with 
the initiator codon of EphB4, which replaces 
the signal peptide- encoding exon, prevent-
ing membrane insertion of the receptor. A 
similar targeting strategy was previously 
used to inactivate ephrin-B2 (Wang et al., 
1998). 
Arc. 1,-.u.!tW:Z J'C,K-f.~(/ 
Targeted ENE r~ E 
locus ~--------+-~------~========' ==r-L-~I~I--______ ~'J'~. 
ATO ~1-'ntZ PGK -r.eo 3' Prob e 
Wildty pe EcoRI ft3gm enr 19 KB 
Recombined EcoRI frngmcnt 12 KB 
B C 
+/- +/+ +/+ +/+ +/+ +/- +/- -/-
WT 
TG 
WTTAU 
- - ~ .. 
-. - ~, ~ 
(B) Confirmation of germ line transmission of 
the correct targeting event by Southern blot-
ting of the progeny of an EphB4,,,,o<zheterozy-
gote 3 CS7BI6/J cross. The genomic DNA 
has been restricted with EcoRI. WT, wild-type 
locus (19 kb ; see [A]) ; TG, targeted locus (12 
kb ; see [B]). 
better visualize the expression of this gene. Surprisingly, 
unlike the broadly expressed ephrin-B2, EphB4 is uniquely 
expressed in vascular endothelial and endocardial cells. 
This analysis also confirms that EphB4 is preferentially 
expressed on veins. Remarkably and unexpectedly, the 
phenotype of homozygous EphB4 mutants is virtually 
symmetric with that of ephrin-B2 mutants. These data 
identify EphB4 as the major essential interaction partner 
of ephrin-B2 in angiogenesis and further indicate that 
the requisite function of this receptor is intrinsic to the 
circulatory system. Furthermore, the symmetry of the 
mutant phenotypes and the largely complementary ex-
pression of ephrin-B2 and EphB4 on blood vessels are 
consistent with the idea (Holland et aI., 1996) that these 
molecules can participate in bidirectional signaling. 
Thus, these data provide further support for the concept 
that ephrin-B2 and EphB4 mediate reCiprocal interac-
tions between arteries and veins that are essential for 
proper angiogenic remodeling of the capillary beds. 
Results 
EphB4 Is Expressed Exclusively within the 
Cardiovascular System and Is Enriched 
on Veins Relative to Arteries 
We (Wang et aI., 1998) and others (Adams et aI., 1999) 
previously provided evidence via in situ hybridization 
that EphB4 mRNA is expressed on veins but not arteries. 
However, because of the relatively low level of expres-
sion of this gene, and the high background obtained 
with the in situ hybridization probes, it was not clear 
whether EphB4 was restricted to the cardiovascular 
(C) Genotyping of E9.S progeny of an Eph-
EJ4U14eZ1+ intercross. WT. primers for the wild-
type locus; TAU, primers for the targeted 
locus. Each sample was independently am-
plified with both primer sets. 
(D) Whole-mount X-Gal staining of an EtO.S 
EphB4,·iJ.a heterozygous embryo. Expres-
sion appears restricted to the cardiovascular 
system. The afTOW indicates the anterior 
cardinal vein (ACV}. 
(E) Morphologic appearance of an Eph-
B4"""<ZI~"o<z embryo (- r) at EtO. Note the 
retarded overall growth and arrested cardiac 
development compared to the heterozygous 
litlerrnate (+r). 
system or whether, like ephrin-B2(Bennett et aI., 1995; 
Bergemann et aI., 1995; Wang and Anderson, 1997), it 
is expressed in many other nonvascular tissues as well. 
To provide a clearer picture of the pattern of EphB4 
expression, therefore, we inserted a tau-lacZ reporter 
gene (Mombaerts et aI., 1996) into the EphB4 targeting 
vector (Figure 1 A; see Experimental Procedures). 
Analysis of EphB"~"'z expression in heterozygotes 
by whole-mount staining for p-galactosidase activity re-
vealed apparently exclusive expression in the vascula-
ture at E10 (Figure 1 D). The vessels of the head (Figure 
2A), intersomitic vessels (Figure 2C), and main trunk of 
the anterior cardinal vein (ACV; Figure 1 D, arrow) were 
particularly apparent. Expression was also strong in the 
heart, especially in the ventricles (Figure 2E). At E8.75, 
expression was detected in the developing ACV (Figure 
2G, open arrow), in the main trunk of the vitelline vein 
(Figure 2G, arrow), and in the yolk sac (Figure 2G, YS). 
To determine more precisely the cellular localiza-
tion of EphB"·u,.cz expression within the cardiovascular 
system, we stained sections of heterozygous embryos 
using antibodies to b -galactOSidase and markers of en-
dothelial and smooth muscle cells. p-galactosidase ex-
pression colocalized with expression of PE-CAM, a pan-
endothelial marker (Figures 2B, 2D, and 21), and not with 
expression of alpha-smooth muscle actin (Figure 2H 
and data not shown), confinning that EphB4 Is ex-
pressed by endothelial and not by smooth muscle cells 
at these stages of development. Similarly, within the 
heart, EphB"~Jocz was coexpressed with PE-CAM in en-
docardial cells (Figure 2F) and was not detected in the 
myocardial layer (not shown). 
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Figure 2. Embryonic Expression of EphB4r..acZ Is Restricted to En-
dothelial Cells and Enriched in Veins 
(A)-(F) are laken from El0 helerozygous embryos_ (A and B) Head 
region. (A) Whole-mount X-Gal staining reveals expression in the 
branches of Ihe ACV. (B) Double immunolabeling with antibodies to 
the pan-endothelial marker PE-CAM (green) and ~-galactosldase 
(red) reveals coexpression of EphB4"""Z In the endothelial cells of 
the lalerally located ACV branches (seen in cross section ; arrows~ 
but not in the medially located branches of the internal carotid 
artery (arrowheads). (C and D) Trunk region. (C) Expression in the 
intersomilic vessels. (D) Expression in the posterior cardinal vein 
(V, arrow) but not the dorsal aorta (A, arrowhead~ (E and F) Heart. 
(E) Expression in the atrium and ventricle. (F) Coexpression with 
PE-CAM indicates expression in endocardial and not myocardial 
cells. 
(G) E8.75 heterozygous embryo. Arrow, vitelline vein ; arrowhead , 
vitelline artery; YS, yolk sac. 
(H and I) E9.S yolk sac vasculature triple- Iabled for ~-galactosidase 
(red), alpha-smooth muscle actin (blue), and PE-CAM (green). (H) 
No overlap between EphB4-lau-lacZ-expressing and smooth mus-
cle cells is observed. (I) Overlap with PE-CAM expressing cells is 
observed. 
This analysis also confinned that EphB4 is preferen-
tially expressed on veins. In the head, for example, ex-
pression overlapped with PE-CAM in the laterally lo-
cated branches of the ACV (Figure 2B, arrows), but not 
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in the medially located branches of the internal carotid 
artery (ICA; Figure 2B, arrowheads; see also Figures 
3E and 3F). Similarly, in the trunk region EphB4 was 
expressed in the posterior cardinal vein (Figure 20, 
arrow) but not in the dorsal aorta (Figure 20, arrowhead)_ 
Similarly, in the yolk sac at E8_7S expression was de-
tected in the vitelline vein (Figure 2G, arrow), but not the 
vitelline artery (Figure 2G, arrowhead). At E9.S, however, 
scattered, punctate expression of ~-galactosidase was 
apparent in the branches of the vitelline artery (see Fig-
ures 7B and 7C), and overdevelopment of the X-Gal 
staining reaction revealed a low level of expression in 
other arteries as well that is below the detection limit 
of immunofluorescence (data not shown). In contrast, 
ephrin-B2 appears to be absolutely arterial specific 
within the cardiovascular system (Wang et al., 1998). 
Nevertheless, EphB4 is much more abundantly ex-
pressed in veins than in arteries and, unlike ephrin-B2, 
appears restricted to the cardiovascular system in em-
bryos_ 
ephB41.ul.cz Homozygotes Display Defective 
Cardiovascular Development 
and Embryonic Lethality 
AHhough our original study failed to detect venous ex-
pression of receptors other than EphB4 (Wang et al., 
1998), a subsequent study detected expression of 
EphB3 in addition to EphB4 in veins (Adams et al., 1999). 
The reason for this discrepancy is not clear but may 
reflect a lower sensitivity of our in situ hybridization 
procedure. Whatever the explanation, these observa-
tions suggested that the function of EphB4 in veins 
might be redundant with that of EphB3 and therefore 
that little or no phenotype would be observed in EphB4 
knockouts_ Indeed, no cardiovascular phenotypes were 
detected in EphB3 single mutants (Adams et aI., 1999)_ 
To our surprise, embryos homozygous for the Eph-
B4'~1BcZ allele displayed cardiovascular defects and em-
bryonic lethality with very high penetrance_ By E9_S-E1 0, 
growth retardation, arrested heart development (see 
also Figure 6 below), and lack of blood flow were obvious 
in homozygous embryos (Figure 1 E, - 1-). Moreover, 
the recovery of homozygous EphB4'·utocZll.uIocZ embryos 
at this age was well below expected Mendelian propor-
tions(17%; n = 47 embryos examined). By E10.S, degen-
eration and necrosis were apparent throughout the em-
bryo. The earliest overt morphologic defects were seen 
at E8.7S-9.0, when heart looping appeared incomplete 
in some homozygous embryos (17%, n = 6 homozy-
gotes from three litters examined). However, heartbeat 
and blood flow were still detectable in many homozy-
gous embryos at E8 .7S-E9.0, and homozygotes were 
recovered at close to the predicted Mendelian ratio 
(23%; n = 26 embryos examined). No apparent defects 
were detected in heterozygous embryos (Figure 1 E, + /- ) 
compared to wild type (data not shown). 
The EphB4 Mutation Affects Morphogenesis 
of Both Arteries and Veins 
The development of the peripheral circulatory system 
was examined in mutant and wild-type embryos by 
whole-mount staining with antibodies to PE-CAM_ At 
E9.S-E10, the fine branches of the head vaSCUlature 
Molecular Cell 
406 
Figure 3. Defective Head Angiogenesis in EphB4 Homozygotes 
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E9.S embryos are shown. (A-D) Whole-mount PE-CAM staining reveals defective remodeling of the major head vessels, and fusion of the 
capillary network (B and D~ Different specimens are shown in (B) and (D~ (E-J) The EphB4 mutation affects remodeling of both arteries and 
veins. Sections through EphB4"ob<ZI· (E-G) and Eph84"""ZI ..... " (H-J) heads double labeled for PE-CAM (E and H) and p-galactosidase (F and 
I). A merged image of the two stains is shown in (G) and (J~ Capillary fusion (reflecting arrested remodeling) of the branches of both the 
anterior cardinal vein (E versus H, arrows) and the internal carotid artery (E versus H, arrowheads) is evident in the mutant Note that arteries 
and veins appear equally affected (E and H), even though the level of EphB4 expression is much higher in veins (F, arrows). The decreased 
expression of b-galactosidase in the mutant (F versus I, arrows) is characteristic and may reflect positive autoregulation by EphB4. 
visible in heterozygous embryos (Figure 3A, arrow; Fig-
ure 3C) were not seen in homozygotes, where extensive 
fusion of the capillary network was visible (Figures 3B 
and 3~). This phenotype is suggestive of an arrest of 
the remodeling of the primitive, dilated vessels of the 
head plexus into smaller branched capillaries. Impor-
tantly, double labeling of sections with antibodies to PE-
CAM and b-galactosidase to distinguish arteries (PE-
CAM+, /3-gal-) from veins (pE-CAM+, /3-gal"1 revealed 
fused vessels in both the branches of the anterior 
cardinal vein (cf. Figures 3E, 3G versus Figures 3H, 3J, 
arrows) where EphB4 expression is detectable in hetero-
zygotes (Figure 3F, arrows), and also in the neighboring 
branches of the internal carotid artery (cf. Figures 3E, 
3G versus3H, 3J, arrowheads) where EphB4 expression 
in heterozygotes is low or undetectable by irnmunostain-
ing (cf. Figure 3E, arrowheads, versus Figure 3F). The 
level of EphB4" u,,,z expression in veins in homozygotes 
was typically much lower than in heterozygotes (Figures 
3F and 31, arrows). The reason for this is not yet clear 
but may reflect a positive autoregulatory function of 
EphB4. Whatever the case, these data indicate that 
Eph84 function is similar1y required for angiogenic re-
modeling of both the venous vessels of the head, where 
the gene is strongly expressed, and the arterial vessels 
where it is expressed at much lower levels. 
An especially prominent feature of the Eph84 mutant 
phenotype was disrupted development of the main trunk 
of the ACV (Figures 4A and 4B, arrows). Cross sections 
revealed that the luminal diameter of the ACV was re-
duced and that the vessel appeared split into multiple 
branches(Figures4C and 40, arrows). This phenotype is 
virtually identical to that observed in ephrin-82 mutants 
(Adams et al., 1999; our own unpublished data) and 
EphB4 Is Essential lor Angiogenesis In Vivo 
407 
E8_7S EP'H-B4 +/- E9_S EPH-B4 +/-
Figure 4. Delective Trunk Angiogenesis in EphB4 Homozygotes 
E9.S embryos are shown. 
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(A and B) Whole-mount PE-CAM staining reveals defective lormatlon 01 the main trunk 01 the anterior ca rdinal vein (arrow ; cl. Rgure 10, 
arrow). 
(C and D) Double-labeling lor PE-CAM (green) and b-galactosidase (red) reveals that the ACV is split into multiple branches in the mutant (0 , 
arrows), while the dorsal aorta appears unaffected (arrowheads~ 
(E-H) Whole-mount PE-CAM staining 01 intersomitic vessels. At E9.S, the remodeling 01 the vessels seen in heterozygotes (F) is delective in 
EphB4 homozygotes (G) and resembles an arrest at an earlier stage 01 normal development (E). (H) An ephrin-B2 homozygous embryo at the 
same stage is shown lor comparison. Note the similarity 01 the phenotypes in (G) and (H~ 
appears to reflect an arrest of remodeling of multiple 
small vessels into the single, large ACV vessel. In con-
trast, the dorsal aorta appeared relatively unaffected (Fig-
ures 4C and 40, arrowheads1 as was observed previously 
In the ephrin-B2 mutant ([Wang et aI. , 1998); however, an 
independently generated ephrin-B2 knockout displayed 
variable defects in dorsal aorta formation [Adams et aI., 
1999]). 
Defects in the development of both arterial and ve-
nous intersomitic vessels were also observed in both 
EphB4 and ephrin-B2 mutants. Whereas in heterozy-
gous E9.5 embryos a finely anastomosed network of 
vessels was detectable with branches extending into 
and sometimes crossing the dorsal midline (Figure 4F), 
in both EphB4 and ephrin-B2 mutants this network ap-
peared fused and truncated (Figures 4G and 4H). This 
appearance was very similar to that observed in hetero-
zygous embryos at E8.75 (Figure 4E), suggesting a de-
velopmental arrest of angiogenesis in these vessels. 
Interestingly, ephrin-B2 is expressed in caudal half-
somites (Krull et al., 1997; Wang and Anderson, 1997), 
and it has been suggested that defective angiogenesis 
of intersomitic vessels in ephrin-B2 mutants could re-
flect signaling from somitic cells to endothelial cells 
rather than between arteries and veins (Adams et aI. , 
1999; Gale and Yancopoulos, 1999). However, reexami-
nation of our ephrin-B2'~/ocZ heterozygous embryos re-
vealed clear expression of ephrin-B2 in arterial intersom-
itic vessels as well (data not shown). Interestingly, the 
ingrowth of these nascent vessels between the somites 
appeared to initiate just as expression of b-galactosi-
dase in the caudal half-somites was fading. 5ince the 
arrest of remodeling by the ephrin-B2 mutation occurs 
at an even later stage of intersomitic vessel maturation 
(E9.0-E9 .5), these data indicate that ephrin-B2 is no 
longer expressed in somites at the time that its function 
in angiogenesis is required. 
Defects in Peripheral Angiogenesis in EphB4 
Mutants Are Observed in Mutant Embryos 
Exhibiting Heartbeat and Blood Flow 
It was important to determine whether or not the periph-
eral angiogenic defects observed in EphB4 mutant em-
bryos were secondary to cardiac defects resulting in 
defective blood flow (see below). Because angiogenic 
remodeling in many areas is not obvious until after the 
onset of heartbeat (E8.0- E8.5 ; 10-13 somites [5]), it is 
often difficult to identify angiogenic defects at stages 
before blood flow is established. As an alternative, there-
fore, we exploited the variability in the time of onset of 
cardiac defects in early EphB4 mutant embryos. Absent 
or defective heartbeat (detected by poor or absent eryth-
rocyte movement in the heart and outflow tracts despite 
rhythmic myocardial contractions) was apparent in virtu-
ally all embryos by E9.5 (see Figure 6, below). We there-
fore asked whether any defects in peripheral angiogenic 
remodeling were visible prior to this stage in mutant 
embryos with manifestly normal cardiovascular function. 
Embryos were collected between E8.75 and E9.0 (15-
185) and individually scored for the presence of heart-
beat and blood flow (detected by the movement oferyth-
rocytes through the embryonic vasculature), prior to 
genotyping. Following whole-mount PE-CAM staining, 
we asked whether any peripheral angiogenic defects 
were observable in those homozygous embryos that 
had exhibited apparently normal heartbeat and blood 
flow prior to fixation. Four homozygous embryos exam-
ined at 155-255 showed normal blood flow and heart-
beat but exhibited defects in angiogenesis of the head 
and ACV; three of these are illustrated in Figure 5. A 
155 embryo exhibited defective formation of the head 
vasculature (Figures SA and 5B, arrows) and ACV (Fig-
ures SA and 5B, open arrowheads), similar to those doc-
umented in later embryos (cf. Figures 3A and 3B, and 
4A and 4B). No apparent defects in cardiac morphology 
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were visible in this specimen (Figures SA and 5B, closed 
arrowheads). Even more striking defects in angiogenesis 
of the head capillaries were observed in an 188 mutant 
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Figure 5. Angiogenic Defecls Are Visible In 
Mutant Embryos Exhibiting Heartbeat and 
Blood Row 
Comparison of homozygous mutant (B, 0 , 
and F) and wild-type or heterozygous (A, C, 
and E) embryos by whole-mount PE-CAM 
staining at E8.75-E9.0. The actual stage of 
the embryos was determined by counting the 
number of somites (S) and is the same for 
nonnal and mutantlillennates. All of the mu-
tant embryos shown exhibited heartbeat and 
visible blood flow prior to fixation. Note the 
presence of defects In head vessel remodel-
ing (arrows) and ACV fonnation (open arrow-
heads) in all of the mutant embryos (B, 0 , and 
F). Staining of the heart endocardium (closed 
arrowheads) appears nonnal In all embryos 
except (D); nevertheless, cardiac function was 
still apparent In this specimen. 
embryo (Figures 5C and 50, arrows), except that in this 
specimen a mild retardation of cardiac development 
was observed by PE-CAM staining (Figures 5C and 50, 
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Figure 6. Arrested Cardiac Morphogenesis in Both EphB4 and ephrin-B2 Mutant Embryos 
Anli-PE-CAM -stained embryonic hearts at E8.7S (A-H) or E9.S (I -P) are shown In whole-mount (A-O and I-L) or cryosectlon (E-H and M-P) 
from both EphB4 homozygous (B, F, J , and N) and ephrin-B2 homozygous (0, H, L. and P) embryos. Normal Iitlermate controls are shown 
for both mutants. Note that heart development appears normal at E8.7S, but growth of the ventricular endocardium, like that of the heart 
itself, appears arrested at E9.S (J, N, L. and Pl. At E10-E10.S, a more pronounced failure of myocardial trabeculation was apparent in the 
mutants (Wang et aI., 1998; data not shown~ Note that the phenotypes of the two mutants are virtually indistinguishable. 
closed arrowheads); nevertheless, this retardation was 
evidently insufficient to prevent heartbeat and circula-
tion at this stage. Finally, a 2SS embryo showed defec-
tive ACV morphogenesis (Figures SE and SF, open ar-
rowheads) despite a morphologically normal heart (Figures 
SE and SF, closed arrowheads). More subtle defects in 
head capillary angiogenesis were also apparent, upon 
close examination as well (Figures SE and SF, arrows). 
These data indicate that although peripheral angio-
genic defects in E9.S EphB4 homozygous mutant em-
bryos are accompanied by defective cardiac develop-
ment and consequent lack of blood flow, similar 
phenotypes can clearly be observed in earlier embryos 
in which such cardiac defects are not yet apparent. 
Taken together with the expression of EphB4 and 
ephrin-B2 in the peripheral vaSCUlature, these observa-
tions support the idea that the angiogenic phenotype 
observed in the mutants reflects a requirement for a 
peripheral action of this ligand-receptor pair. 
EphB4 Is Required for Proper Cardiac Development 
To assess more carefully the cardiac phenotype of 
EphB4 mutants and to compare it directly to that of 
ephrin-B2 mutants, the hearts of homozygous embryos 
from both mutant lines were examined by whole-mount 
PE-CAM staining and subsequent sectioning. As men-
tioned above, obvious defects in cardiac morphogene-
sis or function were rare in homozygotes prior to E9.0 
(Figures SA-SO). This was confirmed by analysis of the 
endocardium in sections (Figures SE-SH). Between E9.0 
and E9.S, a retardation or arrest of cardiac morphogene-
sis appeared to occur in EphB4 homozygotes. The heart 
failed to increase in size, cardiac looping was incom-
plete, and the endocardium failed to expand (Figures 
SI, 6J, SM, and SN). Very similar defects were observed 
in ephrin-B2 homozygotes at these stages (Figures SK, 
SL, SO, and SP). By E10, a clear failure of myocardial 
trabeculation was apparent in those few homozyotes 
that survived (Wang et al., 1998; data not shown). Thus, 
the phenotype of the EphB4 and ephrin-B2 mutants 
in cardiac development is almost indistinguishable and 
appears to reflect a requirement for these genes in 
growth and morphogenetic events that occur 12-24 hr 
after the initiation of heartbeat. 
EphB4 Is Required for Angiogenic Remodeling 
in the Yolk Sac 
ephrin-B2 is required for angiogenic remodeling of the 
yolk sac on both the arterial (posterior)and venous(ante-
rior) sides (Wang et aI., 1998; Adams et aI., 1999). Simi-
larly, phenotypic defects were revealed by PE-CAM 
staining of E9.S EphB4 homozygous mutant embryos in 
both the arterial (Figures 7F and 7G) and venous (Figures 
7H and 71) domains. As in the case of the ephrin-B2 
mutant, the phenotype appeared to reflect an arrest at 
the primitive plexus stage, although this arrest appeared 
more severe on the venous than on the arterial sides 
(Figure 7G and 71). Because extensive angiogenic re-
modeling of the yolk sac has not yet occurred in E8.7S-
E9.0 embryos, it was difficult to detect obvious differ-
ences between mutant and Wild-type tissue at these 
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ages. Therefore, we cannot completely exclude that 
some or all of the EphB4 yolk sac phenotype is second-
ary to defective circulation. However, we did detect an-
giogenic defects in a yolk sac from at least one E8.75-
E9.0 ephrin-B2 homozygous mutant in which heartbeat 
and blood flow were detectable (data not shown). 
To examine the effect of the EphB4 mutation on the 
distribution of EphB4'aulocZ-expressing cells on the yolk 
sac, we examined heterozygous and homozygous em-
bryos by whole-mount X-Gal staining. Two surprising 
findings emerged from this analysis. First, unlike the 
case of ephrin-B2, whose expression is absolutely re-
stricted to the arterial side of the yolk sac (Wang et at, 
1998; Adams et al., 1999), expression of EphB4'au,«z in 
heterozygotes while clearly strongest on the venous side 
(Figure 7 A, arrow) was detected on the arterial side at 
a lower level as well (Figure 7 A, arrowheads). Examina-
tion at higher magnification revealed, however, that this 
arterial expression of EphB-I""acz was not uniform, but 
rather patchy as if confined to individual cells or groups 
of cells (Figure 7C). Expression also appeared punctate 
on the venous side but was clearly more extensive than 
on the arterial side (Figure 7B). 
The second unexpected finding concerned the distri-
bution of EphB-Iau/scz-expressing cells in homozygous 
mutant yolk sacs. In ephrin-B2"'1ocZ homozygotes, ex-
pression of b-galactosidase is similar in intensity to that 
in heterozygotes and is distributed fairly uniformly 
throughout the primitive plexus on the arterial side 
(Wang et al. , 1998). In contrast, expression of b-galac-
tosidase in EphB4 homozygotes is much weaker than 
in heterozygotes and is highly punctate and nonuniform, 
although it stili appears most extensive on the venous 
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Agure 7. Defective Yolk Sac Angiogenesis in 
EphB4 Mutants 
(A-C) Whole-mount X·Gal staining of hetero-
zygous embryos. Note that expression of the 
EphB4t11w eZ allele Is enriched on the venous 
(A, arrow; B) relative to the arterial (A, arrow-
head ; C) side of the yolk sac . Note also the 
patchy nature of the expression ; ~-galactosi ­
dase-expressing cells in the vitelline artery 
(C) are surrounded by EphB4-nonexpressing 
cells. By contrast, expression of ephrin-B2 in 
the yolk sac arteries is more homogenous 
(Wang et aI., 1998). 
(0 and E) ExpreSSion of ~·galactosidase in 
homozygous mutants at E9.S. Note the scat-
tered, punctate nature of the staining, and 
reduced intenSity relative to the heterozygote 
(A). (E) represents a higher magnification view 
of the boxed area in (D~ Arrow indicates the 
entry point of the vitelline vein. Note the in-
creased concentration of ~-gal+ cells in th is 
region. 
(F-I) Whole-mount PE-CAM staining of E9.S 
yolk sacs reveals defective angiogenic re-
modeling on both the venous (H and I) and 
arterial (F and G) sides of EphB4 mutant em-
bryos. Defecls appear slightly less severe on 
the arterial side. VA, vitelline artery; VV, vitel-
line vein. 
side (Figure 7D). Interestingly, the distribution of labeled 
cells appeared graded, with the highest density toward 
the entry point of the vitelline vein (Figures 7D and 7E, 
arrows). Whether this reflects a migration of EphB4-
expressing cells toward or away from the vitelline vein, 
or some other phenomenon, is under investigation. 
Discussion 
Ephrins and their receptors have recently emerged as 
essential regulators of angiogenesis in vivo, equal in 
genetic importance to other ligand-receptor systems 
such as the angiopoietins and VEGFs (reviewed in Gale 
and Yancopoulos, 1999). In contrast to these diffusible 
ligands that can act over many cell diameters, however, 
the ephrin system has evolved to mediate interactions 
between cells that touch each other. Furthermore, the 
restricted and often complementary expression of 
ephrins and their receptors (not only within the circula-
tory system but in other tissues as well [Gale et at, 
1996]) suggests that these contact-dependent interac-
tions often occur between dissimilar cell types. To un-
derstand the role of ephrins in angiogenesis, therefore, 
it is important to define the essential receptors for these 
ligands, the cell-cell interactions they control, and the 
cellular behaviors such interactions regulate. 
EphB4 Is the Major Essential Receptor for 
Ephrin-B2- Mediated Signaling during 
Cardiovascular Development 
The finding that ephrin-B2 is required for angiogenesis 
(Wang et at, 1998) left open the question ofthe function-
ally relevant receptor for this ligand. This question is 
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important, because ephrin-B2 can interact with multiple 
EphB class receptors (Gale et al., 1996), several of which 
are expressed on nonvascular tissues as well as on 
endothelial cells (Adams et al., 1999; Gale and Vanco-
poulos, 1999). The present data identify EphB4 as the 
major genetically essential receptor for ephrin-B2 in car-
diovascular development. This in itself is surprising 
given the functional redundancy that has been demon-
strated for other EphB receptors In angiogenesis (Ad-
ams et al., 1999). Based on such data, we would have 
predicted that the EphB4 mutation on its own would 
yield little or no phenotype. The fact that it phenocopies 
the ephrin-B2 mutation is quite unexpected and sug-
gests that EphB4 is the predominant functional partner 
for ephrin-B2 in this system. 
Why is the loss of EphB4 function not compensated 
by that of EphB3, which also can interact with ephrin-
B2 (Gale et al., 1996) and is like EphB4 specifically ex-
pressed on veins (Adams et al., 1999)? First, the level 
of EphB3 expression may simply not be high enough to 
compensate for the loss of EphB4 function; indeed, we 
have been unable to detect expression of this gene in 
veins by in situ hybridization (Wang et al., 1998). Second, 
EphB4 uniquely binds to ephrin-B2 among all ephrin-B 
family ligands (Brambilla et aI., 1995; Sakano et al., 
1996), while EphB3 is less specific (Gale et al., 1996). 
Activation of EphB4 by ephrin-B2 may therefore send a 
unique Signal that is not mimicked by activation of 
EphB3. This could also explain why ephrin-B1, which is 
expressed on arteries (Adams et al., 1999) and which can 
interact with EphB3 (but not EphB4), evidently cannot 
compensate for the loss of ephrin-B2 (Wang et al., 1998). 
Nevertheless, the fact that EphB2; EphB3 double mu-
tants do have a partial phenotype indicates that these 
receptors must play some redundant role in vascular 
development, perhaps in mediating ancillary interac-
tions between arteries and neighboring cell types, rather 
than between arteries and veins (Adams et aI., 1999; 
Gale and Yancopoulos, 1999). 
Ephrin-Mediated Signaling Is Intrinsic to 
the Developing Circulatory System 
The fact that EphB4 is essential for angiogenesis, taken 
together with the specificity of its expression, allows us 
to resolve the question of whether ephrin-B2-mediated 
Signaling is actually required within blood vessels (Wang 
et al., 1998; Adams et al., 1999). Our tau-lacZ Insertion 
reveals clearly that EphB4 Is exclusively expressed in 
the embryo by vascular endothelial cells. There Is thus 
no ambiguity about whether the essential function of 
this receptor Is exerted withIn the cardiovascular sys-
tem. Given that EphB4 has no other specific ligand than 
ephrin-B2, that ephrin-B2 is specifically expressed on 
arteries and that the two mutations yield symmetrical 
phenotypes, these data also suggest that at least some 
functions of ephrin-B2 in angiogenesis are intrinsic to 
the Circulatory system as well. Our results therefore not 
only reinforce the idea that ephrin-B2 and EphB4 are 
key regulators of angiogenesis, but also demonstrate 
that the requisite activity of EphB4 Is intrinsic to the 
circulatory system. 
An important question Is Whether the angiogenIc re-
modeling defects seen in the ephrin-B2 and EphB4 mu-
tants reflect a local functIon for these molecules In the 
60 
peripheral vasculature, or rather are secondary to im-
paired blood flow caused by defective heart develop-
ment. This confound Is not unique to the ephrins but 
complicates the analysis of many mutants exhibiting 
both cardiac and angiogenic phenotypes. In EphB4 ho-
mozygotes, however, cardiac development appears 
normal up to about E9.0 and then seems to arrest (Figure 
6). Nevertheless, we can clearly observe defective angi-
ogenic remodeling in E8.75-E9.0 mutant embryos where 
heartbeat and blood flow are stili detectable, that is, 
before the onset of the cardiac defects (Figure 5). While 
we cannot exclude that more subtle hemodynamic alter-
ations cause the phenotype, the fact that both ligand 
and receptor are actualiy expressed in the peripheral 
vasculature further argues that their functions are likely 
required there. Selective rescue of the mutants in endo-
cardial cells, or selective knockout in endothelial cells, 
could in principle resolve this issue but is currently pre-
cluded by the lack of appropriately specific promoters. 
The Cellular Function of Ephrin Signaling 
in Angiogenesis 
The cellular function of ephrin-mediated signaling in an-
giogenesis remains unclear. Although ephrins have been 
shown to function as repulsive guidance molecules for 
growing axons (Drescher et al., 1995; Nakamoto et al., 
1996) and migrating neural crest cells (Krull et al., 1997; 
Smith et al., 1997; Wang and Anderson, 1997), the evi-
dence thus far in the circulatory system suggests that 
they promote endothelial cell migration (Pandey et al., 
1995), capillary formation (Stein et al., 1998), and sprout-
ing (Adams et aI., 1999). However, in the Circulatory 
system as in many other places in the embryo, ephrins 
and their receptors are reciprocally expressed at bound-
aries between dissimilar cell types or tissues (Gale et 
al., 1996). Recent functional studies have provided evi-
dence that signaling by ephrin-B ligands and EphB re-
ceptors is important in the maintenance of such bound-
aries (Mellitzer et al., 1999; Xu et al., 1999). By analogy, 
interactions between ephrln-B2 and EphB4-expressing 
endothelial cells could playa role in the establishment 
or maintenance of the arteriovenous (A-V) boundary. If 
so, then the fact that the mutant phenotypes In both 
the ephrin-B7'- and EphB4"i" capillary plexil extend 
beyond the A-V boundary Into the capillary network 
would Imply that proper boundary formation is essential 
for remodeling of the entire network to occur. 
The Expression and Symmetrical Mutant Phenotypes 
of EphB4 and ephrin-B2 Provide In Vivo Genetic 
Evidence Consistent with Bidirectional Signaling 
A great deal of Interest has focused on the possibility 
that ephrin-B class transmembrane ligands may also 
function as signal-transducing receptors, mediating bi-
directional Signaling at boundaries between ephrin-B-
and EphB-expressing cells. Consistent with this possi-
bility, engagement of ephrin-B class ligands with their 
receptors results In tyrosine phosphorylation of the for-
mer on their cytoplasmic tails (Holland et al., 1996; 
Bruckner et al., 1997). Although the biological conse-
quences of this phosphorylation were not established, 
recent gain-of-function experiments In zebrafish have 
shown that the cytoplasmic domain of ephrin-B class 
ligands is required to promote segregation from EphB 
Molecular Cell 
412 
receptor-expressing cells in vivo (Mellitzer et al., 1999; 
Xu et al., 1999). 
A prediction of the bidirectional signaling model is 
that loss-of-function mutations in an ephrin-B class li-
gand and its cognate EphB class receptor, expressed on 
complementary and interacting cell populations, should 
produce symmetrical phenotypes of both an autono-
mous and a nonautonomous nature. The present data 
provide a striking example of such symmetricalloss-of-
function phenotypes. That mutations in a ligand or its 
receptor yield similar phenotypes does not in and of 
itself prove that bidirectional signaling occurs. Never-
theless, the fact that the EphB4 mutation causes a simi-
lar phenotype in arteries as does the ephrin-B2mutation, 
taken together with the preponderant expression of the 
receptor on veins, is consistent with the idea that recip-
rocal signaling occurs. In support of this idea, targeted 
deletion of the EphB2 receptor caused axon guidance 
defects in an apparently non-cell autonomous manner 
(Henkemeyer et al., 1996). This function was indepen-
dent of the EphB2 tyrosine kinase domain, suggesting 
that EphB2 activates an ephrin-B class ligand expressed 
on axons. However, no mutation in any such ligand has 
yet been identified that phenocopies this EphB2 mutant. 
There are two caveats associated with this interpreta-
tion, however. First, the low-level, patchy expression of 
EphB4 in arteries leaves open the possibility that this 
receptor functions autonomously in arteries, in which 
case a reverse signaling function for ephrin-B2 could 
not necessarily be Inferred. However, an autonomous 
requirement for EphB4 function in arteries seems incon-
sistent with the similar strengths of the arterial and ve-
nous EphB4" t- phenotypes (cf. Figure 3G versus 3J), 
given the striking difference in EphB4 expression levels 
between the two vessel subtypes (Figures 3E and 3F). 
Second, even If the arterial requirement for EphB4 is 
exerted nonautonomously In veins, it is still formally 
possible that it is mediated indirectly, for example, by 
mechanical forces or by an unknown ligand whose ex-
pression or secretion are EphB4 dependent, rather than 
by reverse activation of ephrin-B2. However, the fact 
that EphB4 binds tightly and specifically to ephrin-B2, 
taken together with the receptor-induced tyrosine phos-
phorylation of ephrin-B cytoplasmic domains (Holland et 
al., 1996; Bruckner et al., 1997), argues that bidirectional 
signaling is the most likely explanation for the symmetri-
cal mutant phenotypes. 
Ephrln-B2 and EphB4 as Potential Targets 
of Angiogenic Therapy 
Our results establish that the interaction between 
ephrln-B2 and EphB4 is Indispensable for embryonic 
angiogenesis. This raises the question of whether it is 
required in settings of adult neovascularization as well. 
Preliminary observations indicate that expression of this 
ligand-receptor pair perSists in the adult cardiovascular 
system and that ephrin-B2 at least is expressed during 
tumor angiogenesis (D. Shin, and G. Garcia-Cardenas 
et al., unpublished observations). Pharmacologic pertur-
bation of other signaling systems genetically required 
for embryonic angiogenesis, such as angiopoietin1-tie2, 
effectively inhibits tumor vessel formation (Folkman, 
1998a; Goldman et al., 1998; Lin et al., 1998). Byanalogy, 
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functional perturbation of ephrin-B2-EphB4 signaling 
may provide a similar but alternative strategy for antian-
giogenic cancer chemotherapy as well. Furthermore, 
the vessel-specific expression of these molecules may 
permit novel approaches to proangiogenic therapies 
(Folkman, 1998b; Schumacher et aI., 1998) directed se-
lectively at arteries or veins. 
Experimental Procedures 
Targeted Disruption of the EphB4 Gene 
A 156 bp probe starting from the ATG of the mouse EphB4 gene 
was used to screen a 129SVJ genomic library (Stratagene). Analysis 
of overlapping clones revealed that the first exon, Including the 
signal sequence, ended 50 bp after the ATG. To construct a targeting 
vector, a 2.75 kb Xbal-Ncol fragment whose 3' end terminated at 
the ATG was used as the 5' arm. A 5.3 kb tau-/acZ coding sequence 
(Mombaerts et al., 1996) was fused In-frame after the ATG. An Ncol-
Ncol fragment encoding 5 Myc epltope tags was PCR amplified 
from pCS21 MT (Turner and Weintraub, 1994) and Inserted at the 
ATG, resulting In a 5 Myc-Tau-lacZ fusion. A LoxP site-flanked 
PGKneo gene (the generous gift of J. Yoon and B. Wold) derived 
from pPNT (Tybulewlcz et al., 1991) was Inserted downstream of 
the tau-LacZ gene. For the 3' arm, a PCR fragment extending 500 
bp downstream of the end of the first coding exon to the nearest 
Hindlll site was Inserted immediately downstream of the PGKneo 
cassette, and then ligated at Its 3' end to a 5.5 kb Hlndill-Ncol 
fragment. This resulted In deletion of only the first coding exon. 
leaving all downstream Intronlc regions Intact. Normal (19 kb) and 
targeted (12 kb) loci are distinguished by EcoRI digestion when 
probed with a 380 bp PCR fragment representing the fourth coding 
exon (Figure 1 A). Electroporatlon, selection, and blastocyst Injection 
of AB-1 ES cells (strain 129 SvJ) were performed essentially as 
described (Ma et al., 1998), with the exception that FIAU selection 
was omitted. ES cell targeting efficiency via G418 selection was 1 
out of 8 clones. Germllne transmission of the targeted EphB410cus 
was confirmed by Southern blotting (Figure 1 B). Primers for the 
Southern probe are 5' -GCAGAACATCTGACTCGGAAGC-3' (5') and 
5'-CTCTGCATACTTTGTTGCTTTCC-3' (3'). Subsequent genotyp-
ing was done by genomic PCR. A 5' primer In the 5' UTR of EphB4, 
5'-ATCGTTGAGAGGCCCTCGAC-3' (5'), was used for both wlld-
type (235 bp product) and targeted (350 bp product) loci. The 3' 
primers for detecting wild-type and targeted loci are 5'-GTGCTATT 
GGTCCGAAGTGTT-3' (3'), downstream of the first coding exon, 
and 5' -CTGAGCATGATCTTCCATCAC-3' (3') In the tau-/acZ gene, 
respectively. Germllne chimeras were backcrossed onto a pure 
C57B16/J background, and all subsequent breeding was on this 
background, exactly as performed for the ephrln-B2 mutation we 
described previously (Wang et aI., 1998). 
LacZ and Immunohistochemical Staining 
For LacZ staining, embryos and yolk sacs were removed between 
E8.75 and El 0.0, fixed In 0.25% glutaraldehyde/PBS for 5 min, rinsed 
twice with PBS, and stained for 1 hr to overnight at 37!C In X-Gal 
buffer (1.3 mg/ml potassium ferrocyanlde, 1 mg/ml potassium fer-
rlcyanlde, 0.2% Triton X-l00, 1 mM MgCI2, and 1 mg/ml X-Galin 
PBS [pH 7.2D. LacZ-stalned embryos were postfixed prior to being 
photographed. For antibody staining, embryos were first fixed over-
night In 4% paraformaldehyde/PBS at 4!C. Embryos were embed-
ded In 15% sucrose and 7.5% gelatin In PBS, and sectioned on a 
cryostat at 15 mm. Procedures for whole-mount staining with antl-
PECAM-1 antibody (clone MEC 13.3, Pharmlngen, 1 :300 overnight 
at4!C) were done essentially as described (Wang et aI., 1998). HRP-
conjugated secondary antibodies (Jackson, 1 :300, overnight at4!C) 
were used for all whole-mount PECAM-l stalnlngs. For Immunofluo-
rescent detection of PECAM-l on sections, secondary antibodies 
conjugated to FITC or Cy-5 (Jackson, 1 :200) were applied for 1 hr 
at room temperature. For Immunofluorescent detection of b-galac-
tosldase, sections were stained with preabsorbed antl~b-galactosi­
dase antibody (3-prlme 5-prlme, 1:1000) overnight at 4!C, followed 
by secondary antibody conjugated to Cy-5 (Jackson) for 1 hr at 
room temperature. Confocal microscopy was carried out on an LSM 
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510 (Zeiss). Anti-Smooth Muscle Actin antibody conjugated to cya 
(Sigma, 1 :250 overnight at4 C) was used to detect ,,-Smooth Muscle 
Actin. Fortriple labeling experiments, PECAM, b-galactosldase, and 
,,-Smooth Muscle Actin were detected using FITC, Cy5, and cya, 
respectively. 
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Chapter 3 
Cardiovascular EphrinB2 Function is Essential for Embryonic Angiogenesis 
Sebastian S. Gerety and David J. Anderson 
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SUMMARY 
EphrinB2, a transmembrane ligand of EphB receptor tyrosine kinases, is specifically 
expressed In arteries. In ephrillB2 mutant embryos, there is a complete arrest of 
angiogenesis. However, ephrinB2 expression is not restricted to vascular endothelial 
cells, and it has been proposed that its essential function may be exerted in adjacent 
mesenchymal cells. Here we have generated mice in which ephrinB2 is specifically 
deleted in the endothelium and endocardium of the developing vasculature and heart. We 
find that sllch a vascular-specific deletion of ephrinB2 results in angiogenic remodeling 
defects identical to those seen in the conventional ephrillB2 mutants. These data indicate 
that ephrinB2 is required specifically in endothelial and endocardial cells for 
angiogenesis, and that ephrinB2 expression in perivascular mesenchyme is not sufficient 
to compensate for the loss of ephrinB2 in these vascular cells. 
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INTRODUCTION 
The development of the embryonic vasculature involves the remodeling of a primitive 
capillary plexus into a more organized, highly branched vessel network (Risau and 
FIamme, 1995). The primary vascular plexi are laid down during the process of 
vasculogenesis, in which endothelial precursors aggregate to form blood islands in the 
yolk sac and endothelial strands in the embryo proper (Risau and Flamme, 1995). 
Angiogenesis, the adaptive morphogenetic transformation of these simple networks, 
results in organized, highly branched, hierarchical networks of large and small vessels. 
Remodeling during angiogenesis occurs through the sprouting of new branches, the 
pruning of existing branches, the fusion of neighboring capillaries, the splitting of 
individual capillaries (intussuception), as well as endothelial proliferation, apoptosis and 
migration (reviewed in Patan, 2000~ Yancopoulos et aI., 2000). Integral to this process is 
the recruitment of supporting pericytes (Schor et aI., 1995) and smooth muscle cells (Oh 
et aI.. 2000~ Yancopoulos et aI., 2000: Folkman and D'Amore, 1996). 
Angiogenesis involves a complex series of reciprocal interactions between the endothelial 
cells of the developing blood vessels and neighboring cells. Perivascular mesenchymal 
cells provide endothelial cells with signals such as Vascular Endothelial Growth Factor 
(VEGF, Carmeliet et aI., 1996; Ferrara et aI., 1996) and Angiopoietin-l (Ang-l, Davis et 
aI., 1996; Suri et aI., 1996; Sato et aI., 1995; Dumont et aI., 1994). In turn, endothelial 
cells send signals of their own, such as Platelet-Derived Growth Factor (PDGF, 
Hellstrom et aI., 1999~ Hirschi et aL 1999), Transforming Growth Factor-~ (TGF-b 
Goumans et aI., 1999; Pepper, 1997; Oshima et aI., 1996; Dickson et aI., 1995) and 
neuregulin (Kramer et aI., 1996; Meyer and Birchmeier, 1995; Marchionni et aI., 1993), 
to surrounding support cells (reviewed in FIamme et aI., 1997; Hanahan, 1997). 
Endothelial cells must also interact with one another, coordinating vessel integrity, 
identity, growth and remodeling via such molecules as Delta-4 (Krebs et aI., 2000; 
Shutter et aI., 2000), integrin avb3 (Friedlander et aI., 1995; Brooks et al., 1994) and VE-
Cadherin (Gory-Faure et aI., 1999; Breier et aI., 1996). Therefore, both endothelial-
support cell and inter-endothelial communication are required for proper vessel assembly 
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(Gale and Yancopoulos, 1999; Hanahan, 1997; Folkman and D'Amore, 1996; Risau and 
Flamme, 1995). 
EPH receptor tyrosine kinases and their transmembrane ligands, the ephrins (Wilkinson, 
2000), have recently been shown to be expressed in and around the developing 
circulatory system (reviewed in Adams and Klein, 2000). A number of studies have 
implicated ephrin signaling in endothelial cell behavior and angiogenesis (Adams et a!., 
2001; Helbling et a1.. 2000; Adams et aI., 1999; Gerety et a!., 1999; Stein et a!., 1998; 
Wang et aI., 1998; Daniel et a1.. 1996; Stein et aI., 1996). EphrinB2 is specifically 
expressed in arterial endothelial cells, and ephrinB2 homozygous mutant mice die at E9.5 
with severe cardiovascular defects (Adams et aL 1999; Wang et aI., 1998). To date, 
ephrinB2 is the only ephrin ligand whose knockout shows an angiogenic phenotype 
(Adams et a1.. 1999). Deletion of the ephrinB2 cytoplasmic domain yields an identical 
vascular phenotype, consistent with the notion that this transmembrane ligand functions 
in reverse-signaling (Adams et a!., 2001). 
Initial studies suggested that the mam ligand function of ephrinB2 is exerted in the 
arterial endothelium, where it mediates signaling to veins via EphB4, a receptor more 
abundantly expressed on venous endothelial cells (Gerety et aI., 1999; Wang et aI., 1998). 
Consistent with this notion, EphB4 mutant mice show angiogenic defects similar or 
identical to those in ephrinB2-1- mice (Gerety et a1., 1999). However, in contrast to 
EphB4, which is restricted to the cardiovascular system, expression of ephrinB2 is not 
restricted to endothelial cells, but is also found in mesenchymal cells, pericytes and 
vascular smooth muscle cells surrounding sites of active angiogenesis (Gale et aI., 2001; 
Shin et aI., 2001; Adams et aI., 1999; Wang et a1.. 1998). These observations suggested 
that ephrinB2 might mediate support cell to endothelial cell communication, as well as 
inter-endothelial interactions (Adams et aI., 1999; Gale and Yancopoulos, 1999; Gerety et 
a!., 1999). Consistent with this, recent studies in mouse (Adams et aI., 1999) and 
Xenopus (Helbling et al., 2000) have attributed a role to mesenchyme-derived ephrinB2 
signals in restricting blood vessel growth to the intersomitic space. In these experiments, 
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however, ephrin signaling was disrupted throughout the embryo, obscuring its essential 
site of action. 
We were interested in determining whether endothelial ephrinB2 expression is essential 
for angiogenesis, or if ephrinB2 derived from perivascular mesenchyme is sufficient to 
drive vascular remodeling. We therefore constructed a conditional allele of ephrinB2 
which can be excised by the expression of ere recombinase (ere) in a tissue of interest 
(Nagy, 2000: Orban et aI., 1992). Endothelial-specific deletion was accomplished by the 
use of a transgenic Tie2-ere mouse line that expresses ere in endothelial cells of the 
embryo (Kisanuki et aI., 200 1). This endothelial specific knockout of ephrinB2 leads to 
angiogenic remodeling and cardiac defects indistinguishable from that of the 
conventional eplzrillB2 knockout (Wang et aI., 1995). These data demonstrate that 
ephrinB2 is absolutely required in the endothelial and endocardial cells of the deVeloping 
mouse embryo for proper cardiovascular development of both arteries and veins. In all 
cases examined, ephrinB2 expression in adjacent mesenchymal tissue was not sufficient 
to compensate for the loss of endothelial expression in neighboring vessels. 
MATERIALS AND METHODS 
Generation of a floxed ephrinB2 allele 
Genomic clones for the ephrinB2 locus were previously isolated (Wang et aI., 1998). A 
double-stranded oligonucleotide containing the 34bp loxP site sequence and a 3' HindIII 
restriction site was inserted into an EagI restriction site at position -45bp in the 5' UTR of 
an ephrinB2 genomic clone that included the first coding exon. From this modified clone 
an Eagl-EcoRI restriction fragment, which encompassed the sequence from the 10xP site 
through the end of coding exon I, was ligated to a 2.Skb XbaI-EagI genomic fragment 
used as the left taraetina arm. A 100bp EcoRI-XbaI genomic fragment starting at the end b C '-' ~ 
of exon I was cloned downstream of the left targeting arm, thereby restoring the complete 
genomic sequence of this locus. For construction of the right targeting arm, a 5.6kb 
Xbal-Asp71S genomic fragment starting 100bp downstream of first coding exon was 
cloned in multiple steps downstream of a 10xP site-flanked PGK-neomycin gene (Floxed 
PGKneo, the generous gift of J. Yoon and B. Wold) derived from pPNT (Tybulewicz et 
11 
aI., 1991). This PGKneo and right arm fragment was then joined to the left arm 
construct. The resulting targeting construct thus contained 3 10xP sites (Fig. 1 A, 
"Targeting vector," triangles). Cre recombinase mediated deletion between the first and 
second sites results in loss of the ephrinB2 first exon coding region, while deletion 
between the second and third 10xP sites results in deletion of the PG Kneo cassette. 
Electroporation and selection of AB-I ES cells (strain 129 SvJ) were performed 
essentially as described (Ma et aI., 1998), with the exception that FIAU selection was 
omitted. ES cell targeting efficiency via G418 selection was lout of 12 clones. 
Homologous recombination of the targeted ephrinB2 locus in ES cells was confirmed by 
HindIII restriction digest of genomic DNA and Southern blotting. A 1kb HindIII-XbaI 
genomic fragment upstream of the left arm was used as a southern probe (Fig. lA, "Probe 
A") to distinguish wildtype (6kb) or targeted (4kb) EphrinB2 locus (Fig. IB). 
To remove the Floxed PGKneo selection cassette, we used transient expression of Cre 
recombinase. Uncut pBS 185 plasmid (Invitrogen) containing CMV -driven Cre 
recombinase expression was electroporated into homologously recombinant ES cells, and 
the cells were plated at high density. After 48 hours of growth, the cells were trypsinized 
and replated at low density. Between 10 and 14 days of growth, individual colonies were 
picked and replated into 96-well plates. Southern blot analyses of genomic DNA isolated 
from plate replicates identified ES clones that had undergone deletion of the PGKneo 
cassette but retained an intact exon I (Fig. lA, "Floxed locus" and Fig. IC, "Neo 
deleted"). Genomic DNA was cut with HindlII, and a 1.2kb EcoRI-HindlII genomic 
fragment was used as a Southern probe (Fig. 1 A, "Probe B"). Wildtype, exon I-deleted, 
and fully deleted loci were indistinguishable using this southern strategy, as they all 
generate a band of approximately 6kb (Fig. Ie, "Wildtype"). Blastocyst injection of 
floxed ephrinB2 ES cells were performed essentially as described (Ma et aI., 1998). 
Germline chimeras were crossed onto a pure C57/Bl6 background and all subsequent 
breeding was done in a C57/816 background. 
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Genotyping 
PCR genotyping for the conditional ephrinB2 allele (t1oxed allele) was performed with a 
5' pnmer specific for the 5' loxP site insertion. 5'-
AAGTTATAAGCTTCAACGCGTCC-3' (TF3). and a 3' primer in the genomic region 
downstream of exon 1, 5'-GAGCCCCAGGTTCTAGAATAACTTCG-3' (RF1) (product 
size: 320bp). Genotyping of the eplzrinB2-lacZ allele was done with the following lacZ 
specific pnmer paIr: 5'-CGCCCGTTGCACCACAGATG-3' (UX-161) and 5'-
CCAGCTGGCGTAATAGCGAAG-3' (UX-160G) (product size: 370bp). The Tie2-Cre 
trans gene was detected by allele specific primers, with a 5' primer in the Tie2 promoter, 
5'-GGGAAGTCGCAAAGTTGTGAGTT-3' (Tie2T5Fl) and a 3' primer in the Cre gene. 
5'-CTAGAGCCTGTTTTGCACGTTC-3' (Cre2) (product size: 490bp). The wildtype 
eplzrinB2 locus was detected with a 5' primer that includes sequence flanking the inserted 
5' 10xP site, and a 3' primer downstream of the first exon, 5'-
GCTGCCCGCGGCCGGTCCCAACG-3' (BrgFl) and 5'-
CCGTTAGTGGCAACGTCCTCCGTCCTCG-3' (HL-I-R2h) (product size: 580bp). 
Conditional knockout mice were identified by the presence of 10xP-allele specific, lacZ 
allele specific, and Tie2-Cre specific PCR products. Homozygous ephrinB2-lacZ 
embryos were idcntified by the presence of lacZ-specific PCR products and the absence 
of wildtype ephrinB2-specific PCR products (in duplicate). Homozygous eplzrinB2-loxP 
mice were identified by the presence of 10xP-aliele specific PCR products and the 
absence of wildtype ephrinB2-specific PCR products. In all embryos, a small amount of 
tissue was collected from the tail region for genomic DNA isolation and genotyping. To 
demonstrate deletion of ephrinB2-loxP exon I in vivo, the following primers were used to 
distinguish intact (636bp) and deleted (309bp) ephrinB2-loxP alleles: 5'-
CGGCCGGTCCAT AACTTCGT A T AGCA-3' (HLFl) and 5'-
CCGTTAGTGGCAACGTCCTCCGTCCTCG-3' (HL-I-R2h). 
To generate conditionally-deleted eplzrinB2 embryos, we first generated mIce 
heterozygous for both the ephrinB2-lacZ allele and the Tie2-Cre transgene 
. l(/cZI+. + (ephrl1lB2 ;Tle2-Cre ). These mice were then crossed to ephrinB2-1oxP 
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( J . B2!oxPI+ h . !oxPIloxP epzrm ) eterozygous (or ephrmB2 homozygous) mIce. EphrinB2 
conventional knockouts were generated by intercross of eplzrillB2!acZI+ heterozygotes 
(Wang et aI., 1998). For vascular-specific Cre Recombinase expression, we used the 
Tie2-Cre transgenic mouse (Kisanuki et aI., 2001). The Tie2-Cre expression pattern of 
was examined by crossing Tie2-Cre mice to the R26R Rosa lacZ reporter mice (Soriano. 
1999). Embryos were collected at E8.25-E9.5 and processed as described below by X-
gal development or immunofluorescent double-labeling. 
LacZ and immunohistochemical staining 
To examine lacZ expression, embryos were dissected between E8.25 and E9.5, fixed in 
0.25% glutaraldehyde/PBS for 5 minutes, rinsed twice with PBS, and stained overnight at 
37°C in X-Gal buffer (1.3 mg/ml potassium ferrocyanide, 1 mg/ml potassium 
ferricyanide, 0.2% Triton X-100, 1 mM MgCI2, and 1 mg/ml X-Gal in PBS [pH 7.2]). 
For antibody staining, embryos were first fixed overnight in 4% paraformaldehyde/PBS 
at 4°C. For section staining, embryos were embedded in 15% sucrose and 7.5% gelatin 
in PBS, and 15 /-1m sections were collected on a cryostat. Whole-mount staining 
procedures with anti-PECAM-l antibody (clone MEC 13.3. Pharmingen, 1:200 overnight 
at 4°C) and anti-~-galactosidase antibody (3-prime 5-prime, 1:1000, overnight at 4°C) 
were done essentially as described (Wang et aI., 1998). Either HRP-conjugated 
secondary antibodies (Jackson, 1: 200, overnight at 4°C) or secondary anti bodies 
conjugated to FITC or Alcxa-568 (Jackson, 1 :200, and Molecular Probes 1 :250, 1 hr at 
room temperature) were used for whole-mount staining. For immunofluorescent detection 
on sections, secondary antibodies conjugated to FITC or Alexa-568 (Jackson, 1 :200, and 
Molecular Probes 1 :250) were applied for 1 hI' at room temperature. For whole-mount 
immunofluorescent staining, embryos were cleared in Vectorshield (Molecular Probes) 
for 20 minutes subsequcnt to the final antibody wash, then mounted on a slide whose 
coverslip was elevated by a bridge of two covcrslips on each side. This enabled us to 
avoid crushing the embryos. All confocal microscopy was carried out on a Leica SP 
confocal (Leica). All brightfield images were captured using an Axiocam CCD camera 
(Zeiss). 
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In situ hybridization 
In situ hybridization was carried out essentially as described (Wang et aI., 1998: Birren et 
aI., 1993). E9 embryos were cryosectioned at 15 11m, and adjacent sections were 
hybridized with RNA probes against the ephrinB2 EC domain (Wang et aI., 1998), and 
Flk-l (the generous gift of T. Sato). 
RESULTS 
Generation of a conditional ephrinB2 allele 
To study the role of ephrinB2 specifically in the vasculature, we generated a loxP flanked 
(floxed) ephrinB2 allele. A targeting construct was created with one IoxP site inserted 
into the 5' UTR at -45bp, and a second site inserted 100bp downstream of exon I as part 
of a loxP flanked neomycin resistance cassette (floxed PGKneo, Fig. lA, "PGKneo"). 
This arrangement placed IoxP sites flanking exon I, which encodes the ephrinB2 signal 
peptide, followed by the neor cassette. Homologous recombinant ES cells were identified 
by G418 selection and southern analysis (Fig. 1B, "loxP-neo/+"). The floxed neo cassette 
was then deleted by transient Cre expression in ES cells. ES cells with only the neo 
cassette deleted, and an intact 10xP-flanked exon I (Fig. lA, "Floxed locus"), were 
identified by southern analysis (Fig. 1 C), and used to generate chimeric mice. 
Subsequent intercrossing of F 1 I . B?/oxPI+ eplrzn _ mIce generated homozygous 
I . B?/o'(PI/o'(P . d M d l' . ep lrln _. . mIce at expecte en e Ian rat1OS. No obvious detriment to the 
development and reproductive capacity of the mice carrying two floxed alleles was 
observed. This suggests that the genomic alteration introduced had no measurable effect 
on ephrinB2 expression or function. 
To verify that the floxed ephrinB2 allele was able to undergo Cre-mediated deletion, 
I . B?/oxPI+ ' d CMV C . h' h C . d' 11 ep lr!n _ mIce were crosse to a - re mouse, In w IC re IS expresse In a 
cells of the early embryo (Zinyk et aI., 1998). Embryos that inherited both the 
ephrinB210xP allele and the CMV-Cre transgene show deletion of the 10xP allele by PCR 
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analysis (Fig. 1 D, right panel, lower band, "deleted"). Embryos that inherited the 
. loxP 
ephnnB2 allele but no Cre trans gene showed no deletion (Fig. 1 D, left panel, upper 
band, "intact"). Sequencing of these PCR products confirmed the deletion event (data 
not shown). Deletion of eplzrinB2 exon I by Cre recombinase removes the signal peptide, 
creating a null allele similar in structure to the original conventional ephrinB2 knockout 
allele (Wang et ai., 1998), with the difference that no lacZ marker is included. 
Embryonic endothelial-specific ere expression 
To knock out eplzrinB2 specifically in endothelial cells, we used an endothelial-specific 
Cre-expressing transgenic mouse line, Tie2-Cre (Kisanuki et aI., 2001). Tie2, a pan-
endothelial receptor tyrosine kinase, is expressed from the earliest timepoints of vascular 
development (Dumont et aI., 1995: Dumont et aI., 1992). The Tie2 Promoter/enhancer is 
well characterized and has been shown to specifically drive transcription in the majority 
of embryonic endothelial cells (Schlaeger et aI., 1997; Schlaeger et aI., 1995). 
EplzrinB2 expression in the vasculature is first seen around E8.25, immediately after the 
formation of the primary vascular plexus (Wang et aI., 1998). Homozygous 
I . B?lacZllacZ f' h'b' d' I d -I' d E9 (W I ep Inn "- mutants 1rst ex 1 1t car lOvascu ar elects aroun ang et a., 
1998). These two timepoints define the interval during which ephrinB2 function is first 
required in the vasculature. To verify that the Tie2-Cre transgene is expressed during this 
interval, we crossed Tie2-Cre + mice to the Rosa26 reporter (R26R) strain (Soriano, 
1999). In the R26R reporter mice a t10xed transcriptional/translational stop cassette 
(t1oxed STOP Lakso et aI., 1992) is present between the ubiquitously expressing Rosa26 
promoter and the lacZ gene. Any cell expressing Cre will excise the floxed STOP, 
allowing lacZ expression in that cell and all its progeny (Nagy, 2000). Using this 
reporter line, we confirmed that Tie2-Cre is active throughout the vasculature as early as 
E8.25 (Fig. 2). At this stage, the yolk sac, a highly vascularized extra-embryonic tissue, 
shows widespread Tie2-Cre activity (Fig 2A "YS"). The primitive vasculature of the 
embryo proper also shows Tie2-Cre activity (Fig. 2A, arrowheads) throughout the vessels 
of the head, heart region and trunk (Fig. 2C, D, and E respectively, arrowheads). The 
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endothelial lining of the heart the endocardium, is also positive, as expected (Fig. 2E, 
arrows and Kisanuki et al., 2001; Schlaeger et aI., 1997). Since ephrinB2 activity is 
thought to playa role in angiogenic sprouting (Adams et aI., 1999), we wanted to confirm 
that Tie2-Cre was active in endothelial sprouts. Intersomitic vessels derived from 
vascular sprouts of the dorsal aorta showed clear Tie2-Cre activity (Fig. 2B, arrows, 
"DA"). Thus, Tie2-Cre IS specifically expressed in the endothelium, including 
angiogenic sprouts, from a timepoint early enough to delete eplzrinB2 when its 
angiogenic function is first required (Adams et aI., 1999; Wang et aI., 1998). 
Vascular-specific deletion of ephrinB2 results in growth arrest 
I n order to knock out eplzrinB2 in the vasculature, we generated mice heterozygous for 
both the conventional, 1m2-marked ephrinB2 allele (Wang et aI., 1998) and the Tie2-Cre 
transgene ( I . B2/{lcZI+ T' '"' C +) ep Inn ; LeL- re .' and crossed them to I . B2IoxPI+ ep Inn (or 
/ . B2IoxPllurP). W 11 d b f h' E95 d' l' d ep zrlll mIce. e co ecte em ryos rom t IS cross at .. an vlsua lze 
the vasculature by whole-mount antibody staining for PECAM-l, a pan-endothelial 
k (F ' " W b d:l . d d 1 t' I' B?lacZl/oxP T' ? mar er Ig .. )). e 0 serve a (ramatlc un er eve opment 0 ep zrlll _ ; te_-
Cre + embryos (Fig. 3C) compared to wildtype littermates (Fig. 3A): they were smaller, 
and appeared developmentally less advanced. Their hearts were swollen, but were still 
beating. Blood was occasionally seen flowing through the aortic arches, Anterior 
Cardinal Veins (ACVs), and dorsal aorta. The vasculature of conditional knockouts was 
disorganized and less intricately developed than that of wildtype littermates, or 
littermates lacking the Tie2-Cre transgene or one of the targeted ephrinB2 alleles (Fig. 
3D-F). A conventional ephrinB2 mutant was collected and stained side-by-side with this 
I· t' . F' 3B Th I 'f' k k (J' B2 laeZlloxP T' 2 Itter or companson (Ig. ). e vascu ar specI IC noc out ep lrl12 ; Ie -
+ "1 h . 1 I' B"lacZI/acZ . h' Cre ) embryos appeared SImI ar to t e conventlOna ep zrm ""' mutants In t elr 
reduced size, underdevelopment, and vascular disorganization (compare Fig. 3C and B). 
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EphrinB2 is required in endothelial cells for proper peripheral angiogenesis 
Yolk Sac 
A prominent site of angiogenesis in the early embryo is the yolk sac, where a primitive 
vascular plexus of small diameter capillaries is assembled by E8.S. This plexus rapidly 
remodels into a complex, hierarchically branched network. In the yolk sac, ephrinB2 
expression is restricted to the endothelium of the arteries (Wang et aI., 1998), and is 
required for angiogenic remodeling of the primary yolk sac plexus (Adams et aI., 1999; 
Wang et aI., 1998). In situ hybridization of sectioned yolk sac from E9 embryos with 
RNA probes to ephrinB2 and Flk-J confirmed that expression of ephrinB2 is restricted to 
the endotheliaL FIk-1 positive cells (compare Fig. 4A and D). As expected, therefore, in 
both the conditional and conventional knockouts, eplzrillB2 expression is absent from the 
yolk sac (Fig. 4B and C versus A). 
The restriction of cplzrinB2 expression in yolk sac to the endothelium suggested that the 
phenotype of the endothelial specific knockout in this tissue should be identical to that 
seen in the conventional eplzrinB2 knockout. Examination of the yolk sac vasculature of 
I h 1· 1 . f" I' B2 k k b (J' B?!ucZI!oxP T' ") C +) E9 -enc ot e la -spec 1 IC ep Inn Tnoc 'out em ryos ep zrll1 _ ; IC ... - re at .) 
confirmed this, revealing a failure of arterial and venous angiogenesis identical to that 
. h J' B?!C/cZI!(/cZ h b (F' 41 H d d h seen l!1 t e ep lrlrz ... omozygous em ryos Ig. vs ,an ata not sown). 
The yolk sac vasculature in the conditional knockout was a homogeneous capillary bed, 
suggesting an arrest in development of arteries and veins at the primary plexus stage. 
This is in stark contrast to the yolk sac vasculature of littermates, where extensive 
remodeling of vessels is seen by this age (compare Fig. 4G and I). 
EphrinB2 expressed ill arteries is required for remodeling of the Anterior Cardinal 
Vein 
The anterior cardinal veins are the main vessels that transport blood from the head back 
through the sinus venosus to the heart. These lateral vessels appear around E8.S, after the 
formation of the dorsal aorta. Each ACV arises initially from the fusion of multiple small 
vessels present in the lateral mesenchyme of the hindbrain and head (Coffin and Poole, 
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1988). The early, small diameter vessels that will give rise to the ACVs express EphB4 
receptor (Gerety et aI., 1999). EphrinB2 is expressed extensively in the hindbrain 
mesenchyme surrounding the developing ACV as well as in neighboring neuroepithelium 
(Fig. SA-C, red channel, open and filled arrowheads, respectively, and Wang et aI., 
998) B . !aeZ !(feZ . 1 . oth ephnnB2 and £p1zB4 homozygous embryos show a faIlure of ACV 
assembly, resulting in a plexus of disorganized small-diameter vessels (Fig. SN, and 
Adams et aI., 1999; Gerety et aI., 1999). This angiogenic remodeling defect, in a place 
where no Arterio-Venous (A V) interface is apparent at E9.S, suggested that ephrinB2 
from perivascular mesenchymal cells might signal to EphB4-expressing vessels (Gerety 
et aI., 1999).Double-labeling of E9.S embryos from a Tie2-Cre X R26R [acZ reporter 
cross with anti-PECAM-l and anti-~-Gal confirmed that Tie2-Cre is only active in the 
endothelium of the hindbrain (Fig. SD-F. green and red channels respectively, arrows). 
We confirmed vessel-specific deletion by in situ hybridization on conventionally and 
conditionally knocked-out embryos and littermates (Fig. SG-L). Comparison of ephrillB2 
probe and Flk-J probe staining shows that eplzrinB2 was selectively lost in the 
endothelium (Fig. SI and L vs SG and J, arrows), and was still present in the non-vascular 
tissues (Fig. SG vs L arrowheads) of conditional knockout embryos. Flk-J In situ 
hybridization signals confirmed the presence of endothelial cells in these samples (Fig. 
SJ-L). 
We anticipated that the endothelial specific knockout of eplzrinB2 might result in a rescue 
h I h · B'"' f- h ACV h . I /. B2!([cZI!acZ by mesenc yma ep nn _ 0 t e ' p enotype seen conventIOn a ep lrzn 
T . I' B2iacZ/!oxP T' ? C + b E9 5 homozygous mutants. a our surpnse, ep zrm ; ze_- re em ryos at . 
show a failure of ACV assembly and remodeling (compare Fig. SM vs 0, arrows). This 
d t- . d" . h bl f- h '} . B?!C/cZI!acZ h ( e ect was In IstIngUlS a e rom t at seen In ep Inll _ omozygotes compare 
Fig. SN vs 0, arrows). To understand how the loss of endothelial ephrinB2 could affect 
the development of venous vessels apparently not in direct contact with ephrinB2-
expressing arteries, we collected ephrinB2'acZI+ embryos at the 12-13 somite stage 
(E8.S), a timepoint at which the ACV is in the process of forming, and 24 hours before 
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the mutant phenotype is clearly visible in the ACV. The embryos were stained with anti-
PECAM-L and anti-~-gal to detect the ephrinB2-lacZ expression. As expected (Wang et 
aI., 1998), the dorsal aorta was positive for ~-gal (Fig. SP-R, red channel, arrows), as was 
the surrounding mesenchyme (Fig. SP-R, red channel, open arrowheads). We observed 
numerous small branches emanating from the dorsal aorta (Fig. SP-R, filled arrowheads), 
extending to the forming ACV (Fig. SP-R, outlined by dashed white lines). This revealed 
that there is a transient continuity between the developing ACV network and the flllly 
formed dorsal aorta at early stages. This transient contact may represent the locus at 
which arterial ephrinB2 function is required for proper ACV morphogenesis. Thus, these 
data suggest that ephrinB2 expressed in arterial endothelial cells is required for proper 
angiogenesis of veins. 
Endothelial ephrinB2 is required for angiogenesis of arteries ill the head 
Vascularization of the head results in a characteristic hierarchical branching pattern of 
large to small vessels, including morphogenesis of the internal carotid artery (lCA, Coffin 
. /acZ//acZ . 
and Poole, 1988). In ephrznB2 homozygous mutant embryos, thIS network does 
not develop properly, resulting in a disorganized, often fused network of capillaries (Fig. 
6N and Adams et aI., 1999; Wang et a!., 1998). EphrinB2 is expressed in arterial 
endothelial cells of the head (Fig. 6A and B, red channel, arrows), as well as extensively 
in the mesenchyme and neuroepithelium of the developing brain (Fig. 6A and B, red 
channel, open and filled arrowheads respectively and Wang et a!., 1998). PrevioLls 
studies have indicted that ephrinB2 function is essential for angiogenesis of vessels in the 
head, but were unable to distinguish an autonomous requirement for ephrinB2 in the 
blood vessels, from a requirement in the neighboring head mesenchyme or 
neuroepithelium (Adams et aI., 1999; Wang et aI., 1998). 
To examine Tie2-Cre activity in the head, we collected embryos at E9.S from a Tie2-Cre 
X R26R lacZ reporter cross. Double-labeling with anti-PECAM-1 and anti-~-ga1 (Fig. 
6D-F, green and red channels respectively) confirmed that locZ expression was only 
activated in the endothelium of the head (Fig. 6A vs 6D, arrows). To confirm that 
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h . B2 . I' 1 1 . h 1 f J' B2IacZ//o.rP T' 2 C + ep nll expresslOn was se cctlVe yost In t e vesse s 0 epzrzn ; le - re 
mice. in situ hybridization with eplzrinB2 and Flk-} RNA probes was performed on 
conventionally and conditionally knocked-out embryos and littermates. Comparison of 
ephrinB2 probe and Flk-l probe staining indicated that ephrinB2 was selectively lost in 
the vasculature (Fig. 6G-I vs J-L. arrows), and was still present in the non-vascular sites 
(Fig. 6G,I arrowheads), of conditional knockout embryos. As expected, no ephrinB2 
. I . I' B?/acZ//acZ b (F' 6"H" Flk 1 I . h b 'd' . sIgna was present In epzrln _ em ryos Ig. ). -- n SItu y n IzatlOn 
signals in all samples confirmed that the loss of vascular ephrinB2 signals in mutant 
embryos was not due to a loss of endothelial cells in these samples (Fig. 6J-L, arrows). 
In ephrinB/acZ//oxP;Tie2_Cre + embryos the head vasculature fails to assemble correctly 
(Fig. 6M vs 0). The initial head plexus forms, but subsequently remains in a primitive 
d · . d k f'd'l d '11' Th f' B2/acZ//acZ h state, a Isorgal1lze networ 0 1 ate capl anes. e ep 1rtn omozygous 
mutant embryos exhibit an identical phenotype (compare Fig. 6N vs 0). Thus in the 
conditional knockout of eplzrillB2. the absence of endothelial ephrinB2 expression results 
in defective remodeling of the lCA, as well as the branches of the ACV, despite high 
mesenchymal and neuroepithelial ephrinB2 expression at this stage (Fig. 6A and B, red 
channel, arrowheads). These data indicate that endothelial ephrinB2 is required 
autonomously in arteries for proper arterial angiogenesis. 
Endothelial ephrinB2 is required for angiogenesis of intersomitic vessels 
The embryonic trunk is initially vascularized by a series of intersomitic vessels (ISVs) 
that arise from branches of the dorsal aorta (DA) and posterior cardinal veins. These 
vessels grow between adjacent somites to form a simple interconnected network dorsally 
around E8.75. Through extensive angiogenesis this primitive structure elaborates an 
intricate network of small capillaries (Fig. 7M), some of which eventually invade the 
developing neural tube and flanking somites (Drake and Fleming, 2000; Coffin and 
Poole, 1988). 
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EphrinB2 is expressed in the arterial branches of the intersomitic vessels (Fig. 7 A-C, red 
channel, arrows and Gerety et aI., 1999) as well as in the caudal portion of adjacent 
developing somites (Fig. 7 A-C, red channeL arrowheads and Adams et aI., 1999; Gerety 
et aI., 1999; Durbin et al., 1998; Wang et aI., 1998; Wang and Anderson, 1997). 
EphrinB2 homozygous mutants fail to undergo angiogenic remodeling of the intersomitic 
vasculature (Fig. 7N and Adams et aI., 1999; Gerety et aI., 1999). A similar phenotype is 
seen in mutants lacking EphB4, which is specifically expressed in ISVs and not in 
somitic mesenchyme (Gerety et aI., 1999). Somitic ephrinB2 has also been implicated in 
ISV guidance in mouse and Xenopus (Helbling et aI., 2000; Adams et aI., 1999), 
although the penctrance of this phenotype appears variable in mice (Wang et a1., 1998). 
To confirm that Cre activity is restricted to ISVs in the trunk, we examined embryos from 
a Tie2-Cre X R26R lacZ reporter intercross. Double-staining of such embryos for 
PECAM-l and ~-gal confirmed that the lacZ reporter was specifically activated in the 
vessels (Fig. 7 D-F, arrows), and not in the somites or other surrounding tissues (compare 
Fig. 7 A vs 7D). These data suggested that ephrinB2 expression should be selectively 
I·· d· h ISV t' /. B?/{lcZ//oxP y .. ? C + . "T f· h·· . e Imll1ate 111 t e s 0 ep 1nll _ ; le_- re mIce. 0 con Irm t IS, In SItu 
hybridization with ephrinB2 and Flk-l RNA probes was performed. Consistent with the 
Tie2-Cre X reporter data (Fig. 7D-F), these experiments indicated that in the conditional 
knockout, eplzrillB2 is selectively lost in the vasculature (Fig. 7G-J vs J-L, insets, arrows, 
"V"), but is still present in somites (Fig. 7G-L arrowheads, and insets, "S"). Endothelial 
cells are still present, however, as revealed by Flk-I probe signals in all genotypes (Fig. 
7J-L, arrows, and insets, "V"). Complete loss of ephrinB2 in situ signal in the ephrinB2 
conventional knockout confirmed the specificity of the riboprobes used (Fig. 7H). 
Enduthelial-specific ephrinB2 knockout embryos (ephrinB2/acZ//o \P;Tie2-Cre +) show an 
arrest in intersomitic vessel angiogenesis at the primary plexus stage (Fig. 70 compared 
to M). The vessels appear fused dorsally with little or no branching. This phenotype is 
. . I h f' h f· B2/acZllacZ . ( F· 7N 0 1 G t ldentlca to t at 0 t e ep 11'117 mIce compare 19. vs, see a so erety e 
aI., 1999). These data indicate that ephrinB2 is required in the intersomitic arteries for 
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proper angiogenesis to occur. Thus, remodeling of ISVs reqUlres eprhinB2-EphB4-
mediated interactions between ISVs. Somite-derived ephrinB2 signal is apparently not 
sufficient to compensate for the requirement for ephrinB2 in these vessels. 
We did not observe aberrant branching of ISVs into somitic mesenchyme in either our 
conventional or conditional eplzrinB2 knockouts (Fig. 7N and 0, arrowheads). This is in 
contrast to the phenotype described by Adams et a1. in their conventional ephrinB2 
knockout (Adams et aI., 1999), as well as in a study employing mis-expression of 
dominant-negative EphB4 alleles in Xenopus (Helbling et aI., 2000), both of which 
describe aberrant ISV branches into adjacent somites. The difference in the penetrance of 
the ISV branching phenotype between the two conventional ephrinB2 mutations may 
reflect differences in genetic background (Gupta et a1., 2001; Rohan et aI., 2000). 
Consequently, we were unable to determine whether arterial eplzrinB2 expression is 
required for proper intersomitic guidance of the ISVs. The question of whether ephrinB2 
in somitic mesenchyme plays a role in guidance of ISV s will require a conditional 
knockout of the gene specifically in that tissue, on a genetic background allowing the 
penetrance of that phenotype. 
Endocardial ephrinB2 is required for heart development 
The endothelial lining of the early embryonic heart, the endocardium, is similar in many 
respects to the rest of the vasculature, in terms of gene expression, and cell behavior 
(reviewed in Gale and Yancopoulos, 1999; Brutsaert et aI., 1998; Dumont et aI., 1995; 
Dumont et aI., 1992). Subsequent interactions with its specialized tissue environment 
leads to morphological changes including heart looping and myocardial trabeculation, the 
formation of endothelial-cell lined projections from the supporting myocardium (Fishman 
and Chien, 1997). In the heart, ephrinB2 is expressed primarily in the endocardium (Fig. 
8A-C, red channel, arrows, and Wang et a1., 1998). ephrinB2 is also weakly expressed in 
myocardium or other support cells (Fig. 8A-C, red channel, arrowheads, and Wang et aI., 
1998). The heart phenotype in the conventional eplzrinB2 knockout is an arrest of 
development resulting in no looping and little or no myocardial trabeculation, and 
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frequent abnormal swelling of the heart (Adams et ai., 1999; Gerety et ai., 1999; Wang et 
aI., 1998). 
The Tie2-Cre deleter line we used excised in the heart (Fig. 8D-F, red channel, and 
Kisanuki et al., 200 1), as early as E8.25 (Fig. 2E, arrows). No Tie2-Cre activity was seen 
outside of the endocardial lining (Fig. 8D-F, arrows, compare red and green channels for 
~-gal and PECAM-l respectively). Specific loss of ephrinB2 from the endocardium, and 
not from the myocardium, of conditional knockout embryos was confirmed by in situ 
hybridization (data not shown). In such conditionally deleted embryos 
( 1 . B?lacz/lo.rP T' ? C +) b d d "" . h h . ep 1nn _ : ze_- re , we 0 _ serve elective eart morp ogenesls, including 
looping defects, swelling (Fig. 81 vs G) and severely reduced trabeculation (Fig. 8L vs ], 
arrowheads) compared to littermate controls. We observe the same phenotype in 
ephrinBlacZ/lacZ homozygous embryos (Fig. 8H and K versus 1 and L. and Adams et aI., 
1999; Gerety et ai., 1999; Wang et ai., 1998). Thus, endocardial ephrinB2 is essential for 
heart morphogenesis. We observe heart beat and circulating erythrocytes in the aortic 
arches and dorsal aorta of some conditional eplzrinB2 mutant embryos with vascular 
defects, suggesting that cardiac function is not completely lost at stages when peripheral 
angiogenic defects are visible. 
DISCUSSION 
Previous work established that ephrinB2 is specifically expressed in arteries and is 
required for embryonic angiogenesis (Adams et al., 1999; Wang et ai., 1998). However, 
since ephrinB2 is expressed not only in endothelium, but also in mesenchymal tissues 
surrounding sites of angiogenesis, these studies could not distinguish between a vascular 
requirement and a mesenchymal requirement for the ephrinB2 signal. Understanding 
which tissues provide angiogenic ephrin signals influences the way we think about 
angiogenesis and the regulation of its morphogenetic processes (Yancopoulos et ai., 
2000). By knocking out eplzrinB2 specifically in the developing vasculature, we have 
shown that endothelial and/or endocardial ephrinB2 expression is absolutely required for 
embryonic angiogenesis. The extensive mesenchymal expression of eplzrinB2 around 
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sites of active angiogenesis is not sufficient to compensate for the loss of endothelial 
ephrinB2. 
The functional requirement for ephrinB2 is intrinsic to the cardiovascular 
system 
Our data demonstrate that ephrinB2 is required in arterial endothelium for the remodeling 
of veins of the head, ACV, and yolk sac, most likely by signaling through EphB4 
receptor in these vessels. This ligand appears to be required cell-autonomously in arteries 
as well, without which angiogenic remodeling of the lCA and vitelline artery is disrupted 
in the head and yolk sac, respectively. Although ephrinB2 is expressed at high levels in 
the somites nanking the developing ISVs, endothelial ephrinB2 is still required for the 
elaboration of a fine capillary network from the primitive intersomitic arteries and veins. 
These data, therefore, appear to reveal instances of forward, reverse, and bi-directional 
signaling between arterial and venous vessels. Our results also demonstrate that even at 
sites of high mesenchymal ephrinB2, vascular expression is still absolutely essential, and 
argue that mesenchymal ephrinB2 alone is unable to support angiogenesis. 
Our data do not exclude the possibility, however. that somitic ephrinB2 contributes to 
lSV growth and guidance. Adams et a!. observe lSVs branching aberrantly into the 
somites in their ephrinB2 knockout, suggesting that ephrinB2 in the somites plays 
repulsive role, restricting the growth of lSVs to the intersomitic space (Adams et a1.. 
1999). Our ephrinB2 knockout mice do not show a similar aberrant branching phenotype 
(Gerety et a1., 1999). The reason for this difference is not clear. Strain differences may 
account for this discrepancy (Gupta et al., 2001; Rohan et aI., 2000). Consistent with 
this, Adams et a1. find ephrinB2 heterozygous offspring at half the expected proportions 
(scc materials and methods of Adams et aI., 1999), while our ephrinB2 offspring are 
found at Mendelian ratios, suggestive of a reduced penetrance of the ephrinB2 mutant 
phenotype. Forced expression of ephrins or dominant-negative EphB4 receptor 
throughout the developing Xenopus embryo has a similar effect on lSV growth (Helbling 
et al., 2000). This lSV guidance model fits well with the repulsive guidance role ascribed 
to ephrinB2 signaling in neural crest migration and axon pathfinding in and around 
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somitic tissue (Krull et ai., 1997; Wang and Anderson, 1997). However, somite-specific 
deletion of ephrinB2 will be required to confirm that it exerts this ISV guidance function 
from non-vascular tissue. 
Necessity vs sufficiency: does mesenchymal ephrinB2 have a role in 
angiogenesis? 
Our loss-of-function results provide evidence of the necessity of endothelial ephrinB2 in 
angiogenesis, and indicate that mesenchymal ephrinB2 is insufficient to compensate for 
its loss from vessels. However, this does not address whether mesenchymal ephrinB2 
expression is also required for angiogenesis. Given the extensive expression of ephrinB2 
in the mesenchyme surrounding vessels in the head, trunk (Adams et aI., 1999: Wang et 
aI., 1998) and in smooth muscle (Gale et aI., 2001; Shin et aI., 2001), it is possible that 
this non-endothelial expression is required for angiogenesis in parallel with its 
requirement in the endothelium. If so, then the fact that the phenotypes of the 
conventional and endothelial-specific ephrinB2 knockouts are identical argues that such a 
parallel function for ephrinB2 in endothelial and mesenchymal cells must be non-
redundant. Alternatively, the presence of ephrinB2 in the early embryonic mesenchyme 
may be irrelevant to angiogenesis, but instead reflects other potential roles, sLlch as 
somite patterning (Durbin et aI., 1998), neural crest migration (Adams et aI., 2001; Krull 
et al., 1997; Wang and Anderson, 1997), hindbrain segmentation (Xu et aI., 1996; Xu et 
aI., 1995) and axon guidance (Frisen et al., 1998: Drescher et aI., 1995). The direct test 
of a mesenchymal requirement for ephrinB2 in angiogenesis awaits the identification of 
mesenchymal promoter elements with which to generate mesenchyme-specific ere 
deleter mice. 
ACV remodeling requires artery to vein ephrin signaling 
It has been hypothesized that the failure of Anterior Cardinal Vein (ACV) primordium to 
remodel into single-vessel structures in the eplzrinB2 and EphB4 mutants was the result 
of a loss of ephrinB2 stimulation from the adjacent mesenchyme (Adams et aI., 1999; 
Gerety et aI., 1999). An important factor in that interpretation was the lack of obvious A-
V interface between this venous structure and any arterial, ephrinB2 expressing vessels. 
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Based on this we expected that in an endothelial-specific knockout of ephrinB2, we 
would see rescue of the ACV phenotype. Surprisingly, to the contrary, the ACV 
phenotype of our conditional knockout is identical to that of the conventional ephrillB2 
knockout (Adams et aI., 1999; Gerety et aI., 1999). This suggests that an arterial source 
of ephrinB2 is required for ACV morphogenesis, such as the dorsal aorta. How could a 
physically remote tissue send a signal that is by nature membrane bound, requiring cell-
cell contact for transmission? Further analysis revealed transient endothelial continuity 
between the dorsal aorta and the developing ACV plexus at developmentally relevant 
stages during the assembly of these vessels. Based on the combination of conditional 
knockout phenotypes and the dorsal aorta-ACV contacts present in young embryos. we 
believe that the development of the ACV may require transient artery-vein interactions. 
Alternately, defective angiogenesis in the ACV might instead be due to insufficient blood 
flow resulting from aberrant cardiac development and function (see next section). 
Heart morphogenesis requires endocardial ephrinB2 expression 
During embryonic hcart morphogenesis, essential interactions take place between 
endocardial cells (Gory-Faure et aI.. 1999), and between endocardial and myocardial cells 
(Meyer and Birchmeier, 1995) in a reciprocal manner (Carmeliet et a1.. 1996: Suri et aI., 
1996). These tissue relationships are essential for the remodeling of the primitive heart 
tube to the looped, highly trabeculated structure that emerges at E9.5 (Gale and 
Yancopoulos. 1999). EphrinlEph signaling has been implicated in these morphogenetic 
events both by expression and mutant phenotypes (reviewed in Adams and Klein, 2000). 
Because EphB4 is expressed in endocardial and not myocardial cells, the failure of 
myocardial trabeculation in the EphB4 knockout demonstrates that Ephrin signals must 
be received by the endocardium (Gerety et a\., 1999). Establishing the required source 
for the ephrinB2 signal is complicated again by the presence of this ligand in both the 
endocardium and the myocardium (Wang et aI., 1998). Although the expression levels in 
the myocardium are much lower than in the endocardium, the possibility remained that 
the requisite Ephrin signal originates in the myocardium. We now show that endocardial 
ephrinB2 function is absolutely required for heart morphogenesis, and is not compensated 
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for by myocardial ephrinB2. This indicates that ephrinB2-EphB4 mediated signaling 
between endocardial cells is required for this morphogenetic program to be executed. 
The close temporal relationship between vascular and cardiac phenotypes in knockouts of 
most genes encoding angiogenic signaling molecules or their receptors (Gerety et aI., 
1999: Gory-Faure et aI., 1999: Asahara et aI., 1998: Carmeliet et al.. 1996: Ferrara et al.. 
1996: Dickson et al.. 1995; Sato et aI., 1995: Dumont et al., 1994) invariably complicates 
phenotypic analysis and interpretation: a defect in peripheral angiogenesis could be the 
result of defective cardiac development and aberrant blood flow: conversely, defective 
heart development could be due to an obstructed or disorganized vasculature. We do 
observe heartbeat and blood flow in some conditional eplirinB2 mutant embryos with 
vascular defects, arguing that the defective peripheral angiogenesis in such mutants is not 
simply due to a complete lack of blood flow. However, aberrant hemodynamics could 
still contribute to the peripheral angiogenic defects seen in mutant embryos. Resolution 
of this issue awaits the development of appropriate ere deleter transgenic mouse lines to 
temporally bypass the early cardiac requirement for ephrinB2 function, or alternatively 
identification of endothelial- or endocardial-specific promoter elements (Fishman. 1997), 
for loss-of-function or rescue experiments, respectively. 
EphrinBl does not compensate for loss of endothelial ephrinB2 
EphrillB 1 is co-expressed with ephrinB2 in arteries (Adams et al., 1999), but cannot 
compensate for the loss of ephrinB2 in a conventional knockout (Adams et al.. 1999: 
Wang et al.. 1998). The perivascular expression of these ligands, however, does not fully 
overlap (Wang and Anderson, 1997). Previously, therefore, one could have argued that 
the failure of ephrinB I to compensate for ephrinB2 in the conventional knockout might 
reflect a requirement for ephrinB2 function in tissues where ephrinB 1 is not expressed. 
However, the present data indicate that ephrinB 1 cannot compensate for ephrinB2 within 
the cardiovascular system. This failure may reflect critical differences in expression 
levels between the two ligands (Stein et aI., 1998), or alternatively structural differences 
that create different functional properties. For example, ephrinB2 is the only ligand that 
can bind efficiently to EphB4 (Sakano et aI., 1996; Brambilla et aI., 1995). While veins 
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express other EphB receptors that can interact with ephrinB 1, only EphB4 is essential for 
angiogenesis (Adams et a!., 1999: Gerety et a!., 1999). Finally, differences in expression 
patterns within the cardiovascular system could explain the inability of ephrinB I to 
compensate for ephrinB2: while ephrinB2 is expressed only in arterial vessels (Adams et 
a!., 1999: Wang et aL 1998), ephrinB 1 is expressed in all vessels (Adams et a!., 1999). 
The arterial restriction of ephrinB2 may therefore be an important aspect of its role in 
angiogenesis. Gene swapping experin1ents should reveal \vhcther differences in the 
expression or activity of ephrinB I and ephrinB2 account for their functional distinction. 
Reverse signaling by ephrinB2 in angiogenesis 
The interpretation of the vascular defects in the original epizrinB2 knockout was that 
reciprocal signaling between arterial ephrinB2 and venous EphB4 is required for the 
remodeling of both arteries and veins (Wang et aL 1998). An essential feature of this 
model is that upon engaging EphB4 receptors on veins, ephrinB2 functions as a receptor 
in arteries. This idea is supported by studies demonstrating that ephrinB cytoplasmic 
domains can undergo phosphorylation upon receptor binding (reviewed in Adams et a!., 
2001; Wilkinson, 2000: Mellitzer et a!.. 1999: Xu et al., 1999: Bruckner et a1.. 1997: 
Holland et a!., 1(96). Furthermore, a knockout of the ephrinB2 intracellular domain 
shows that the cytoplasmic tail of ephrinB2 is required for vascular morphogenesis 
(Adams et aL 200 I). These data, and the fact that the EphB4 mutation causes arterial as 
well as venous defects, suggest a requirement for reciprocal signaling by Eph receptors to 
ephrinB2 in vascular remodeling. Our results take this one step further, showing that in 
fact this reverse signal must be received by arterial endothelial cells and/or endocardial 
cells for angiogenesis to occur. Taken together, these data reinforce the idea that bi-
directional signaling between ephrinB2 and EphB4 in the cardiovascular system is 
essential for angiogenesis (Wang et a!., 19(8). 
Recent publications have highlighted the fact that many ephrins and Eph receptors are 
expressed in and around the adult vasculature at sites of active angiogenesis such as 
wound-healing and tumor angiogenesis, both in mice (Gale et a!., 200 I: Shin et a1.. 
200 1), and in humans (reviewed in Takai et a!., 2001; Dodelet and Pasquale, 2000; 
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Ogawa et al., 2000; Berdaz et al., 1996). These reports hint at potential roles for ephrins 
and Ephs in normal and pathological angiogenesis in the adult. Establishing whether the 
adult expression patterns of these ligands and receptors reflect functional roles in these 
angiogenic events will be an important step in determining the potential relevance of 
ephrin/Eph targeting drugs for pro- or anti-angiogenic therapies of cardiovascular disease 
and cancer. respectively. Our study has demonstrated the potential of conditional 
knockouts in understanding ephrin function and expression. and provides a useful mouse 
model system to further examine these issues in the adult. 
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FIGURE LEGENDS 
Figure 1. Generation of the Floxed ephrinB2 locus 
(A) Restriction maps of the wildtype ephrinB2 locus, the targeting vector, the initial 
targeted locus, noxed locus after neo deletion, and targeted locus after complete deletion. 
The targeting vector contains 10xP sites (arrowheads) nanking the first coding exon (Grey 
bar). It also contains a floxed PGK-neomycin ("PGKneo") selection cassette which was 
subsequently removed by transient Cre expression to avoid disturbing normal eplzrillB2 
transcription (see [C]). 
(B) Confirmation of homologous recombination of the targeting vector by Southern 
blotting. The ES cell genomic DNA has been digested with HindUI, and hybridized with 
Southern probe A (see [A». Wildtype (6kb) and targeted (4kb) locus differ by a HindIII 
site flanking the 5' loxP site (see [A]). 
(C) Identification of ES cells having undergone PGKneo cassette deletion (see [AJ) after 
transient Cre recombinase expression. Genomic DNA was digested with HindIIL and 
hybridized with southern probe B (see [AJ). "Neo deleted" indicates loss of PGKneo 
cassette with retention of the first exon. Deletion of the entire region or deletion of the 
floxed exon are not distinguishable from wildtype in this Southern blot. 
(D) Confirmation of eplzrinB2 exon 1 deletion in mice. Progeny of an ephrinBloxP1+ X 
CMV-Cre cross show intact (long) or deleted (short) PCR products with primers specific 
for the 10xP allele. 
Figure 2. Tie2-ere activity in early embryogenesis is restricted to the vasculature 
(A-E) Widespread vascular activity of Tie2-Cre in the progeny of a Tie2-Cre X R26R 
lacZ reporter cross at E8.25, revealed by X -gal staining (blue color). 
CA) The highly vascularized yolk sac (YS) shows intense Tie2-Cre activity. The 
prilllitive vasculature throughout the embryo proper (arrowheads) also shows Tie2-Cre 
activity. 
(B) Close-up photograph of intersomitic sprouts C arrows) from the dorsal aorta CD A) of a 
similar embryo to CA) shows Tie2-Cre activity in vessels undergoing angiogenic 
sprouting. 
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(C-E) Sections of littermates of CA) showing Tie2-Cre activity in vessels (arrowheads) of 
the head (C), hindbrain (D) and tnmk (E). The endocardial lining of the heart is also 
positive (E, arrows), as expected (Kisanuki et aI., 2000). Sections were counter-stained 
with Hematoxylin. 
Figure 3. Gross morphology of conditional ephrinB2 knockout embryos and 
Iittermates 
Comparison of embryos from an ephrinB/acZI+ ;Tie2-Cre + X eplzriIlB2/oxP1+ cross (A and 
C-F), and from an ephrinB21clcZI+ intercross (B) by anti-PECAM-l staining at E9.S. The 
conditional ephrinB2 knockout embryo (C) is growth retarded compared to its wildtype 
littermates (A) and littermates lacking either the Tie2-Cre allele or one of the targeted 
eplzrinB2 alleles (D,E,F). An eplzrinB2-!acZ homozygous embryo (B) shows 
developmental arrest similar to the conditional knockout embryo (B versus C). 
Figure 4. Yolk sac angiogenesis is defective in conditional ephrinB2 knockout 
embryos 
(A-F) Restriction of eplzrinB2 mRNA expression to endothelial cells of the E9 yolk sac 
is revealed by in situ hybridization with ephrinB2 (A-C) and Flk-J (D-F) RNA probes on 
. f / . B?!{{cZI+ I A D /. B2!wZI!ucZ (B E d I" I I' B? sectIOns 0 ep Inll _ contro ( , ) ep zrzn , ) an cone 1tlOna ep Inn ... 
knockout (C,F) yolk sacs at E9. EphrinB2 mRNA in controls is expressed in Flk-J-
positive endothelial cells (A versus D), and is lost in both conventional (B) and 
conditional (C) ephrinB2 mutants. 
G I ld . 1 d I' . lk I d l' . I' B?!acZllacZ H d ( -) ennca elects 111 yo sac vesse remo e mg are seen 111 ep Inn _ ( ) an 
conditional eplzrinB2 (I) knockout embryos compared to ephrinB2!ucZI+ controls (G) are 
revealed by whole-mount anti-PECAM-l staining of E9.S yolk sacs. The large (arrow) 
and small (arrowheads) branches in control yolk sacs (G) is instead a plexus of equally-
sized capillaries (arrowheads) in both mutants (HJ). 
100 
Figure 5. Defective remodeling of the Anterior Cardinal Vein of conditionally 
deleted ephrinB2 embryos 
(A-C) EphrinB2 expression is widespread in the hindbrain. EphrinB2/acZ/+ mice at E9.5 
were sectioned and stained for PECAM-l (A and C, green channel) and ~-gal (A and B, 
red channel). A merged image in CA) shows ephrinB2 expression in both arterial 
endothelium (yellow, arrows) and non-endothelial mesenchyme (red. open arrowheads) 
and neuroepithelium (red. filled arrowheads). 
CD-F) Tie2-Cre activity is restricted to endothelial cells of the hindbrain. Embryos from a 
Tie2-Cre X Rosa-/acZ reporter cross at E9.5, sectioned and stained for PECAM-l (D and 
F, green channel) and ~-ga1 CD and E, red channel) show complete overlap (arrows). A 
merged image is shown in CD). 
(G-L) EphrinB2 mRNA expression is lost specifically in the hindbrain vasculature of 
conditional knockout embryos. Sections through . /acZ/+ ephrzl1B2 (G and J). 
. /ocZ//([CZ . /aeZ//ox? + ' , 
ephrznB2 (H and K) and ephnnB2 ;Tlc2-Cre (condltlOna1 knockout, I and 
L) hindbrain regions were hybridized with RNA in situ probes to eplzrinB2 (G,H,I) and 
Flk-l (an endothelial-specific marker, J.K.U. and show loss of ephrinB2 in vessels of 
conditional knockout embryos (compare G and J versus I and L, arrows). EphrinB2 
RNA ' 1 1 b . h f' B?!wZ//acZ 'I k k 'H b m IS comp ete y a sent 111 t e ep lnTl _ conventlona noc out ( ) ut 
remains in the mesenchyme (open arrowheads) and neuroepithelium (filled arrowheads) 
of conditional knockout embryos (compare G versus 0. 
(M-O) Whole-mount PECAM-l staining shows a failure of assembly of the Anterior 
Cardinal Vein (ACV) in conditional knockout embryos compared to ephrinB2'acZ/+ 
) E h 'B",!acZ//({cz b h 'd' I controls (compare 0 versus M. arrows. p nn L em ryos s ow an 1 entlca 
vascular phenotype (compare 0 versus N). Image in (0) is a close-up of embryo in Fig. 
3C. 
(P-R) Vascular sprouts connect the ACV to the dorsal aorta at E8,5. Whole-mount 
staining for PECAM-l (P and R. green channel) and ~-gal (P and Q. red channel) of 
ephrinB2/acZ/+ mice show multiple vascular branches (P and R, filled arrowheads) 
interconnecting the ACV primordium (P-R, outlined by broken white lines) and the 
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ephrinB2 expressing dorsal aorta (arrows), A merged image in (p) shows mesenchymal 
ephrinB2 expression (red, open arrowheads) surrounding the immature ACY plexus 
(green channeL outlined by broken white lines), 
Figure 6. Defective angiogenesis in the heads of conditionally deleted ephrinB2 
embryos 
(A C) E h ' B'" "'d d' h h d E h' B",/([cZI+, E9 5 - P nn L expreSSIOn IS WI esprea In t e ea, p nn L mIce at ,were 
sectioned and stained for PECAM-I (A and C, green channel) and ~-gal (A and B, red 
channel), A merged image in (A) shows ephrinB2 expression in both endothelial (yellow) 
and non-endothelial (red) mesenchymal (open arrowheads) and neuroepithelial (closed 
arrowheads) tissues; ICA, internal carotid artery, 
CD-F) Tie2-Cre activity in the head is restricted to endothelial cells, Embryos from a 
Tie2-Cre X Rosa-lacZ reporter cross at E9,5, sectioned and stained for PECAM-l (D and 
F, green channel) and ~-gal (D and E, red channel), show complete overlap, A merged 
image is shown in (D), 
(G-L) EphrinB2 mRNA expreSSIOn IS lost specifically in the vessels of conditional 
. , !c/(ZI+ , /acZI/acZ knockout embryos, SectIOns through ephnnB2 (G and J), ephrlllB2 (H and 
K' j I' B,)/ac7.//oxP T' ') C + d" I k k I I L h b 'd' d 'h ) ane ep Inn ~ ; le~- re (con ItIona 'noc out, ane ) were y n lze WIt 
RNA in sitl! probes to eplzrinB2 (G,H,I) and Flk-l (an endothelial-specific marker, 
J,KL), and show loss of ephrinB2 in vessels of conditional knockout embryos (compare 
G and J versus I and L, arrows), EplIrinB2 mRNA IS completely lost in the 
,/acZllacZ ' 
eplzrmB2 conventIOnal knockout (H), but remaInS In the mesenchyme (open 
alTowheads) and neuroepithelium (closed alTowheads) of conditional knockout embryos 
(compare G versus l), 
(M-O) Whole-mount PECAM-l staining shows arrested vascular remodeling in the heads 
of conditional ephrinB2 knockouts compared to littermate controls (compare 0 versus 
M E h ' B,,/acZI/acZ h d h 'd' I I h ( 0 [), P nn L ea s s ow an I entlca vascu ar p enotype compare versus 
N), Images in (M) and (0) are close-ups of embryos in Fig, 3F and 3c' respectively, 
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Figure 7. Angiogenic arrest of the intersomitic vasculature in conditional ephrinB2 
knockout embryos 
(A-C) EphrinB2 expression IS present 111 vascular and non-vascular trunk tissues. 
EphrinB2/acZI+ mice at E8.S were stained in whole-mount for PECAM-1 (A and C, green 
channel) and ~-gal (A and B, red channel). The dorsal aorta and its intersomitic sprouts 
(A-C, arrows) express eplzrinB2-lacZ (red channel), as does the caudal half of each 
somite (A and B arrowheads). 
(D-F) Tie2-Cre activity is restricted to endothelial cells in the trunk. Whole-mount 
staining for PECAM-l (D and F, green channel) and ~-gal (D and E, red channel) of E8.S 
progeny of a Tie2-Cre X R26R lacZ reporter cross shows that ~-gal expression. reflecting 
Tie2-Cre activity (El, is restricted to endothelial cells of the dorsal aorta and intersomitic 
vessels (D-F, arrows), as seen in merged image (D, yellow). 
(G-L) EphrinB2 mRNA is still expressed in the somites of the conditional ephrillB2 
knockout, as revealed by in situ hybridization with eplzrinB2 (G,H,I) and Flk-l (J,K,L) 
. . /ocZI+ . /acZI/acZ RNA probes 111 E9 ephnnB2 control (G), eplzrlllB2 mutant (H,K), and 
conditional ephrinB2 knockout (I,L) embryos. Somite expression of ephrinB2 in caudal 
half of somites (G-I, arrowheads) is completely lost in conventional knockout (H) but is 
still present in the vessel-specific knockout (I), compared to control embryos (G). Insets 
in (G-U confirm eplzrinB2 expression in ISVs of eplzrinB2hlLZ1+ control emhryos (G vs J, 
arrows), and its ahsence from these vessels in conventional (H vs K. arrows) and 
conditional mutants (I vs L, arrows): S, somite: V, vessel. 
(M-O) Absence of intersomitic vessel remodeling at E9.S is revealed by whole-mount 
staining for PECAM-l in control ephrinB/acZI+ (M), eplzrillB21acZllucZ (N) and 
conditional knockout (0) embryos. The ISV network is fused dorsally in both 
cOllventional (N) and conditional (0) ephrinB2 mutants, as compared to the elaborated 
network in control embryos (compare Nand 0 versus M). ISV guidance appears normal 
in both conventional and conditional mutant embryos CM-O, arrowheads). Images in (M) 
and (N) are close-ups of embryos in Fig. 3F and 3B, respectively. 
103 
Figure 8. Defective heart morphogenesis in both ephrinB2 conventional and 
conditional mutant embryos 
(A-C) EphrinB:2 is primarily expressed in the endocardial lining (arrows) of the heart, as 
revealed by sections of E9.5 ephrillB2'{/cZI+ embryos stained for PECAM-I (A and C, 
green channel) and ~-gal (A and B, red channel). Some non-endocardial staining is seen 
(A-C, red channel not overlapping with green, arrowheads). 
CD-F) In the heart, restriction of Tie2-Cre activity to the endocardial lining is revealed by 
E9.5 sections of Tie2-Cre X R26R 10cZ reporter cross embryos double-labeled for 
PECAM-l (0 and F. green channel) and ~-gal (0 and E. red channel). A merged image 
(D) shows Tie:2-Cre activity is only found in the PECAM-I-positive endocardial lining 
(arrows). 
(G-I) EphrinB:2 conventional and conditional embryos show swelling and defective 
looping of the heart compared to control eplzrinB2!c/(ZI+ embryos (compare Hand r versus 
G), revealed by whole-mount anti-PECAM-l staining at E9.5. 
(J-L) PECAM-l stained sections of hearts reveal little or no myocardial trabeculation 
(arrowheads) in both the conditional and conventional mutants (compare Land K) 
compared to control embryos (compare K.L vs 1. arrowheads) at E9.5. 
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Chapter 4 
Concluding Remarks 
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Although it has been suspected for the last decade that ephrinlEph signaling might 
playa role in angiogenesis (Pandey et aI., 1995; Sarma et a!., 1992; Holzman et al., 
1990), it is only in the last few years that direct genetic test of their role has been 
undertaken (reviewed in Adams and Klein, 2000). Analysis of mouse mutants of 
Eph/ephrins expressed in endothelial cells has contributed greatly to our understanding of 
Eph signaling in embryonic angiogenesis (Adams et a!., 1999; Gerety et a!., 1999; Wang 
et aI., 1998). These studies are revealing an important role for this large RTK family in 
vascular remodeling. The expression patterns and knockout phenotypes of ephrinB2 and 
EphB4 (Adams et aI., 1999; Gerety et aI., 1999; Wang et a!., 1998) in mouse highlight the 
unique role of this RTK system in inter-endothelial communication between arteries and 
veins, a new paradigm in angiogenesis first uncovered in the original ephrinB2 knockout 
study (Wang et aI., 1998). 
Outstanding issues 
Although these and other Eph receptors have been analyzed by mouse knockout 
experiments, important information is still missing. Do ephrinB 1, ephrinA 1, and EphA 
receptors also play a role in vascular remodeling? While their expression patterns 
suggest they might the answer to these questions await the analysis of mouse knockouts 
for these genes. Given the pan-endothelial expression of ephrinB 1, for example. whether 
it has an angiogenic mutant phenotype is very important to our understanding of how and 
what Eph signaling contrihutes to vascular development. The conditional ephrinB2 
knockout mouse developed for Chapter 3 is most likely only the first in a series of more 
carefully targeted genetic manipulations of the Eph system, which will hopefully clarify 
the importance of different tissue interactions. Although I have shown that ephrinB2 is 
absolutely required in vascular endothelial cells, and that perivascular ephrinB2 cannot 
compensate for its loss (Chapter 3), we still do know if non-vascular ephrinB2 has any 
role in angiogenesis. The generation of additional tissue-specific Cre deleter lines (i.e., 
mesenchymal, perivascular, cardiac specific) should help refine our models of Eph 
signaling in angiogenesis. 
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Is the A-V restriction of ephrinB2 and EphB4 important for their angiogenic 
functions? 
Through the major focus of my work, I have established a clear requirement for 
venous expression of EphB4 receptor, and arterial expression of ephrinB2 ligand during 
vascular remodeling in the mouse embryo (see Chapter 3, Gerety et a1.. 1999). So faL 
EphB4 and ephrinB2 are the only members of these large gene families that have been 
shown to be absolutely necessary for angiogenesis. How important is it that these are 
restricted to venous and arterial domains, respectively? According to our present models, 
this restriction is essential, as we believe that the specialized morphology of the arterio-
venOllS boundary requires a unique set of signaling events during development. In order 
to test this hypothesis, I have generated transgenic mice, in which ephrinB2 expression 
should no longer be restricted to arterial cells (see Figure 9). In these mice, tissue-
specific cre recombinase expression can activate ephrinB2 expression. By crossing these 
mice to Tie2-cre mice (Kisanuki et aI., 200 I), we can force expression of ephrinB2 in 
vein endothelial cells of the developing embryo, thereby altering its normally restricted 
expression pattern. Future analysis of these crosses, to be carried out by a fellow 
graduate student Dong Hun Shin, should help address the importance of the A-V 
restriction of ephrinB2 and EphB4. 
LoxP LoxP 
CMVPromoter HPLAP 
LoxP 
MV Promoter EphrinB2 
Figure 9 - Conditional overexpression of ephrinB2 
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Two independent Eph pathways in angiogenesis? 
The specificity of the EphB4 receptor for ephrinB2 (Sakano et aI., 1996; 
Brambilla et aI., 1995) provides a mechanism by which development can overlay two 
relatively independent signaling modalities using notoriously promiscuous receptors and 
ligands. Although ephrinB I is expressed in a pan-endothelial manner, EphB4 does not 
"see" this ligand. The EphB3 receptor, although restricted to veins like EphB4, may not 
"see" the A-V boundary, due to its affinity to both ephrinB ligands. In this way, EphB4 
may mediate signaling specifically at the A-V interface, while EphB3 mediates vein-
specific autocrine ephrin signals (see Figure 7). It is important to note that EphB3 
knockout mice show no angiogenesis phenotype (Adams et a!., 1999), raising questions 
as to its role in this process. Gene swapping experiments may help us understand the 
differences in the roles of each receptor and ligand. 
Is the phenotype of the ephrinB2 knockout secondary to cardiac defects? 
Most knockouts of angiogenic genes result in lethality around E9.5 in mouse. 
This timepoint marks the earliest requirement for cardiac and vascular function in the 
development and survival of the embryo. Most of these mouse mutants show not only 
defects in vessel remodeling, but also defective. or stunted heart development. The 
nearly simultaneous onset of both cardiac and vascular phenotypes has made it difficult 
to positively ascribe an autonomous role to these genes in remodeling the peripheral 
vasculature. As discussed in Chapters 2 and 3, the vascular phenotypes, and resulting 
poor or occluded blood flow, could be the cause of observed heart defects. Conversely, 
poor cardiac development and resulting blood flow defects could be depriving the 
vasculature of a necessary angiogenic stimuli, including flow-induced shear forces and 
blood pressure differentials. This confusion arises only when the gene is question is 
present in both the peripheral vasculature (or supporting tissues) and the developing 
heart. Given that the endocardial lining of the heart is comprised of endothelial cells, it is 
not surprising that this is the case for all but one known case so far (Connexin-40, 
D.Shin, unpubl. obs., and Delorme et aI., 1995). While the in vitro data together with 
careful mutant analysis (see Chapter 2, Gerety et aI., 1999) strongly argues the Eph 
signaling has a role in angiogenesis, the direct test of a requirement for ephrins in the 
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peripheral vasculature requires a conditional knockout in vessels, but not the heart, or 
alternately a selective rescue of ephrinB2 expression in the endocardium (see Chapter 3, 
discussion) on and ephrinB2 mutant background. Promoter elements with the necessary 
expression patterns (endothelial + non-endocardial, or endocardial + non-endothelial) 
with which to generate transgenic mice have yet to be identified. 
Is there a role for Eplz signaling in the adult vasculature? 
One area of considerable interest in vascular biology is angiogenesis in the adult 
(Takai et aL 2001: Dodelet and Pasquale, 2000; Ogawa et aL 2000; Tang et al., 1999; 
Patan et aI., 1996; Folkman, 1995; Shibuya, 1995). Tumor vascularization is believed to 
occur through angiogenic remodeling and recruitment of nearby vessels, co-opted to 
supply a growing tumors needs (Neufeld et aI., 1999; Folkman, 1995). A growing body 
of evidence supports the notion that the molecular underpinnings embryological 
angiogenesis are recapitulated to some degree in adult settings of blood vessel growth. 
Anti-tumor therapies that target a tumors blood supply are being developed. therefore, 
using the molecular discoveries in embryonic vascular biology. VEGF has proven to be 
an important target for such therapies (review in Robinson and Stringer, 2001; Carmeliet, 
2000; Poltorak et aJ.. 2000; Carmeliet and Collen. 1999; Dvorak et aI., 1999; Ferrara. 
1999a; Ferrara. 1999b; Kim et aI., 1993). A growing number of studies have identified 
the expression of Eph receptors and ephrin ligands in and around sites of normal and 
pathological angiogenesis in postnatal mice and humans (reviewed in Gale et aI., 2001; 
Shin et aI., 200 I; Takai et al., 2001; Dodelet and Pasquale, 2000; Ogawa et aI., 2000; 
Berclaz et a1.. 1996). In a study from our laboratory (see appendix II), ephrinB2 ligand 
was detected in a subset of microvessels invading implanted tumors in adult mice, 
invading wounds, and in corneal micropocket-induced neoangiogenesis (see also Gale et 
al.. 2001; Shin et aI., 20(1). During the period of retinal angiogenesis from PO to P8, 
arterial vessels express ephrinB2 (see Figure 10). While these studies demonstrate the 
presence of both Eph receptors and ligands in the adult vasculature, it remains to be 
determined whether they playa role in these angiogenic processes (see below). 
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Figure 10 - ephrinB2 expression during retinal angiogenesis 
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Experimental approach to future postnatal studies 
Since knockouts of most known angiogenic factors lead to early embryonic 
lethality, conventional loss-of-function studies have not been able to establish the 
importance of these genes in late embryonic, postnatal, and adult vascular development 
(except VEGF, see Gerber et ai., 1999). The conditional ephrinB2 knockout mice 
generated for Chapter 3 are an important tool in determining the involvement of Eph 
signallng in adult angiogenesis. By conditional knock out of ephrinB2 in postnatal mice, 
we can examine the role of this ligand in adult angiogenesis. These studies are a 
necessary step in determining whether Eph signaling may serve as a useful target for 
therapeutic intervention. The temporal control of cre activity can be achieved by the use 
of inducible cre recombinase-estrogen receptor fusion (Cre-ER), which is only active in 
the presence of tamoxifen, an estrogen analog (Danielian et aL 1998; Kellendonk et al.. 
1996). By crossing a Tie2-creER or VEGFR2-creER deleter strain to our conditional 
ephrinB2 mice, we can bypass the early lethality of the conventional ephrinB2 mutant, 
and induce deletion of ephrinB2 after bi11h. These experiments await the development of 
such tissue-specific inducible Cre transgenic mice. Alternately, direct retinal injection of 
cre expressing virus would provide deletion in the retina, though not in a vascular-
specific manner. Tumor cells engineered to secrete cre expressing viruses and implanted 
into ephrinB2 conditional knockout mice might provide a way of examining the role of 
ephrinB2 in tumor angiogenesis: any co-opted vessel invading the tumor mass would 
become infected. express cre. and thereby delete ephrinB2 in invading endothelial cells. 
The last decade has seen tremendous progress in our understanding of vascular 
biology and the molecular mechanisms that underlie the development, maintenance, and 
pathology of blood vessels (Risau, 1997; Folkman and D'Amore, 1996; Risau, 1995). 
Discoveries in the last 3 years on the importance of Eph signaling to embryonic 
angiogenesis have opened up a whole new area of research on this RTK system (Adams 
et a1., 200 L Yancopoulos et aI., 2000; Gale and Yancopoulos, 1999). Growing interest in 
this particular aspect of vascular biology, namely the role of artery and vein restricted 
molecules in angiogenesis, is likely to accelerate the pace of discovery (Gridley, 2001; 
Herzog et al.. 200 J; Lawson et aI., 2001; Moyon et aI., 200 L Adams et aI., 1999; Gerety 
[22 
et aI., 1999). The many outstanding issues raised by this work will be the subject of 
further study, and promises to contribute to our understanding of this important 
developmental process, in both basic biology and human disease. 
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Appendix I 
Preliminary Comparative Analysis of EphB4 and EphrinB2 Expression 
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Initial studies of EphB4 in the vasculature (Adams et aI., 1999; Wang et a1., 1998) 
described restricted expression in veins, and not arteries. EphrinB2, the only EphB4 
ligand (Sakano et aI., 1996; Brambilla et a1.. 1995), is expressed in arteries, and not veins 
(Adams et a1.. 1999; Wang et a1.. 1998). By detecting expression of the lacZ replacement 
allele, the expression pattern of ephrinB2 appears to have a sharp boundary, around the 
midpoint of most capillary beds (Wang et a!., 1998). It was assumed that EphB4 
expression had a similar such boundary, thereby delimiting a clear interface between 
arterial and venous domains (Wan£: et al.. 1998). The sensitivity of in situ hvbridization, 
l...- ~ .., -' ' 
however. appears to have been misleading. When the EphB4-LacZ mouse was 
generated, it revealed different distribution of EphB4 expression. While EphB4 is 
strongly expressed in all veins, weaker expression can be detected in arteries. upon longer 
X -gal incubation (see Chapter 2, Gerety et al., 1999). This expression in arteries is not 
detectable by immunolluoresccnt detection of ~-gal by antibody staining (Gerety et al., 
1999). 
Arterial EphB4 expression is often restricted to a subset of cells (personal obs.). 
This is clearly seen in the yolk sac, where the density of EphB4-lacZ positive cells 
diminishes as the distance from the A-V interface increases, into the arterial bed (Gerety 
et a!., 1999). These data suggest that rather than a clean A-V interface at which receptor 
and ligand bearing cells meet, there may be a graded distribution of EphB4 expression 
between arteries and veins. One consequence of the observed arterial expression of 
EphB4 is that EphB4/ephrinB2 signaling may not be restricted to a highly restricted A-V 
border population of endothelial cells. Rather, signaling could be distributed over a 
wider area of the capillary plexus. The decreasing density of EphB4 expression further 
into the arterial domain suggests that arterial vessels may experience a graded Eph/ephrin 
activation depending on distance from the A-V midpoint. The graded appearance of 
vessel diameters approaching the A-V midpoint is consistent with a graded signaling 
system controlling remodeling. This would be necessary for validation of a model in 
which Eph/ephrin activity results in smaller diameter vessels, either by promoting 
splitting and branching of vessels, or inhibiting fusion of vessels (see Chapter 1, and 
Adams and Klein, 2000; Yancopoulos et aI., 2000; Gale and Yancopoulos. 1999). As 
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discussed in Chapter 1, none of these models appears to explain all of the observed 
phenotypes of ephrinB2 and EphB4 knockout mice. Nonetheless, a subset of tissues may 
respond to Eph signaling through these mechanisms. 
The presence of EphB4 positive endothelial cells in arterial vessels raises another 
issue: is reverse signaling through arterial ephrinB2 essential to angiogenic remodeling? 
The observed arterial defects in both ephrinB2 and EphB4 mutants lead us to suspect that 
ephrinB2 in arteries was transducing important signals from veins to arteries (Adams et 
aI., 1999; Gerety et aL 1999; Wang et aL 1998). The presence of EphB4 in arterial 
vessels raises the possibility that remodeling of arteries depends on ephrinB2 signaling 
through arteri(f/ EphB4, away from the A-V interface, rather than relying on reverse 
signals through ephrinB2 (binding to venous EphB4) at the A-V interface. Two points 
make this less likely. Given the severity or arterial vascular defects in both ephrinB2 and 
EphB4 mutant mice, it is unlikely that the low levels and low density of arterial EpHB4 
expression could fulfill the necessary angiogenic role. Second, the angiogenic phenotype 
seen in mice lacking the intracellular domain of ephrinB2 suggest that reverse signaling 
through ephrinB2 is essential (Adams et ai., 2001). Nonetheless, this reverse signaling 
could be transmitted by arterial, rather than venous, EphB4. To address the issue of 
whether arterial EphB4 expression is necessary for angiogenesis, one could knockout 
EphB4 specifically in arteries. This would require generating an EphrinB2-Cre knock-in 
mouse, and an EphB4 conditional knockout mouse. Since neither mouse has been 
reported to date, the question remains an open one. 
Whether such a genetic ablation would work as intended depends on one 
important factor: is ephrinB2 expressed in EphB4-expressing arterial cells'? To knockout 
arterial EphB4 expression, with an ephrinB2-Cre mouse, these two genes would have to 
be co-expressed. The issue of co-expression of receptor and ligand is important for 
understanding the role of Eph signaling in angiogenesis, for example in the yolk sac, 
where arterial cells may be expressing both receptor and ligand. It is also important for 
understanding its role in cardiac development. Although EphB4 and ephrinB2 expression 
is generally restricted to the different vessel domains (with the above exceptions), in the 
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heart, cells expressing these and other Eph/ephrin molecules appear intermingled (Adams 
et aI., 1999: Gerety et a!" 1999: Wang et aI., 1998). The absence of EphB4 or ephrinB2 
leads to severe defects in heart development, including reduced or lacking myocardial 
trabeculation (Adams et aI., 1999; Gerety et aI., 1999; Wang et aI., 1998). Is this Eph 
stimulation autocrine? Or are there separate populations of ligand-expressing and 
receptor-expressing endocardial cells that must interact to orchestrate the morphological 
changes seen in the wildtype heart? 
Another outstanding issue emerging from the EphB4 knockout was whether the 
Eph system undergoes any autoregulation. This has been seen in both tie2 and 
angiogopoietin systems, where loss of ligand expression results in downregulation of 
receptor expression. We noticed that although ephrinB2-lacZ expression is maintained in 
the ephrinB2 knockout, EphB4-LacZ expression appears drastically reduced in the 
EphB4 knockout (personal obs.). This suggests that signaling through EphB4 is 
necessary to maintain EphB4 expression. This would provide a mechanism by which 
Eph signaling could be amplified, and thereby reinforced, at the A-V interface, where 
EphB4/ephrinB2 interactions are highest. If this is true, we would expect that in the 
ephrinB2 mutant, where EphB4 stimulation is lost, we would observe a similar decrease 
in EphB4 expression. 
Because both the ephrinB2 and EphB4 knockout mice used lacZ replacement as 
gene expression indicators. we were unable to address most of these issues with these 
mice (Gerety et a1.. 1999: Wang et aI., 1998). To address some of these questions, I have 
generated an EphB4 mouse in which human placental alkaline phosphatase (AP) is used 
as the indicator gene. Since there are antibodies to both lacZ and AP, we can examine 
the expression of both genes, representing ephrinB2 and EphB4 expression respectively, 
simultaneously in double heterozygous mice (ephrinB2IaCZ/+:EphB4API+). The EphB4-
AP mice were generated in an identical fashion to the original EphB4-lacZ mice, except 
that the lacZ cassette was replaced with a cDNA encoding AP, followed by an SV40 
polyadenylation signal. 
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Initial analysis of ephrinB21acZ/+;EphB4AP/+ mice by double labeling has begun to 
answer some of these questions. Litters were collected at ElO, and stained for ~-gal 
(anti- ~ -gal, 3-prime-Sprime) and AP (anti-AP, Dako). Contrary to our experience with 
EphB4-LacZ mice, we were able to detect arterial EphB4-AP expression using 
immunotluorescence. Figure 11 shows a section through the trunk of a double-labeled 
embryo. EphrinB2 staining (red channel) clearly indicates arteries (arrow, A), and not 
veins (arrow, V). EphB4, on the other hand (green channel), is seen in both veins and 
arteries, although the expression in arteries is much weaker. Similar sections in the 
hindbrain region show that a subset of endothelial cells in the dorsal aorta are positive for 
EphB4-AP (Fig. 12B, arrowheads). Again, the exprcssion levels in arteries is much 
weaker than in veins (compare Fig. 12B arrowheads, green channel, to Fig. 12A, arrow, 
"AC. Vein," green channel). In the heart (see Fig. 13), double-labeling reveals that a 
subset of endocardial cells co-express EphB4 and ephrinB2 (Fig. 13, arrowheads), while 
others express either receptor, or ligand alone (Fig. 13. arrows). Although EphB4 
expression using the AP reporter is not seen in the endocardial lining of the myocardial 
trabeculae (Fig. 13, "TR"), this is contrary to the expression seen when using the EphB4-
lacZ reporter mice (See Chapter 2, Fig. 2, Gerety et aI., 1999). As expected (Wang et a!., 
1998), ephrinB2 expression is seen in these cells (Fig. 13, red channel, "TR"). It is not 
clear why the expression pattern of the EphB4-AP and EphB4-1acZ reporter genes appear 
to have slightly different expression patterns. Since the AP reporter gene gives higher 
sensitivity staining in other tissues (i.e., trunk, Fig. 11 compared to Chapter 2, Fig. 2), we 
would expect that the EphB4-lacZ to represent of subset of those cells detected by 
EphB4-AP, which is clearly not the case. It is possible, however, that the genetic 
modifications of the EphB4 loclls have had different modifying effects on gene regulation 
due to the displacement by the reporter genes of downstream, intronic regulatory 
sequences. Careful analysis of EphB4-Ap and lacZ mice side-by-side may help resolve 
this issue. 
To examine whether ephrinB2 signaling through EphB4 upregulates EphB4 expression, 
.. d bl h . ( h' B,")lacZ/+ E hB4AP/+ Th we hrst need to generate Oll e eterozygolls mice ep nn -'- ; p ). ese 
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mice would then be crossed to single ephrinB2-LacZ heterozygotes, in order to generate 
ephrinB21aCZ/lacZ; EphB4 AP/+ mice. A preliminary set of intercrosses between ephrinB2-
LacZ and EphB4-AP mice yieJded a lower-than-mendelian number of double 
heterozygotes, all of which died within 4 weeks of birth. Although this does not 
represent a large sample size, it does suggest that decreasing both ligand and receptor 
copy number from 2 to 1 has an effect on the survival of mice. Additional matings will 
be needed to determine the penetrance of this perinatal phenotype of 
h . B,)lacZ/+ E hB4AP/+. W' h d t I h d I . bl ep nn _ ; p mice. It out OU) e eterozygoLis aut mice. we are una e 
to address the issue of autoregulation. 
Although preliminary, these data indicate that in some arterial cells, both 
ephrinB2 ligand and EphB4 receptor are expressed together. This is in contrast to the 
situation of ephrinB2, where venous expression is never seen. This opens the possibility 
for autocrine Eph signaling in some arterial cells, as well as paracrine ephrinB2 signaling 
within arteries. The same appears to be true in the heart, although differences in EphB4 
reporter stains unfortunately confound interpretation of its role in heart development. 
Whether the arterial EphB4 expression represents a functional role in angiogenesis, or 
some other function in these cells, remains to be examined. The conditional knockout 
EphB4 in arteries, as mentioned above, would be a direct way of testing this. Although 
the significance of this expression is not known, it may prove to be important in 
explaining the complex phenotypes of Eph/ephrin knockout mice. 
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Figure 13 - EphB4 and ephrinB2 expression 
is partially overlapping in the endocardium 
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Expression of EphrinB2 Identifies a Stable Genetic 
Difference Between Arterial and Venous Vascular 
Smooth Muscle as Well as Endothelial Cells, and 
Marks Subsets of Microvessels at Sites 
of Adult Neovascularization 
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The transmembrane ligand ephrinB2 and its receptor tyrosine kinase EphB4 are molecular markers of embryonic arterial 
and venous endothelial cells, respectively, and are essential for angiogenesis. Here we show that expression of ephrinB2 
persists in adult arteries where it extends into some of the smallest diameter microvessels, challenging the classical view 
that capillaries have neither arterial nor venous identity. EphrinB2 also identifies arterial microvessels in several settings 
of adult neovascularization. including tumor angiogenesis, contravening the dogma that tumor vessels arise exclusively 
from postcapillary venules. Unexpectedly, expression of ephrinB2 also defines a stable genetic difference between arterial 
and venous vascular smooth muscle cells. These observations argue for revisions of classical concepts of capillary identity 
and the topography of neovascularization, They also imply that ephrinB2 may be functionally important in neovascular-
ization and in arterial smooth muscle, as well as in embryonic angiogenesis. © 2001 Academic Press 
INTRODUCTION 
The vertebrate Circulatory system comprises arteries 
and veins, defined by the direction of blood flow. Re-
cently, we discovered serendipitously that arterial and 
venous endothelial cells (ECs) arc genetically distinct, 
from the earliest stages of angiogenesis (Wang et al .. 
1998). EphrinB2, a transmembrane ligand (Bennett et al., 
1995; Bergemann et al., 1995), is expressed by arteries but 
, These two authors contributed equally to this work. 
2 To whom correspondence should be addressed. Fax: (626) 
564-8243. 
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not veins. whereas one of its receptors, the tyroSine 
kinase EphB4, is more abundantly expressed by vcins 
than by arteries (Wang et ai., 1998). 
The genes cphrinB2 and EphB4 are also essential for 
proper development of the cardiovascular system. Tar-
geted null mutations in these genes cause embryonic 
lethality by ElO.D, accompanied by defects in angiogenic 
remodeling of the peripheral vasculature and defective 
myocardial trabeculation in the heart (Adams et al" 1999; 
Gerety et aI., 1999; Wang et aI., 1998). As EphB4 is 
known to interact only with ephrinB2 among all ephrinB-
class ligands (Bergemann et al., 1998; Brambilla et aJ.. 
1996; Brambilla et aI., 1995; Sakano et al., 1996), the 
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FIC . 1. S PCC irlC cxprcs~ iul1 or cphrill B2 ill urlc ri cs but Ilot ve ills ur adult orgall~. The tissues illustrated arc kidlley (!\l. hCUrl (B). li ver (C. 
E). spleen (D). inlestinal ral (F). leg l11uscle (C). and brain (1-1). (1\- 0). X Ca l and hel11aloxylin sla ining: (E- C). X ·Ca l ami PECI\M I antibody 
staining; (H) X -Gal staining alone. /\rrowlwads indicmc cphrinB2 ' arteries: arrows indicate cphrinB2 ve ins. 
sy mnwt ri c<l l mulant phe noty pes of this ligand- receptor 
pair s ugges t that their inte raction is essential fo r cardio-
vascular devc )opnlCnl. Furthcrnl0n', since cphrinB-c lass 
transmembrane ligands are capab le ofsignaltransduclion 
upon engageme nt or EphB-class receptors (Bruckner cL 
a l .. 1997: I-Ioll<lnd e( a l .. 1996) . these genetic data are 
consistent with the idea that ephrinB2 and EphB4 medi-
a te bidirec tional sig llaling (Mellitze r cL a l .. [999 : Xu cL 
a l.. 1999) . 
One outs till1fling ques tion raised by our prC'v ious studies 
is whether the arterial-specific expression of ephrinB2 per-
s ists into adulthond . in pithe r stabl" anll /or newly forming 
blood vesse ls. This question is important for lWO reasons. 
Firs t. it was not clea r w hether the idenlity dislinctions 
between arteries and ve ins required to assemble the c ircu-
latory system necessarily need to be maintained once 
developme nt is complele. Second . lhe essenlial require-
ment of ephrinB2 for embryonic angiogeneSiS raised the 
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FIG . 2. COl11parisoTl or cphrinB2 alld Eph-B4 ex pression belwCCIl dorsa l aorla alld vella cava or adulls. EpltrinB2 expressiun in dorsal aurla 
(1\. C) and vena cava (8. D) was delecled by X-Ga l sla ining for 3 II (1\. B), allli by d Ollulc labc l inllllullunuoresccllce confocal microscupy (C . 
D) w ilh anl ibodies to PECI\M -I (green) and {3-ga lactosidase Ired) . Arrows in (B. D) indica te longiludinal slripes of ephrinB2 expression ill 
CUI'\lriglll l:' lOOl by i\cadPlll k I'rf''''~ , A ll rlghl ~ (lr rt'l' foduClluli ill ,lilY fllrl1lli~rvt·d . 
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possibility that it might be functionally important in set-
tings of adult neovascularization, like other signaling mol-
ecules involved in angiogenesis (Lin et al., 1998). The data 
presented here indeed suggest a role for ephrinB2 in neovas-
cularization of arteries and uncover an unexpected poten-
tial role for the ligand in arterial smooth muscle cells as 
well. 
MATERIALS AND METHODS 
Corneal Micropocket Assay, Bromodeoxyuridine 
(Brdu) Labeling, and Wound Healing Model 
Corneal pockets were made as described (Kenyon ct aI.. 1996) 
and implanted with pellets containing 200 ng of VECF at 1.0 mm 
from the corneal limbus. llrdU was delivered at a rate of 26 p.g per 
hour for 7 days. by a subcutaneous osmotic pump (Alzet) implanted 
immediately after corneal micropocket surgery. Full-thickness 
skin wounds were rnade us.ing a sterile, disposable 4-rnrn punch 
biopsy (Baker Cummins Dermatological) and were examined 7 days 
afterward. 
Tumor Models 
Lewis lung carcinomas or BI6F10 melanomas were grown in the 
dorsal subcutaneous space of adult female cphrinB2"'UMcb+ mice as 
previously described (O'Reilly et al., 1997). Mice bearing 200-mm' 
tumors were anesthetized and sacrificed. and tumors were embed-
ded in OCT. sectioned at 20 p.m. and double-stained with X-Gal 
and anti-PECAM immunoperoxidase histochemistry. Procedural 
details are available on request. 
Histochemical and Immunocytochemical Analysis 
Animals were anesthetized and perfused with 0.1 M Pipes (pH 
7.0) followed by 2% paraformaldehyde (PFA)/O.I M Pipes. Vessel 
segments were excised and placed in 0.2% PFNPipes overnight at 
4"C, rinsed. and stained for 3.5 h in X·Cal buffer. LacZ-sraincd 
vessels were embedded in OCT. sectioned at 10 !Lm, air-dried, and 
postfixed in 2% PFA/PBS. Organs were excised, embedded in OCT, 
and sectioned at 20 I'm. Sections were stained in X-Cal buffer for 
6 h to overnight at 30"C and postfixed in 2% PFNPBS for 5 min. 
Antibody staining of cutaneous wound and corneal tissues was 
performed as described (Cerety et al .. 1999: Wang ot aJ., 1998). on 
unstained or X -Cal-stained cryostat sections. using t.he following 
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primary antibodies: anti-mouse PECAM-I (clone MEC 13.3, 
Pharmingen). anti-f3 gal (5-prime. 3·prime). anti-Brdu (Accurate), 
and Cy3-conjugated anti-SMA (Sigma). 
RESULTS 
ephrinB2 Is Expressed in Adult Arteries, 
Microvessels, and Capillaries 
We examined the expression of ephrinB2 lIsing a tau1-
acZ reporter (Lundgren et a1., 1995; Mombaerts ct a1., 
1996) targeted to the ephrinB210cus (Wang el al., 1998), 
which provides a histochemical indicator of ephrinB2 
transcripLion. A comparison of ephrinB2,"uiw· expression 
with that of authentic ephrinB2 mRNA previously indi-
cated that the taulacZ reporter faithfully reproduces the 
expression pattern of the endogenous gene in embryos 
(Bergemann et a1., 1995; Sakano et a1., 1996; Wang and 
Anderson, 1997; Wang et a1 .. 1998). Similar ephrinB2 
reporter mice have been independently generated by 
others and show essentially the same expression pattern 
(Adams et a1., 1999; see Gale et aI., 2001). The viability 
and fertility of adult cphrinB2,"Ui.CV+ heterozygous "indi-
cator·' mice allowed us to examine the expression of the 
taulacZ marker gene in the vasculature of adult animals. 
Sections through various adult organs of 
ephrinB2,acuoevl mice revealed expression in arteries of 
varied diameters (Fig. 1. arrowheads), but not veins (Fig. 
I, arrows). These tissues included the kidney (Fig. IA), 
heart (Fig. IB), liver (Fig. IC, E). spleen (Fig. ID). fat (Fig. 
IF), muscle (Fig. IG). and brain (Fig. IH). In some 
sections, there appeared to be a patchy, low-level expres-
sion of the reporter in veins. To examine this more 
clearly, we stained the dorsal aorta and vena cava of 
indicator mice in whole mount and opened the vessels to 
visualize the luminal surface en face (Fig. 2). With X-Gal 
reaction times (3 h) that completely saturated the stain-
ing in the dorsal aorta (Fig. 2A), patchy staining was 
visible in the vena cava (Fig. 2B). This staining had two 
characteristic morphologies: narrow longitudinal stripes 
(Fig. 2B, arrow). and smaller patches (Fig. 2B, arrowhead). 
Double-label confocal immunofluores~ence microscopy 
with antibodies to J3-galactosidase (Fig. 2D, red) and the 
pan-endothelial marker PECAM-l (Fig. 2D, green) re-
the vein; arrowheads Indicate individual ephrinB2' endothelial cells. Eph-B4 expression In dorsal aorta (E, G. I) and vena cava (P. H . .D was 
detected by X·Gal staining (E, F) for 3 h, by Nlckel-DAB·enhanced immunoperoxidase staining with anti-f3-galactosldase antibody (G. H) 
and by confocal microscopy (I, Jl with anU-PECAM-I (green) and j3-gal (red) antibodies. All pictures were taken with a 40X objective. 
Individual EphB4 - cells can be detected in the artery by X-Gal histochemical staining (E, an-ow and arrowhead). but the level of expression 
appears much lower than that in veins when detected by anti-J3gal antibody staining (G vs H). which is more proportional to protein levels 
than is the histochemical reaction. Note the characteristic wavy deformation of the intimal surface of the artery (C, I) compared to the vein 
(D, J). which may reflect differences in blood flow rates andlor shear forces. Most of the EphB4· cells in the artery appear associated with 
the narrow peaks of the waves (E, T, arrows) although a few are seen in the broader ··troughs" (E, arrowhead). The levels of i3-gal expression 
in (C) vs (I) or (D) vs OJ are not directly comparable. 
Copyright Il:l 2001 by Academ:c Press. All rights of reproduction in any fann reserved. 
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vealed that the patches of weak {3-galactosidase expres-
sion occurred in endothelial cells (Fig. 2D. arrowheads). 
while the longitudinal stripes did not (Fig. 2D. arrows). It 
is possible that these longitudinal stripes represent 
smooth muscle cells (see below) in the vaso vasorum. the 
small vessels of arterial origin that supply blood to the 
walls of large veins. or neural structures surrounding the 
vessel wall. Interestingly, the en face visualization re-
vealed a characteristic wavy pattern of endothelial cells 
in the aorta (Figs. 2C. 1) that was not seen in the vena cava 
(Figs. 2D. J). This difference in the distortion of the 
intimal surface may reflect differences in the ambient 
conditions of the two vessel types at the time of fixation. 
The recent availability of EphB4""i",7/, indicator mice 
(Gerety et aI., 1999) permitted us to determine whether the 
preferential expression of EphB4 in veins persists into 
adulthood as well. Expression of EphB4 was clearly detected 
in adult veins such as the vena cava (Fig. 2F and data not 
shown). However EphB4 expression in the vena cava was 
not uniform, but rather distributed in islands of contiguous 
endothelial cells (Figs. 2F. H. ]). revealing an apparent 
cellular heterogeneity in the composition of the venous 
endothelial wall. Individual EphB4- cells could also be 
detected in the dorsal aorta (Fig. 2E, arrow). as well as in 
other arteries (data not shown). The level of EphB4 expres-
sion in these scattered arterial endothelial cells was clearly 
lower than that in veins. however. when detected by 
anti-j3-galactosidase antibody staining (Fig, 2G vs Figs. 2H. 
21 vs Fig. 2J). 
Expression of ephrinB2 in the adult vasculature was 
evident not only in major vessels. but persisted into the 
smallest diameter microvesscls and capillaries. Double-
labeling with antibody to PECAM-I revealed that ephrinB2 
was expressed in a subset ofthese microvessels (Fig. 3). This 
was evident in multiple tissues. including pancreas (Fig. 
3A), muscle (Figs. 3B, J-L). intestinal fat (Fig. 3C). kidney 
glomeruli (Figs. 3D-F) and brain, liver, adrenal cortex, and 
adrenal medulla (data not shown). Similarly, expression of 
EphB4'd"idCL extended fI'om larger diameter veins into a 
subset of microvessels and capillaries in the glomerulus of 
the kidney (Figs. 3G-I) and muscle (Figs. 3M-O). 
ephrinB2 Is Expressed in Vascular Smooth Muscle 
of Arteries but Not Veins 
In the course of examining the expression of the 
ephrinB2""i"Z indicator gene in arteries we noted that 
expression of the marker appeared to extend from the 
endothelial into the smooth muscle layer (Figs. 4A-0). 
Such smooth muscle expression of ephrinB2 was not de-
tected in the veins examined in this study (Fig. 4D. VC). 
Double-labeling with antibodies to {3-galactosidase (Fig. 4F, 
red) and alpha smooth muscle actin (SMA) (Fig. 4F, green) 
confirmed that ephrinB2 is expressed in smooth muscle 
cells in the arterial walls (Fig. 4F. yellow patches). although 
not all of the smooth muscle cells were ephrinB2 +. Because 
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of the close apposition of endothelial and smooth muscle 
cells in these adult vessels and diffusion of the X-Gal 
reaction product, it was difficult to determine whether 
ephrinB2 expression was in fact maintained in arterial 
endothelial cells (Figs. 4A-D, arrows). This was confirmed. 
however, by double-label immunofluorescence with anti-
bodies to ,a-galactosidase and PECAM-l (Fig. 4E. yellow 
staining). 
The observation of ephrinB2 expression in adult arterial 
smooth muscle cells was surprising. as initial studies of its 
expression in embryonic arteries had failed to detect it in 
the smooth muscle layer (Adams et aI., 1999; Wang et aI., 
1998). However, these studies were performed in very early 
embryos (E9.5-EI0.5). raising the possibility that ephrinB2 
became expressed in arterial smooth muscle cells at later 
stages of development not previously examined. In confir-
mation of this idea, double-label immunofluorescence 
staining with antibodies to {3-galactosidase and alpha SMA 
revealed that ephrinB2 was not expressed in the smooth 
muscle layer of the dorsal aorta even at El 1.5 (Figs. SA-C), 
but first became detectable in this region at E12.5 (Figs. 
50-F), 4 to 5 days after its expression in arterial endothelial 
cells can first be detected (Wang et al .. 1998; D. Shin and 
D. J. Anderson. unpublished observations). Strikingly. the 
initial expression of ephrinB2 in arterial smooth musclc~ 
cells occurred in those alpha SMA' cells closest to the 
endothelial layer (Fig. 5F. yellow staining). By EI3.5. expres-
sion of ephrinB2 had extended more deeply into the smooth 
muscle layer (Fig. 5G). At these embryonic stages. expres-
sion of ephrinB2 in the endothelial layer was stronger than 
in the smooth muscle layer. However in adults, the levels of 
expression in the two layers were comparable (Fig. 5J and 
Fig.4E). 
ephrinB2 Is Expressed in Subsets of Microvessels at 
Sites of Adult Neovascularization 
We next used ephrinB2,·ui"Z/' indicator mice to deter-
mine whether ephrinB2 is expressed in different settings 
of adult neovascularization. One model system is the 
corneal micropocket assay (Kenyon et aI., 1996). Implan-
tation of a pellet of VEGF into a corneal micropocket 
caused new ephrinB2' vessels to sprout from the limbus 
artery towards the pellet (Figs. 6A-6C). Double-labeling 
using X-Gal and anti-PECAM immunoperoxidase histo-
chemistry indicated that ephrinB2 expression was de-
tected in a subset of the ingrowing vessels and extended 
into the smallest diameter capillaries of the microvascu-
lature. (Figs. 60. E). This was confirmed by double-label 
immunofluorescence staining with antibodies to 
,a-galactosidase and PECAM-l (Fig. 6H. arrowheads). To 
verify that expression of ephrinB2 occurred in newly 
formed rather than preexisting vessels, dividing endothe-
lia! cells were labeled in vivo by an injection of BrdU and 
the tissue was processed for double-label immunofluores-
cence staining with antibodies to BrdU and 
Copyright <0 2001 by Academic Press. All rights of reproduction in any fonn reserved. 
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FIC .5. Induction of cphrinB2 express ioll in the ;';l11oolh muscle layer of embryonic I runk dorsal aorla fo llows t.hal i n the endothelial layer. 
Sections were taken froll1 em bryos at E 11.5 (A-C). E 12.5 (0-1'1. E 13.5 (e - I). and Adu lt U-L) . III a ll case. the sectiolls arc double-labeled with 
allti-SMA to visualize ,1I100th lI1uscle ce lls (greell). a lld allti -i3-galactosidase (red) [0 v isual ize ephrillB2 expression. Note that ephrillB2 is 
expressed Dilly in elldO[heli ,,1 ce lls aJl(1 not ill the s ll1oO[h lIlu scie layer at E 11.5 (A-C). a",1 is first detected ill the sn looth 1I1l1scle layer at 
E12.5 (1'1. in the layer immediately adjacellt to t he e lldotheli al layer. Note a lso the heterogeneity of cp hrill1l2 expressioll in the slllooth 
Illllscle layer of tlte adult aorta U- L). 1\. 11 cOllfucal illlages were capt u red using 4UX ol>jecLive . 
FIG. 3. EphrinB2 expression is cielecleci in subsels of Inicrovcssels of adu ll [issues. (A- C) Sec tions double labeled by X Cal hislochemisllY for 
13 galactosidase and allti PECJ\M I iTlllllunopcroxidasc histochemistry. (I) 0) double labeled confocal microscopic images with (lnLi (3 gal (red) 
il lld Pf.CANI ~ J (green) i.lll t ilxxl iL's. (O- F. J- L) Frolll cp},rinBZ'u" ... / I lIl ice. (C- 1. NI-G) are from EphB.,r.'oI1.'/" . mice. The tissucs shown arc pancreas 
(A). leg muscle (Il. J-O). illtestillal r"t (C). allci kidlley glOlllcruli (0-0. All confoca l images were cil ptun'(lusi llg a 40X objeclive. 
FIC.4. EphrillB2 is expressed ill smooth l11uscle cells as \·ve ll as ill c lldothe li al ce lls of cHlult arteries. (A-D) X-ell l s ta ining of nl)( lol1l illa l 
aorta (A) . thoracic aorta (8) . iliac aorta (e)' dorsal aorta and vClla cava (0). Arrows indicate e ndothelial cclls ill t hc aorta and arrowheads in 
(D) indi cale lhose ill the veml cava. IE. [7) Doubl e-labe l im lllullohistoc he lliistry of a n artery ill the k idney. (E) J\nli -PECJ\M- l (green) \IS 
illlti -f:$ -galac tosidilse (red) delllollstrates epilrillB2 express io ll ill the e mloL ile lia l layer (yel low) . (F) /\111 i-SM/\ (green) a lld illlli -~-galaC l(}s idasp 
(red) demo list rate ephrinB2 expression ill the SlllOOlh Illllscle laye r (yelluw) . 
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/3-galactosidase. This experiment confirmed that eph-
rinE2' vessels growing into the cornea indeed contained 
BrdU' cells (Fig. 6K, arrowheads) and therefore repre-
sented neovascularization. 
We also examined ephrinB2 expression in a more physi-
ological setting of neovascularization, wound healing. 
Strong staining in what appeared to be blood vessels was 
apparent in wounded tissue undergoing healing (Figs. 7 A, 
B). This was confirmed by double-labeling with X-Gal 
histochemistry and anti-PECAM-I antibody staining (Figs. 
7C, D), which also indicated that ephrinB2 was expressed 
by a subset of the small vessels in the wounded region (Fig. 
7C, D, arrowheads). Staining was also detected in a subset 
of vessels in normal skin, albeit at apparently lower levels 
(not shown). 
Finally, we addressed the question of whether ephrinB2 
is expressed during tumor angiogenesis by implanting 
either Lewis Lung carcinoma or B16 Melanoma cells subcu-
taneously into ephrinB2,"",acZ./' Indicator mice. After several 
weeks, the tumors were sectioned and double-labeled by 
X-Gal immunohistochemistry and anti-PECAM antibody 
staining. In both cases, extensive expression of ephrinB2 was 
observed within the tumor vasculature (Figs. 8A, B). Double 
labeling confirmed that the ephrlnB2' elements were Indeed 
PECAM-I- blood vC'.ssels (Figs. 8C, 0, arrows), and indicated 
that a subset of the PECAM -I ' vessels were ephrinB2 In both 
tumor models {Figs. BB-D, arrowheads}. 
DISCUSSION 
EphrinB2 and its r('ceptor EphB4 arc expressed by devel-
oping arteries and veins, respectively, and are essential for 
embryonic heart development and angiogenesis (Adams et 
ai., 1999; Gerety el aI., 1999; Wang et ai.. 1998). Here we 
show that the speCific expression of this ligand-receptor 
pair in arterial and venous endothelial cells. respectively. 
persists into adulthood in most tissues we examined. Sur-
prisingly, cphrinB2 is also expressed in arterial smooth 
muscle cells, but this expression is delayed by several days 
relative to its onset in the endothelium. In addition to it5 
steadY-Slate expression in mature vessels. ephrinB2 expres-
sion is also observed in newly forming blood vessels in 
several settings of adult angiogenesis. 
These findings are significant for several reasons. First, 
they indicate that molecular distinctions between arteries 
and veins are not simply a transient feature of the develop-
ing Circulatory system, but perSist into adulthood as well. 
Second. they identify a stable genetic difference between 
the smooth muscle cells of arteries and veins. Third, they 
challenge several traditional concepts about the identity of 
vessels in capillary beds and the topography of neovascular-
ization. Finally. given the essential role of ephrinB2 and 
EphB4 in embryoniC angiogenesis, the data suggest that 
these genes may play an important role in neovasculariza-
tion as well. 
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Molecular Distinctions between Arteries and Veins 
Persist into Adulthood 
ephrinB2 is the first gene to be described that is expressed 
in an arterial-specific manner from early in embryogenesis 
into adulthood, and which is functionally essential for 
angiogenesis as well. Recently, the transmembrane receptor 
protein tyroSine phosphatase (RPTP) /L has been shown to 
be expressed in adult arteries but not veins in a variety of 
tissues (Bianchi et aI., 1999). However in contrast to eph-
rinB2. RPTP/L is expressed in an apparently pan-endothelial 
manner in the embryo (Fuchs et al.. 199B; Sommer et a1.. 
1996). Furthermore, no functional role for RPTPj.t in angiO-
genesis has yet been demonstrated. Recently, a novel Notch 
ligand, D114, was shown to be artery-specific in both 
embryos and adults (Shutter el al .. 2000). A functional 
reqUirement for this gene in angiogeneSiS has not yet been 
directly demonstrated (Krebs ct ai.. 2000). 
In addition to the aforementioned cell surface mol-
ecules, several transcription factors have been reported to 
be specifically expressed in arterial endothelial cells. 
Sox-l3, an HMG box factor, is expressed in embryonic 
arteries but not veins of midgestational embryos (Roose 
et al.. 1998). However, unlike ephrinB2 which is ex-
pressed in developing blood vessels as early as E8-E8.5, 
expression of Sox-13 is not detected until EI3.5. It is not 
yet clear whether the artery-specific expression of Sox-13 
is maintained into adulthood. Arterial-specific expres-
sion of EPAS-l. a close relative of the hypoxia-inducible 
factor let transcription factor (Ema et ai., 1997; Flamme 
et a1.. 1997; Tian e[ aI., 1997), has been detected as early 
as El 1.5 (Tian ct ai., 1998). Other studies, however, have 
reported low-level expression of this gene in the cardinal 
veins (Flamme et aJ.. 1997). Whether vessel-specific ex-
preSSion of EPAS-l persists into adulthood is not yet 
known. Members of a novel family of Hairy-related 
bHLH transcription factors. HRTI-3, have also heen 
shown recently to be expressed specifically in arterial 
cells during embryonic development, but whether this 
arterial specifiCity persists into adulthood is not yet clear 
(Nakagawa et aI., 1999). Interestingly. these genes appear 
closely related to the zebrafish gene gridlock, which is 
expressed early in arterial development and is required 
for prnper aorta assembly (Zhong c[ al .. 2000). 
It is particularly striking that expression of ephrinB2 and 
EphB4 in the adult vasculature extends into the smallest 
diameter microvessels and capillaries in a variety of tissues. 
This observation suggests that capillaries. as well as larger 
diameter vessels, can have arterial and venous identity. 
Previous support for this idea derived from enzymatic 
histochemical staining of the capillary beds: the arterial 
side of the capillary bed expresses alkaline phosphatase, 
while the venous side expresses dipeptidylpeptidase IV 
(OPP!V) (Koyama et aI.. 1998; Lojda, 1979; Mnizkova et al .. 
1986). Whether these enzymatic differences reflect differ-
ences in gene expression. or differences in activity due to 
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posttranscriptional or posttranslational mechanisms, is not 
clear. The nature of the transition between the arterial and 
venous domains of the capillary bed also remains uncertain. 
The above-mentioned histochemical staining technique 
demonstrated a "transitional zone" in which both the 
arterial and the venous activities overlap (Mr;i.zkova et ai., 
1986), but whether this reflects coexpression of both activi-
ties in individual endothelial cells or a zone of intermixing 
between cells expressing one or the other marker remains 
to be determined. Double labeling for ephrinB2 and EphB4 
may help to resolve this issue, once the appropriate reagents 
are available. 
ephrinB2 Is Expressed Preferentially in Arterial 
Vascular Smooth Muscle 
An unexpected finding was that cphrinB2 is expressed in 
an artery-specific manner in smooth muscle as well as 
endothelial cells. The only other documented examples of 
such arterial-specific smooth muscle gene expression are 
EVECIDANCE, an EGF-like-repeat-containing secreted 
protein (Kowal et al., 1999; Nakamura et aJ .. 1999), and the 
.. latent TGFJ3-binding protein-2" (L TBP-2) (Fang et ai., 
1997). Unlike ephrinB2, however, expression of EVECI 
DANCE is down-regulated after development and is virtu-
ally undetectable in adult arterial smooth muscle, although 
it can be reinduced upon injury (Kowal et ai., 1999; Naka-
mura et a1., 1999). L TBP-2 expression has only been exam-
ined in mid- to late-gestational embryos (Fang el aI., 1997), 
so it is not clear whether its expression persists into 
adulthood, and if so whether its artery specificity is main-
tained. To our knowledge, therefore, ephrinB2 constitutes 
the first example of a stable genetic difference between 
arterial and venous smooth muscle cells. The existence of 
persistent differences in gene expression between arterial 
and venous smooth muscle cells may underlie the funda-
mental differences observed in the organizational architec-
ture of arteries and veins of comparable internal diameters. 
Interestingly, the observation that promoter elements of 
the smooth muscle-speCific SM22 gene direct expression in 
arterial but not venous smooth muscle cells in transgenic 
mice (U et al .. 1996) suggests that even genes which are 
expressed in all vascular smooth muscle cells may be 
controlled by distinct transcriptional regulatory programs 
in arteries and veins. 
The expression of ephrinB2 in arterial vascular smooth 
muscle was missed in initial studies of ephrinB2 expres-
sion in the cardiovascular system (Adams et ai., 1999; 
Wang et a1., 1998), because the analysis was restricted to 
embryonic stages before E10.5, and the gene is not 
activatpd in smooth muscle until EI2.5. This observation 
suggests that distinct mechanisms may control the tim-
ing of onset of ephrinB2 expression in endothelial cells 
and vascular smooth muscle cells. Interestingly, the first 
detectable expression of ephrinB2 in VSMCs was in the 
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layer immediately adjacent to the endothelium. This 
suggests that an inductive signal from arterial ECs to 
VSMCs may induce expression of ephrinB2 in the latter 
cells. The confirmation of such an inductive process and 
the identification of the relevant signal(s) will be inter-
esting topics for future study. 
The fact that the onset of ephrinB2 expression in 
vascular smooth muscle occurs at E12.5 precludes an 
analySis of its functional requirement in this tissue in 
ephrinBZ /- embryos, which die by E1 0.5. The availabil-
ity of conditional knockouts in the ephrinB2 gene should, 
in principle, permit a determination of whether its ex-
pression in arterial smooth muscle reflects an essential 
function in these support cells as well as in endothelial 
cells. 
Expression of ephrinB2 in Adult 
Neovascularization 
ephrinB2 is expressed at sites of adult neovascularization 
in at least three different settings: VEGF-induced angiogen-
esis in the cornea, cutaneous wound healing, and tumor 
angiogenesis. In each case, the marker is expressed in a 
subset of newly forming vessels. This strongly suggests that 
such vessels have arterial or venous identity, and that such 
identity differences may therefore be important for the 
formation of new vascular circuitry. These observations 
also challenge prevailing concepts about the topology of 
neovascularizalion. For example, in both corneal neovascu-
larization and tumor angiogeneSis, it had been thought that 
pairs of new vessels sprout from the postcapillary venule to 
form a "bucket-handle"-like structure that shunts blood 
out of the venule into the adjacent tissue (Gimbrone et al.. 
1974; Grunt et aI., 1986). How such loops acquire an 
afferent and efferent sidedness was not clear, however. Our 
data in the cornea clearly reveal ephrinBr vessels sprout-
ing toward the VEGF pellet implant (Fig. 6). The presence of 
this arterial marker suggests that the traditional classifica-
tion of all new vessel sprouts as being of venous origin, 
based purely on morphological criteria, may have been 
incorrect. If a subset of neovessels sprouts from arteries and 
connect with corresponding sprouts deriving from veins, it 
could explain how the "bucket-handle" structure develops 
with an intrinsic afferent-efferent polarity. A similar sce-
nario could occur during tumor angiogeneSis. More detailed 
studies of the topological origin of ephrinBZ- vessels in 
tumor angiogenesis and their relationship to neovessels 
derived from the postcapillary venules should shed further 
light on this issue. 
The fact that ephrinB2 is expressed at sites of neovas-
cularization, taken together with its essential require-
ment for angiogenesis in the embryo, suggests that this 
ligand (and by extension, its receptor(s) (Gerety et ai., 
1999)) may be functionally important for adult blood 
vessel remodeling as well. In support of this idea, other 
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FIG. 6. EphrinB2 is pxpressed during adult neovilsculari zation in 
lhe cornea l Tlli cropockel. assay. (A) Image or li ve cornea conl aining 
implanled VEGF pe\lel. s howi ng hlood-fi\l ed vesse ls growing Io-
waI'd the implant. (B. C) X-Gil l staining of whole l1lourned corneil 
dcrnorlstratcs tllar tlc\v ly established arteria l bl oo< l vessels express 
ephrinl12. (D. E) Douhl" s taining for X-Gal and "nti-I'ECAM- I 
delllollstn.lt es ephrinH2 express ion ill the reg ion conlaining newly 
fonn ed blood vesse ls. (f-II) Douole- Iabe l conrocal illllTlUnOnUores-
cen ce Ini croscopy witlo "ntioodies to PECAM- I (F. red) and 
{:l-galac tosidase (C. green) directly denoonslrates lloal e piorinB2 is 
expressed ill a subsel or blood vesse ls (H . arrov . !heads) . (I - K) 
Duublc- lalJc lillg wilh alltibudies lU I3rd U 0, red) clTld /3-galaclosiliasc 
U. green) denlonstrates tloat t loe e pllrinB2 · olood vessel s arc new ly 
ronned (K. arrowheads) . Tioe s[rong band o r {:l -gal ex pression (E. H. 
arrows) rcprcscnlS cphri nB2 expression in epilhcJiaJ cells and was 
not detected in wild-ly pe animals (not shown) . 
liganLl-rece pLOr systems initially shown to be important 
in embryonic angiogenesis have also proven esse ntial for 
adult neovasculari7.ation (reviewed in Yancopoulos e[ al .. 
1998). It is c urre ntly not yet poss ible to examine this in 
epilrillB2 knockout mice because of the elllbryonic le -
thality of the homozygous mutation . However . condi -
Shill ct al. 
Lewis LUlIg Carcinoma II BI6 Melanoma 
,\ ~ll~~~~~~~--~ 
c o 
8 
FIG. 7. Expressioll of ephrinB2 il1 a subseL of vessels during 
c ulaneous wound healing. (1\ . B) X-Cal his loc h emis try a mi 
hcmaL oxylin sta ining of woundcd cutaneous ti ssue aL low 
(i\) a nd high (B) m agnifi ca ti o n shows e phrinB2 ' bl ood vesse ls in 
hcaling tissuc. Arrow in (/\) indic;u cs the wound canal. 
(C. D) Double labeling wirh X G al hi s toc he misrry and a nri 
PECt\M antiborly sta ining (brown) reveals apparent communi 
ration between cphrinB2 ~ (arrow heads) lind ephrinB2 (arrows) 
vessels. (D) II higher magnification v iew or t he tkld s hown 
in (C) . 
FIG. 8. Expression of ephrinB 2 in a subser of rumor vesse ls. 
Sections through rUlllors in ('phrinB2 IJU ' ... .l- l1lice irnplantecl with 
Lewis Lung carc inoma (A . C ) or B 16 m e lanoma lB . D) ce ll s were 
double-labeled with X-Gal (blue) and anti -PECIIM irnmuno his -
[Oc hemisrry (brown) . (C. D) lligher magnifi ca tion views or rhe 
fi e lds show n in (1\) and 18). res pec tively. Arrowheac1s indi ca te 
PF.CA M -. an e phrinB2" vessels and arrows indicate doubl e -
posit ive vessels. 
COl'yri).!lil 'C ZOO I l1 y /w;HII'Ilik I'rt",s. :\ 11 riAhl '" Urr(' I"Odlll'lillll II I .IIIY runll II,!,>!' .. ,,!,.I 
153 
Arterial-Specific Expression of EphrinB2 in Adults 
tional knockouts of the gene in the adult vasculature 
should provide one approach to addressing this question. 
If ephrinB2 and its receptor(s) prove to be important in 
adult neovascularization, it would suggest that pharma-
cologic manipulation of this ligand-receptor interaction 
may provide an alternative route to pro- and anti-
angiogenic therapies for heart disease and cancer. respec-
tively (Folkman, 1998a,bl, as has been demonstrated for 
other signaling systems important in angiogenesis (Lin et 
ai., 1998). 
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